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Abstract
Pyroglutamyl Peptidase I (PAP1, EC 3.4.19.3) hydrolytically cleaves pyroglutamic acid 
(pGlu) from the N-terminal o f most pGlu-peptides. In higher organisms Thyrothropin 
Releasing Hormone is a notable biologically active substrate o f PAP1. The sequence o f 
human PAP1 was obtained from GenBank at NCBI (www.ncbi.nlm.nih.gov). Using 
suitable primers cDNA was synthesised using RNA isolated from a human cell line. 
Functionally active recombinant human PAP1 was expressed in Escherichia coli. To 
facilitate both high expression levels and ease o f purification a C-terminal His-tag 
fusion was made. It was shown that this fusion did not affect enzymatic activity. Yields 
o f up to 25 mg purified recombinant human PAP1 per litre o f culture were achieved. 
Gel filtration chromatography and SDS-PAGE data showed that the recombinant 
human PAP 1 exists as an active monomer. The Michaelis-Menten constant (KJ for the 
fluorometric substrate pGlu-7-amino-4-methyl coumarin was determined as 51.8 juM 
and the turnover constant (Kcat) was determined as 3.75 s'1. The activity o f the enzyme 
displayed an absolute requirement for a thiol-reducing agent such as DTT. Optimal 
enzyme activity was observed at pH  range 8.0-9.5 and temperature range 30-50 °C. The 
inhibitory effect o f a range o f compounds (e.g. 2-pyrrolidone) was measured. The three 
dimensional structure o f human PAP1 was modelled on existing homologous PAP1 
structures. Several amino acid residues were selected for site-directed mutagenesis. 
Kinetic analysis o f the mutant PAP1 enzymes gave insight into the role these residues 
play within catalytic site, substrate binding pocket and other significant regions o f 
PAP1. Preliminary determination o f conditions under which recombinant human PAP1 
forms protein crystals was carried out.
XVI
1.0 Introduction
1.1 Pyroglutamyl peptidase
Pyroglutamyl Peptidase (PAP) hydrolytically removes pyroglutamic acid (pGlu; 5- 
oxopyrrolidine-2-carboxylic acid) from the N-terminus of pGlu-peptides (Figure 1.1). 
To date two classes of PAP have been described, as reviewed by Cummins and 
O’Connor (1998). Type I (PAP1) is a widely distributed cytosolic cysteine peptidase 
with broad specificity for pGlu-substrates, found in a wide range of prokaryotic and 
eukaryotic organisms, including Homo sapiens. PAP1 is the topic of this study and is 
reviewed in Section 1.3. Type II (PAP2, Section 1.4) is highly specific toward the pGlu- 
His bond of Thyrotropin-releasing hormone (TRH; Table 1.1, Figure 1.1) or very 
closely related peptides. PAP2, a zinc-dependent metallopeptidase, exists in both a 
membrane-bound and serum form.
1.2 pGlu-peptides
pGlu is a cyclised derivative of glutamic acid (Figure 1.1), first described by Haitinger 
(1882) who reported that when glutamic acid was heated at 190°C it converted to a new 
compound that differed from glutamic acid in having lost a molecule of water. There are 
many reports of the enzymatic formation of pGlu from glutamic acid and glutaminyl 
peptides, as reviewed by Orlowski and Meister (1971), suggesting important 
physiological relevance. This relevance is highlighted by the fact that a number of 
bioactive peptides (e.g. neuropeptides) exhibit an N-terminal pGlu residue (Table 1.1).
Table 1.1 Some peptides with an N-terminal pGlu residue
Peptide* Sequence
Thyrotropin-releasing Hormone pGlu-His-Pro-NH2
Luteinizing Hormone-releasing Hormone pGlu-His-Trp-Ser-Tyr-
Bombesin pGlu-Gln-Arg-Leu-Gly-
Neurotensin pGlu-Leu-Tyr-Glu-Asn-
Gastrin pGlu-Gly-Pro-Trp-Leu-
Eledoisin pGlu-Pro-Ser-Lys-
a Further examples are given by Awadé et al. (1994).
Neuropeptides released in the autocrine, paracrine or endocrine contribute to 
intracellular communication which is essential in integrating the basic processes of life 
such as metabolic activity, cell differentiation and growth. Neuropeptides are typically 
short polypeptide chains with specific modifications to individual residues, such as an 
N-terminal pGlu residue. Such a modification can provide resistance against
2
degradation by various proteolytic enzymes and thus PAP possesses the unique ability 
to degrade or un-block members of this group of peptides.
An N-terminal pGlu residue can define the highly specific biological properties of 
neuropeptides, such as their ability to recognize and bind cell surface receptors. For 
example, TRH binds to its receptor via specific interactions between the pGlu ring and 
certain residues of the trans-membrane TRH receptor (Perlman et al., 1994a; 1994b). 
Slight structural substitution in the pGlu ring results in an almost complete loss of 
receptor binding ability. TRH is one of the most widely documented biologically active 
pGlu-peptides. It was initially defined as a hormone for its ability to stimulate the 
release of Thyrotropin Stimulating Hormone (TSH) from the anterior pituitary gland 
and prolactin from the pituitary gland (Jackson, 1982). It has features that also qualify it 
as a neurotransmitter or “neuro modulator”, namely its extrahypothalamic distribution in 
the brain combined with its localisation and release at the synaptic level as well as its 
attachment to high affinity receptors, which show remarkable degree of anatomical 
localisation. It exhibits specific effects on neuronal activity and stimulates a wide range 
of centrally mediated behavioural effects. For comprehensive reviews of TRH see 
Griffiths (1985) and O’Leary and O’Connor (1995).
Figure 1.1 PAP cleavage of TRH
The cleavage o f  TRH by PAP liberates pGlu. The remaining His-Pro-NH2 undergoes non-enzymatic 
cyclisation to cyclo(His-Pro). Illustrated using ChemSketch (Section 2.11).
The cleavage of TRH by PAP yields free pGlu and His-Pro-NH2 (Figure 1.1). The 
subsequent non-enzymatic cyclisation of His-Pro-NH2 generates cyclo(His-Pro) which 
has been shown to posses pharmacological, endocrine, electrophysiological and 
cardiovascular activity of its own (Prasad, 1995). Functions of free pGlu are less clear
cydo(H is-Pro) O
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but some pharmacological properties have been described and elevated plasma levels of 
free pGlu have been demonstrated in patients suffering from Huntington’s disease and 
pyroglutamic academia (Cummins and O’Connor, 1998). He and Barrow (1999) and 
Russo et al. (2002) reported that amyloid-/? peptides beginning with pGlu residues have 
a higher tendency of forming insoluble aggregates than other amyloid-/? peptides. 
Alzheimer’s disease is a neurodegenerative disorder characterised pathologically by the 
progressive deposition of amyloid-/? peptides both intra-neuronally and extra-cellularly 
in the brain.
1.3 PAP1
As mentioned in Section 1.1 PAP1 is capable of cleaving pGlu from a variety of 
biologically active pGlu-peptides and pGlu-substrates (Figures 1.1 and 1.3), with 
exception of those commencing with pGlu-Pro (Section 1.3.8). PAP1 has been 
exploited commercially in peptide sequencing since N-terminal pGlu residues pose a 
problem in structural analysis of peptides (Martini et al., 1985; Awade et al., 1994; 
Mozdzanowski et al., 1998). Such a blocking group prevents application of the Edman 
degradation procedure.
1.3.1 Physiological significance of PAP1
At present, there is a varied view as to the exact physiological function of PAP 1. Albert 
and Szewczuk (1972) suggested a possible role in the adsorption of peptides from the 
alimentary tract by virtue of PAP1 presence in the intestinal mucous membrane and 
duodenum (Pierro and Orsatti, 1970). Its wide distribution in such dissimilar tissues as 
skeletal muscle, brain, kidney, spleen, heart, liver and intestine suggests that PAP1 may 
contribute to the intracellular catabolism of peptides to free amino acids, thus being 
involved in regulating the cellular pool of free pGlu (Szewczuk and Kwiatkowska, 
1970; Lauffart et al., 1989; Mantle et al., 1990; 1991). The physiological implications 
of this involvement were highlighted by Falkous et al. (1995), who found significantly 
increased levels of PAP 1 in spinal cord of patients suffering from motor neuron disease. 
The identification of characteristic deposits of proteins in degenerating spinal cord 
neurons in motor neuron disease cases suggests that an abnormality of intracellular 
protein catabolism may contribute to the pathogenesis of this disorder.
The cytosolic location of PAP1 excludes a significant role in extracellular peptide 
degradation (Charli et al., 1987; Abe et al., 2004). Instead it is suggested that PAP1 may
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contribute toward a means of returning pGlu terminating neuropeptides released from 
damaged or ageing vesicles back to the cellular amino acid pool (O’Cuinn et al., 1990). 
PAP1 may be part of a system to degrade peptides that are produced in excess when 
secretion from neuropeptide-synthesising cells is suppressed. Supporting this are the 
findings by Faivre-Bauman et al. (1986) that the addition of specific PAP1 inhibitiors to 
TRH-synthesising hypothalamic cells in culture, results in significant increase of TRH 
content and release from cells under both basal and K+ stimulated conditions.
A correlation between PAP1 activity and TRH levels in developing mammalian brain 
has been reported in a series of studies (De Gandarias et al., 1992; 1994; 1998; 2000). 
As brain development progresses, a decrease in PAP1 activity coincides with increasing 
levels of TRH. The authors thus indicate that PAP1 plays a part in the normal 
development of mammalian brain. The same study shows that during earlier stages of 
development, high PAP1 activity is linked to elevated levels of cyclo(His-Pro) (Section 
1.2), a correlation which was previously indicated (Prasad et al., 1983).
The activity of PAP1 in the functionally connected retina and hypothalamus of rats 
exhibits a highly significant periodic fluctuation, coinciding with environmental light 
and dark conditions (Ramirez et al., 1991; Sánchez et al., 1996). A similar diurnal 
rhythm exhibited by TRH further demonstrates a possible association with PAP1.
Recent findings (Valdivia et al., 2004) indicate that PAP1 participates in regulating the 
levels of seminal TRH and close analogues, and in mediating sperm death associated 
with necrozoospermia. However, the possibility that an increase in PAP1 activity may 
be due to sperm death in order to catalyse the remaining peptides must be considered. 
Further studies are ongoing to clarify if the increased levels of activity are a cause or 
consequence of sperm cell death.
In prokaryotic organisms PAP1 is likely to be a factor in the degradation and utilisation 
of pGlu-peptides as nutrients (Awadé et al. 1994; Gonzales and Robert-Baudouy, 1996). 
To this end Doolittle and Armentrout (1968) found that Pseudomonas fluorescens could 
grow on media having free pGlu as the sole carbon and nitrogen source (Section 1.3.3). 
PAP1 may also be involved in the detoxification of pGlu-peptides since high levels of 
such peptides would abnormally acidify the cell cytoplasm. Of note is the fact that 
PAP1 is not present in all bacteria (Section 1.3.3). Therefore PAP1 could contribute to 
such functions when present, rather than being uniquely responsible for them.
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1.3.2 Classification of PAP1
Enzymes are classified by the Enzyme Commission (EC) list, which is maintained by 
the Nomenclature Committee of the International Union of Biochemistry and Molecular 
Biology (NC-IUBMB, http://www.chem.qmul.ac.uk/iupac/jcbn). Proteolytic enzymes 
are of class 3, the hydrolases, and subclass 3.4, the peptide hydrolases or peptidases. 
Peptidases are either exopeptidases cleaving one or a few amino acids from the N- or C- 
terminal, or endopeptidases that cleave internally in polypeptide chains. Exopeptidases 
that act at a free N-terminal to liberate a single amino acid are known as 
aminopeptidases while those that act at a free C-terminal to liberate a single residue are 
known as car boxy peptidases. Exopeptidases that release several amino acid residues are 
known as oligopeptidases. Omega peptidases (EC 3.4.19) are exopeptidases that remove 
terminal residues which are substituted, cyclized (e.g. pGlu, Figure 1.1) or linked by 
isopeptide bonds.
Peptidases can also be grouped according to the residues responsible for catalysis. The 
main catalytic types are Cysteine, Serine, Aspartic and Metallo. In cysteine peptidases 
the catalytic mechanism requires a nucleophile and a proton donor. The nucleophile is 
the thiol group of a Cys residue. The proton donor is usually the imidazolium ring of a 
His residue. In some cases a third acidic residue is required to orientate the imidazolium 
ring of His (Barrett et al., 1998). A generalised mechanism of cysteine peptidase 
catalysis is represented in Figure 1.2.
Over 40 families of cysteine peptidases have been shown to come from at least eight 
different evolutionary origins (Barrett and Rawlings, 2001). The notable MEROPS 
Peptidase Database (http://merops.sanger.ac.uk, Rawlings et al., 2004) has grouped 
each of these origins as a clan (CA, CD, CE, CF, CH, CK, PA and PB) as an alternative 
classification system to the EC list. Each clan has distinctive functional, sequence and 
structural properties.
PAP1 was initially classified as EC 3.4.11.8 and has been referred to under several 
different names including pyrrolidonyl peptidase, pyrrolidone carboxyl peptidase, 5- 
oxoproly 1-peptidase, PYRase and pyroglutamyl aminopeptidase. PAP1 is currently 
classified as a cysteine omega peptidase (EC 3.4.19.3), which hydrolytically removes 
the amino terminal L-pyroglutamic acid (pGlu) residue from specific pGlu-substrates 
(Figures 1.1 and 1.2). In the MEROPS database PAP1 has been assigned as family C l5,
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clan CF. As yet, no other peptidases have been assigned to this family or clan (Barrett 
and Rawlings, 2001).
Figure 1.2 Catalytic mechanism of cysteine peptidases
The catalytic mechanism o f  cysteine proteases is represented via a generic dipeptide (blue-red). The 
thiolate ion o f  the Cys residue is the catalytic nucleophile and is stabilized through the formation o f  an ion 
pair with neighbouring imidazolium ring o f  a His residue (1). Catalysis proceeds through the formation o f  
a covalent intermediate (2). The dipeptide is cleaved (3) and both fragments are liberated (4). For amino 
acid information see Appendix D. Illustrated using ChemSketch (Section 2.11).
1.3.3 Discovery and occurrence of PAP1
PAP1 activity was first identified in prokaryotes (Doolittle and Armentrout, 1968). The 
authors had actually intended to source an enzyme capable of opening the pyrrolidone 
ring of pGlu-peptides to benefit peptide sequencing (Section 1.3). An organism able to 
use free pGlu as sole carbon and nitrogen source was isolated from soil and identified as 
Pseudomonas fluorescens. A crude extract of P. fluorescens was able to liberate free 
pGlu from pGlu-alanine. This catalytic hydrolysis was attributed to the novel enzyme 
PAP1 (PflPAP1). Of a wide range of known peptidases, none were active toward this 
peptide. No PAP1 activity was found in E. coli.
PAP1 was subsequently documented in a wide range of prokaryotes including Bacillus 
subtilis (BsuPkP 1, Szewczuk and Mulczyk, 1969), Klebsiella cloacae (KclPAP 1, 
Kwiatkowska et al., 1974), Streptococcus cremoris (ScrPAPl, Exterkate, 1977),
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Streptococcus faecium (S/aPAPl, Sullivan et al., 1977), Bacillus amyloliquefaciens 
(BamPAPl, Tsuru et al., 1978), Streptococcus pyogenes (Spy PAP1, Cleuziat et al., 
1992), Staphylococcus aureus (SawPAPl, Patti et al., 1995), Enterococcus faecalis 
(EfaPAPX, Mineyama and Saito 1998), Pyrococcus horikoshii (PhoPAPX, 
Kawarabayasi et al., 1998), Pyrococcus furiosus (PfuPAPX, Tsunasawa et al., 1998), 
Thermococcus litoralis (77/PAP 1, Singleton e/ al., 1999a) and Mycobacterium bovis 
(M>oPAPl, Kim e/ #/., 2001)
Szewczuk and Kwiatkowska (1970) found PAP1 activity in various vertebrates and 
plants. Among the vertebrates were human (Homo sapiens: HsaPAPX), bovine (Bos 
Taurus: BtaPAPX), porcine (Sus scrofa: SscPAP 1), rabbit (Oryctolagus cuniculus: 
OcwPAPl), mouse (A/ws musculus: A/mwPAPl), Rat (Rattus norvegicus: /tooPAPl), 
guinea-pig (Caviaporcellus: CpoPAPX), pigeon (Columba: ColPAP 1), chicken (Gallus 
gallus: GgtfPAPl) and fish (Cyprinus carpio: CcaPAPl). Different tissues were tested 
including liver, kidney, spleen, lung, heart, brain, skeletal muscle and intestines. Among 
the plants were bean, oats, wheat, parsley, carrot, cabbage, potato and cauliflower. 
Tissues tested included leaves, seeds, sprouts, bulbs and roots. PAP1 activity was found 
in all samples screened. In vertebrates the highest activity was noted in liver and kidney 
tissues. PAP1 was later reported in hamster hypothalamus (Mesocricetus auratus: 
MauPAP 1, Prasad and Peterkofsky, 1976) and feline brain (Felis domesticus: FdoPAPX, 
DeGandarias et al., 1992).
1.3.4 Detection of PAP1 activity
PAP1 activity was initially determined by monitoring the release of alanine from pGlu- 
alanine (Doolittle and Armentrout, 1968). Mulczyk and Szewczuk (1970) developed a 
simple and rapid assay using the synthetic PAP1 substrate L-pyrrolidonal-/?- 
naphthylamide (pGlu-/?-NA). The assay exploits the release of /?-NA by PAP1, which 
can be colourimetrically determined upon coupling with azotised o-dianisidine. A 
number of commercial kits involving pGlu-/?-NA for the detection of PAP1 activity 
were confirmed as useful in preliminary and presumptive identification of enterococci 
and streptococci (Mitchell et al., 1987; Kaufhold et al., 1989; Dealler et al., 1989).
A more direct assay for PAP1 activity, requiring fewer steps than with pGlu-/?-NA, was 
developed using synthetic chromogenic (pGlu-/?-nitroanilide) and fluorogenic (pGlu-7- 
amino-4-methylcoumarin; pGlu-AMC) substrates (Fujiwara and Tsuru, 1978). The 
former substrate is cleaved by PAP1, releasing p-nitroanilide which leads to an increase
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in absorbance at 410 nm. pGlu-AMC is cleaved to yield free AMC, a fluorogenic 
compound with an emission of 440 nm upon exitation at 370 nm (Figure 1.3). The 
pGlu-AMC assay is used in this work and is one thousand fold more sensitive than the 
pGlu-/?-nitroanilide assay.
pGlu AMC 9 h3
PAPI
o . r r S
N COOH H2N -Q
/  \
440 am  370 nm
Figure 1.3 PAP1 cleavage of pGlu-AMC
PGlu-AMC is cleaved by PAP1 to yield free AMC, which fluoresces at 440 nm when exited at 370 nm. 
Illustrated using ChemSketch (Section 2.11).
Besson et al. (1994) have reported on the use of conductimetry to measure the activity 
of PAP 1. Hydrolysis of pGlu-Ala by PAP1 was continuously monitored by measuring 
the variation in conductance. A drawback of this approach is the limitation to low ionic 
strength solutions, as sensitivity is defined by the relative change of conductance.
1.3.5 Purification of PAP1
Prior to the availability of a recombinant source, PAP1 was purified from various 
prokaryotic cell cultures and a wide range of eukaryotic tissues including human 
skeletal muscle, kidney and brain (Doolittle and Armentrout, 1968; Armentrout, 1969; 
Szewczuk and Mulczyk, 1969; Szewczuk and Kwiatkowska, 1970; Mudge and Fellows, 
1973; Kwiatkowska et al., 1974; Prasad and Peterkofsky, 1976; Exterkate, 1977; 
Sullivan et al., 1977; Tsuru et al., 1978; 1982; 1984; Browne and O'Cuinn, 1983; 
Lauffart and Mantle, 1988; Lauffart et al., 1989; Mantle et al., 1989; 1990; 1991; 
Cummins and O'Connor, 1996; Mineyama and Saito, 1998).
Various stages of ammonium sulphate fractionation, gel filtration, anion exchange 
chromatography, hydrophobic interaction chromatography and thiol-affinity 
chromatography were used to obtain pure enzyme. The PAP1 substrate analogue 2- 
pyrrolidone (Section 1.3.8) was frequently included during purification at a 
concentration of 100 mM. This competitive reversible inhibitor of PAP1 has a 
stabilising effect on activity and could consequently be removed by dialysis. Thiol-
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reducing agents dithiothreitol (DTT) or 2-mercaptoethanol (2-ME) were also frequently 
used to aid in stabilisation.
The cloning of PAP1 genes (Section 1.3.6) allowed for the high level expression of 
several active recombinant prokaryotic PAP1 enzymes in E. coli (Gonzales and Awade, 
1992; Awade et al., 1992; Yoshimoto et al., 1993; Gonzales and Robert-Baudouy, 
1994; Tsunasawa et al., 1998; Singleton et al., 2000; Sokabe et al., 2002). In some 
cases a fusion with six histidine codons allowed expression of PAP1 enzymes having a 
6xHis tag on their N-terminal (Patti et al., 1995; Kim et al., 2001), facilitating one-step 
purification by nickel chelate affinity chromatography (an approach used in this work). 
High yields of purified PAP1, up to 45 mg per litre of recombinant E. coli culture, were 
obtained from these recombinant sources. At the time this project was initiated, no 
eukaryotic PAP1 had been expressed from a recombinant source.
1.3.6 Sequence data and analysis of PAP1
The genes for Bsu?A?\ (Awade et al., 1992) and S/?yPAPl (Cleuziat et al., 1992) were 
the first PAP1 genes to be cloned and sequenced. Genomic libraries of B. subtilis and S. 
pyogenes were constructed and transformed into E. coli. Since this host is PAP1 
negative, it was possible to develop a screen for PAP1 activity by a plate colony assay 
using pGlu-/?-NA as described by Mulczyk and Szewczuk (1970). Positive clones were 
analysed by restriction mapping followed by DNA sequencing and the open reading 
frames (ORFs) of BsuPAP 1 (Bsu-papl) and SpyPAPl (Spy-papl) were identified. The 
sequences showed no homology to any other data available on GenBank (Benson et al., 
1996) at that time. Later, by similar approaches, several other prokaryotic PAP1 genes 
were sequenced (Table 1.2).
Genomic digests of B. subtilis, S. pyogenes and P. fluorescens were southern blotted 
and probed with PCR fragments internal of Bsu-papl, Spy-papl and Pfl-papl 
respectively (Awade et al., 1992; Cleuziat et al., 1992; Gonzales and Robert-Baudouy, 
1994). In each case only one signal was detected concluding that the genes are present 
as single copies. B. subtilis and S. pyogenes total RNA samples were northern blotted 
and probed with the same Bsu-papl, Spy-papl internal PCR fragments respectively, 
establishing the mRNA sequences to be around 700 bp in length, consistent with the 
length of the ORFs.
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Table 1.2 Prokaryotic PAPI sequences
O rganism PAPI G enB ank O R F PAPI A m ino M olecular R eference
G ene A ccession (bp) E nzym e A cids W eight
B. subtilis Bsu-papl X 66034 645 ZfawPAPl 215 23,774 A wade et al., 1992
S. pyogenes Spy-papl X 65717 645 SpyPAPl 215 23,132 Cleuziat et at., 1992
B. amyloliquefaciens Bam-papl D 11035 645 BamPAPX 215 23,287 Yoshim oto et a l 1993
P. fluorescens Pfl-papl X 75919 639 PflPAPl 213 22,438 Gonzales and Robert- 
Baudouy, 1994
S. aureus Sau-papl U 19770 636 SauPAP\ 212 23,227 Patti e ta l ., 1995
P. furiosus Pfu-papl ABO 15291 624 PJuPAPl 208 22,822 Tsunasawa et al., 1998
T. litoralis Tli-papl Y 13966 660 77/PAP 1 220 24,745 Singleton et al., 2000
M. bovis Mbo-papl U 91845 666 MboPAPX 222 23,193 Kim etal., 2001
P. horikoshii Pho-papl A P000002 618 PhoPAPX 206 22,640 Sokabe et al., 2002
[Molecular weights were deduced from amino acid sequences]
An alignment of prokaryotic PAP1 amino acid sequences is shown in Figure 1.4. 
Sequence homology is represented in gray scale shading, with black being the highest 
homology. The four most highly conserved segments have been labelled domains 1 to 4. 
Domains 2 and 3 had previously been noted by Cummins and O’Connor (1998). As can 
be seen in Figures 1.6 and 1.7 these domains coincide closely with the active site region 
of PAP1. Table 1.3 summarises the homology scores corresponding to this alignment. 
The highest degree of sequence homology exists between Z&wPAPl and Bam?K?\ 
(72% identity, 85% similarity) and the largest divergence exists between Mbo?A?\ and 
&H/PAP1 (27% identity, 48% similarity).
11
BamPAP1 
B su P A P l 
SpyP A P 1 
S a u P A P l 
P f l P A P l  
P fu P A P l 
T l i P A P l  
P h o P A P l 
M boPA Pl
iWEAVKI
EAAKI
GAAEGP-AS 
G FET E E-A I 
ALEAIKKgPAT IHG— 1& 
|W E AVT QgENI I  -  GT -  HT 
WEAVRQ DGVQLGSD 
ERIAKD D GIK IG D- 
EQIAKYFDRKQIGN-
DIVEAfflSERI PE
q l t a e e 3 d g r t i a g - a t
KSLAVfflRE 
RSALDTfflRQ 
QKSADVgQQ 
KKVDTIHNK
t a g e c Ht r
GKAKEVfflEK 
SVKRATIEgKR
s Hk r a r e k Ql k
t S f e s ia a a q q
5 6
5 6
53
53  
5 6
54
55  
5 1  
55
domain 1
BamPAP1 
B su P A P l 
S py  PAP 1 
S a u P A P l 
P f l P A P l  
P fu P A P l 
T l i P A P l  
P h o P A P l 
M boPA Pl
110
110
107
107  
110
108  
109  
105  
112
BamPAP1 a ^ B ^ t  gW B rHve  eHk k e
B su P A P l A B  ,T R 1  SrS t a k S k e h
S pyP A P 1
A 1  S T I  «S a u P A P l PRM SN J  iSAwTQSBiNQ
P f l P A P l A B  TT 1  h SAfi VKAq REA
P fu P A P l T |  ST 1  iiSK M K kBhER
T l i P A P l L f t 1! AT J  |  SaHt Kt Br DN
P h o P A P l A S  AT I  T S eB v Ee Bk KN
M boPA Pl vW h a tB S  B aJ v LaJ r KA
BamPAP1 
B su P A P l 
SpyP A P 1 
S a u P A P l 
P f l P A P l  
P fu P A P l 
T l i P A P l  
P h o P A P l 
M boPA Pl
¡HaFBGI^jDEI SRHHPHIF
f J g l J d h i s r t s p h x J
iHfflMaQAgYLVDKYC PNAfi 
H LHHLGYLQDKHYPH]
QQFHllQhalags—Gî
LSgHHSATKGYPKMSI
k tHh f s k ie g y p l SH
LTfflHT S AT KGY PK I a | 
GVHHHLAQKGL PV^A if f l
dom ain  3
167
1 67
164
164
165
165
1 6 6  
162  
169
SAüfflS0DHITKAllKlgAVTAAVHED— DIETGGGELH : 2 1 5  
I0AVTAAQYDE— DVKSPGGTLH : 2 1 5  
IFAIVDFKDRSDLKRVGGATH : 2 1 5
EAISDHD DLRIALGTTE : 2 1 2
LTAWHTPV--DVKEAGGQVS : 2 1 3
E VALE ELL--------------------------- : 2 0 8
[KVSLDYLEKDRDDIKI PL—  : 2 2 0
[RVAQSALHSSQLR-----------------: 2 0 6
EAAIRQSADIRE P IPSR L Q I : 2 2 2
dom ain  4
Figure 1.4 Amino acid sequence alignment of prokaryotic PAP1
Alignment was created using MultAlin with B losum 62-12-2 parameters and edited using GenDoc 
(Section 2.11). Sequence hom ology is represented by grey scale shading, with black being the highest 
homology. The most highly conserved domains have been labelled 1 to 4. For amino acid information see 
Appendix D.
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Table 1.3 Homology scores for prokaryotic PAPI sequences
BsuPAPl SpyPAPÌ SauPAPl Pfl PAPI PfuPAPi 77/PAP1 PhoPAPl MboPAPl
Bam?A PI 72 (85) 48 (68) 41 (62) 43 (63) 38 (57) 32 (57) 41 (59) 32 (52)
BsuPAPl 47 (65) 43 (62) 46 (65) 39 (57) 36 (59) 3 7 (5 6 ) 33 (50)
SfcvPAPl 4 9 (6 6 )  4 1 (6 1 ) 36 (57) 34 (59) 39 (60) 31 (49)
SauPAPl 43 (60) 35 (50) 34 (54) 36 (51) 27 (48)
PfiPAPl 38 (56) 37 (55) 40 (57) 36 (51)
PfuPAPi 53 (71) 51 (73) 33 (54)
77/PAP1 53 (69) 32 (53)
[Identity scores are given, with similarity in parenthesis] PhoPAPl 34 (47)
A BLAST search (Section 2.11) of known PAP1 sequences against the current 
GenBank data (August 2004) reveals a number of confirmed and putative eukaryotic 
PAP1 gene sequences (Table 1.4) many of which have not yet been documented in 
publications. Sequence homology is also seen with several putative prokaryotic PAP1 
sequences and un-identified protein products (not tabulated).
Table 1.4 Eukaryotic PAPI sequences
O rganism C om m on Nam e PAPI
G ene
G enB ank
Accession
O R F
(bp)
PAPI gene  
product
A m ino
A cids
M olecular
W eight
H. sapiens Human Hsa-papl A J2788288 627 HsaPAPi 209 23,138
M. musculus Mouse Mmu-papl AJ278829a 627 MmuPAPX 209 22,934
R. norvegicus Rat Rno-papl A B 098134b 624 RnoPAP\ 208 22,800
Tetraodon
nigroviridis
Green Pufferfish Tni-papl * C A A E01014609 615 TniPAPl* 205 22,376
Takifugu
rubripes
Japanese Pufferfish Tru-papl * AJ301641 633 TruPAPl* 211 23,331
Apis mellifera Honey Bee Ame-papl* XM 392560 573 Ame PAPI* 191 21,941
Drosophila
melanogaster
Fruit Fly Dme-papl * NM 168616 672 Dme PAPI* 224 24,807
Anopheles
gambiae
Mosquito Aga-papl * XM 308793 627 AgaPAPX* 209 23,940
Arabidopsis
thaliana
Cress Ath-papl* N M _ 104547 657 AthPAPX* 219 24,046
Caenorhabditis
elegans
ra  I-V _ j  _
Nematode
;  / b * >
Cel-papl *
r . ±
NM 060090 822 CelPAPX* 274 31,007
[a Dando et al., 2003; b Abe et al., 2003; * Putative sequences; Molecular weights were deduced from
amino acid sequences]
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Figure 1.5 Amino acid sequence alignment of eukaryotic PAP1
Alignment was created using MultAlin with Dayhoff-8-0 parameters and edited using GenDoc (Section 
2.11). Sequence homology is represented by grey scale shading, with black being the highest homology. 
The most highly conserved domains have been labelled A to E. For amino acid information see Appendix 
D.
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Figure 1.5 shows an alignment of eukaryotic PAP1 amino acid sequences. On this 
alignment the regions of highest homology have been designated domains A to E. These 
domains have a degree of overlap with the prokaryotic segments of high homology 
(Figure 1.4) as can be seen in Figure 1.6.
The Cel?API sequence has several distinct regions of added sequence. Table 1.5 has a 
summary of the homology scores for this alignment. Highest homology exists between 
the rodent sequences Mmu?A?\ and Rno?A?\ (98% identity/similarity). These also 
show closest homology to Hsa?A?\ (94% identity, 96% similarity). Such high 
homology is not observed among the insect sequences DmePAP1, Aga?AP\ and 
Ame?A?\ (at best 35% identity, 56% similarity). Interestingly, the insect sequences 
show a similar degree of homology with Hsa?A?\ as they do with each other (-30% 
identity, -50% similarity). The plant sequence AthPAPX and nematode sequence 
Ce/PAPl exhibit the greatest divergence from all other eukaryotic sequences.
Table 1.5 Homology scores for eukaryotic PAPI sequences
MmuPAPX RnoPAPX 7/i/PAPl Tri/PAPI AmePAPÌ Dme  PAPI AgaPAPX AthPAPX CWPAP1
HsaPAPX 94 (96) 94(96) 71 (84) 68(85) 31 (50) 30 (46) 29 (51) 22 (38) 22 (36)
AfmwPAPl 98(98) 69(81) 68(83) 30 (49) 30 (47) 29 (50) 22 (38) 22 (36)
RnoPAPX 69 (80) 67 (83) 30 (49) 31 (47) 29 (50) 22 (38) 22 (36)
TniPAPÌ 87(91) 29 (50) 29 (44) 28 (47) 22 (37) 20 (34)
7>wPAPl 32 (52) 31 (46) 29 (47) 23 (38) 20 (35)
AmePAPÌ 28 (46) 29 (48) 21 (38) 21 (35)
Dme  PAPI 35 (56) 20 (36) 18(32)
AgaPAPX 20 (36) 20 (36)
[Identity scores are given, with similarity in parenthesis] AthPAPX 14(31)
The prokaryotic sequence that Hsa?A?\ shows most homology to is Bam?A?\. Figure
1.6 shows an alignment of these two sequences. They exhibit an identity of 25% and a 
similarity of 45%, which is a higher score than seen among some of the eukaryotic 
sequences (Table 1.5). The conserved domains from Figures 1.4 and 1.5 have been 
shown in association with Bam?A?\ and Hsa?AJ*\ respectively. Also indicated are 
several residues of functional significance in Bam?A?\. Cysl44, Hisl68 and Glu81 
constitute the catalytic triad of Bam?A?\ (as described in Section 1.3.7) while PhelO 
and Phel3 contribute to the hydrophobic binding pocket of Bam?API (as described in 
Section 1.3.10.2). Although the conserved eukaryotic and prokaryotic domains do not 
complement completely they do overlap at these key residues.
15
Bam PAP 1 : SB  B KE S B 5 LlB 3£  B k RBr^  GAAEg P A s I  g  S E Q V P Tgp BKggAV : 53
H s a P A P l  : !1H q P r I9.aJ B B B B 9 ' hB J aB B i S S  E ^ B K L G L g ) SVDHHVYEI P B E B q B q R : 5 6
domain A domain B
domain 2
Q71 S  l
Bam PAP 1 : B r e HB kB p B dU H cŒ qaB grm qB pBBvAI J lh E A R flpB H f r c l V ^ l M s  : 108 
H sa P A P l : J l p H HE B S s0 i2 ^ B H jE ''/ s BMATT H L H c,:;HjKGYKGa-BBcRFcBGSBCCVgD : 1 1 1
domain C
domain 3
domain 1
Bam PAP 1 : ffiAAYwBGHpHKRBvEEBKKEHPAAB--BYTraT^raHLBBGLM DEl|RHHPffll : 162
H sa P A P l : S ID B lH DBDAB CKRB TTLM DVSgT i B qdsE rB B B f Tg ---------TgLYQSgG : 162
domain D
Bam PAP 1 : 9 g g JK E B Y iB e Q tB q B sA P S L s9 d H ItQ k B a a X tA A X h B d D IE T G G G E lB  : 2 1 5  
H sa P A P l : | saI1BIW--H  lGBpYNADQBGKALHH-HEE®LDLiE isE G K IN Y C H K j : 2 0 9
domain E
Figure 1.6 Amino acid sequence alignment of /fraPAPl and BamPAPI
Alignment was created using MultAlin with Blosum62-12-2 parameters and edited using GenDoc 
(Section 2.11). Sequence homology is represented by grey scale shading, with black being the highest 
homology. The domains introduced in Figures 1.4 and 1.5 are shown. Several functionally relevant 
residues have been marked in red (numbering applies to Bam?A?\). For amino acid information see 
Appendix D.
Furthermore, these functional residues together with the prokaryotic conserved domains 
are shown on a ribbon diagram of the BamPAP\ monomer (described in more detail in 
Section 1.3.10.2) in Figure 1.7. It can be seen that the conservation is in correlation with 
the catalytic region of itamPAPl.
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Figure 1.7 Location of conserved domains on BamPXPl monomer
The prokaryotic conserved domains introduced in Figure 1.4 are coloured in red on ribbon diagram o f  
BamPAPl monomer. Catalytic residues C ysl44 , H isl68  and Glu81 (Section 1.3.6 and 1.3.10.2) and 
residues PhelO and P hel3 contributing to hydrophobic pocket (Section 1.3.10.2) are shown. For amino 
acid information see Appendix D. Generated using DeepView (Section 2.11).
1.3.7 Catalytic residues of PAP1
The catalytic importance of a cysteine thiol group in PAP1 activity has been 
demonstrated by its absolute requirement for a thiol-reducing agent such as DTT or 2- 
ME. (Armentrout, 1969; Szewczuk and Mulczyk, 1969; Szewczuk and Kwiatkowska, 
1970; Kwiatkowska et al., 1974; Tsuru et al., 1978; Tsuru et al., 1982; Tsuru et al., 
1984; Prasad, 1987; Mantle et al., 1991; Cummins and O’Connor, 1996; Tsunasawa et 
al., 1998; Singleton and Littlechild, 2001, Dando et al., 2003).
Further demonstrating this are the findings that PAP1 activity is highly sensitive to |iM 
concentrations of thiol-blocking compounds such as iodoacetate, iodoacetamide, p- 
chloromercurybenzoate (p-CMB), /?-mercuriphenylsulphonate, TV-ethylmaleimide and 
sodium tetrathionate (Doolittle and Armentrout, 1968; Szewczuk and Mulczyk, 1969; 
Szewczuk and Kwiatkowska, 1970; Mudge and Fellows, 1973; Kwiatkowska et al., 
1974; Prasad and Peterkofsky, 1976; Tsuru et al., 1978; Bauer and Kleinkhauf, 1980; 
Tsuru et al., 1982; Browne and O'Cuinn, 1983; A wade et al., 1992; Gonzales and 
Robert-Baudouy, 1994; Patti et al., 1995; Cummins and O’Connor, 1996; Tsunasawa et 
al., 1998; Mineyama and Saito, 1998; Singleton et al., 2000; Singleton and Littlechild, 
2001; Dando et al., 2003).
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A serine peptidase inhibitor phenylmethylsulphonyl fluoride (PMSF) had no effect on 
the activity of PAP1 (Tsuru et al., 1982; Lauffart et al., 1989; Mantle et al., 1990; 
Gonzales and Robert-Baudouy, 1994; Singleton et al., 2000).
PAP1 being established as a cysteine peptidase, this implicated the presence of a His 
residue as proton donor and perhaps a third acidic residue such as Glu or Asp to 
orientate the imidazolium ring (Section 1.3.2). Site-specific mutagenesis studies were 
conducted to identify the catalytic residues of PAP 1.
The two cysteine residues of Bam?AP\, Cys68 and Cysl44, were mutated to Ser 
(Yoshimoto et al., 1993). The mutant ZtamPAPl_C68mS had wild type activity while 
/tamPAPl_C144mS was completely inactive, implicating Cysl44 as providing the 
active site thiol group. Also, by titration with 5,5'-dithio-bis-(2-nitrobenzoate), it was 
shown that the Cys68 is located internally.
Le Saux et al. (1996) investigated several residues as possible contributors to the active 
site of PflPAP1, based on homology alignments with known PAP1 sequences. 
Substitutions of Cysl44 and His 166 by Ala and Ser, respectively, completely abolished 
activity of P/7PAP1 without affecting protein conformation as shown by gel 
electrophoresis. Similarly, one of Glu81, Asp89 or Asp94 was shown to be a likely third 
member of an active triad of PflPAP 1.
Tsunasawa et al. (1998) substituted the Cysl42 residue of Pfu?A?\ with Ser, resulting 
in loss of activity. In light of published data and by sequence analysis, these authors 
proposed the catalytic triad of Pfu?A?\ to consist of Cysl42, His 166 and Glu79, which 
correspond to Cysl44, Hisl68 and Glu81 of Bam?A?\ respectively. This catalytic triad 
was later confirmed by solution of the tertiary structure of Bam?A?\ and Pfu?A?\ as 
outlined in Section 1.3.10.2.
1.3.8 Substrate specificity of PAP1
Many studies have contributed to an accurate definition of the substrate specificity of 
PAP1 (Doolittle and Armentrout, 1968; Uliana and Doolittle, 1969; Szewczuk and 
Mulczyk, 1969; Armentrout, 1969; Mudge and Fellows, 1973; Kwiatkowska et al., 
1974; Sullivan et al., 1977; Podell and Abraham, 1978; Fujiwara et al., 1979; Tsuru et 
al., 1982; Browne and O’Cuinn, 1983; Lauffart et al., 1989; Mantle et al., 1990; Mantle 
et al., 1991; Cummins and O’Connor, 1996; Mineyama and Saito, 1998; Tsunasawa et 
al., 1998).
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PAP1 can be said to hydrolytically remove L-pGlu from L-pGlu-L-X, where X is any 
amino acid (except proline), a peptide or an arylamide (e.g. AMC). PAP1 exhibits 
specificity toward optical isomers. Pfl?A?\ had no activity toward o-pGlu-L-Ala and 
only slight trace o f activity toward L-pGlu-o-Ala (the latter possibly due to slight 
contamination by L-pGlu-L-Ala). z-D-pGluCK and z-D-pGluDK, optical isomers o f site- 
specific inhibitors mentioned below were inert toward PAP1.
The residue directly adjacent to pGlu affects the rate of hydrolysis. The order of 
preference is: Thr > Glu > Met > Ala > Lys > Gly > Ser > Tyr > Arg > Phe > His > Trp 
> Asp > Leu > He »  Val as determined for Bam?A?\, which is generally in agreement 
with the other PAP Is tested. pGlu-Pro was not hydrolysed by PAP1, with one notable 
exception being Kcl?A?\. However, the hydrolysis of pGlu-Pro by Kcl?A?\ was 
significantly slower than pGlu-Ala or even pGlu-Val.
The size of the peptide substrate does not affect specificity. Pfl?A?\ removed pGlu 
from the relatively large bovine fibrinogen without splitting any other peptide bond. 
Specific cleavage of pGlu from several bioactive peptides including TRH, LHRH, 
Liliberin, Neurotensin and Bombesin was widely demonstrated, as well as for other 
large peptides such as immunoglobulin polypeptide chains.
Synthetic analytical substrates pGlu-/?-NA, pGlu-AMC and pGlu-His-Pro-AMC were 
shown to be hydrolysed at satisfactory rates, CpoPAPl having five times greater affinity 
toward pGlu-AMC than for TRH.
A recent study by Abe et al. (2004) has shown that PAP1 can tolerate some single atom 
substitutions on the pGlu ring (Figure 1.8). PAP1 cleavage was observed for substrates 
having the carbon atom at position 4 of the pGlu moiety of pGlu-Ala replaced with 
sulphur (L-OTCA-L-Ala), oxygen (L-OOCA-L-Ala) and nitrogen (L-OICA-L-Ala). The 
affinities of these substrates to PAP1 were reduced. The carbon atom at position 4 is 
located inside the hydrophobic pocket during binding as shown by Ito et al. (2001), 
described in Section 1.3.10.2. Thus the larger size of a sulphur atom or the hydrophilic 
nature of oxygen or nitrogen compared to carbon might interfere with insertion into the 
hydrophobic pocket. The tolerance of PAP1 for a nitrogen atom substitution had 
previously been reported by Capecchi and Loudon (1984), who also demonstrated that a 
six membered ring was not accepted, highlighting the sensitivity of PAP1 to the ring 
size of pGlu.
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L-pClu l -OTCA l -OOCA L-OICA
Figure 1.8 Substitution analogues of L-pGlu
Synthetic analogues o f  L-pGlu (L-5-oxopyrrolidine-2-carboxylic acid) having the carbon atom at position 
4 replaced by sulphur (L-5-oxothiazolidine-2-carboxylic acid, L-OTCA), oxygen (L-5-oxooxazolidine-2- 
carboxylic acid, L-OOCA) and nitrogen (L-5-oxoim idazolidine-2-carboxylic acid, L-OICA). Illustrated 
using Chem Sketch (Section 2.11).
2-pyrrolidone (Figure 1.9) acts as a competitive reversible inhibitor of PAP1 
(Armentrout and Doolittle, 1969; Armentrout, 1969; Mudge and Fellows, 1973; 
Sullivan et al., 1977; Cummins and O’Connor, 1996). Up to 50% inhibition was 
observed with 10 mM 2-pyrrolidone while complete inhibition was not achieved by 
increased concentration. Activity could be completely restored upon removal of 2- 
pyrrolidone by dialysis. This compares with the inhibitory effect free L-pGlu has on the 
catalysis of other pGlu-substrates (Szewczuk and Mulczyk, 1969; Szewczuk and 
Kwiatkowska, 1970; Tsuru et a l 1978). A synthetic aldehyde analog of pGlu, 5- 
oxoprolinal was also found to be a potent inhibitor of PAP 1 (Friedman et al., 1985). 
Competitive inhibition by these compounds is due to their binding to the PAP1 active 
site instead of the substrate. The similarity in their structures can be seen in Figure 1.9. 
Other structurally similar molecules such as L-proline and L-hydroxyproline (Figure 1.9) 
did not inhibit PAP1 activity (Sullivan et al., 1977). A synthetic TRH analogue having 
pGlu replaced with a sulphonamido analogue (Figure 1.9) was resistant to hydrolysis by 
PAP1 (Brunetti et al., 2002). Ito et al. (2001) have given insight into this specificity by 
showing that together the nitrogen and carbonyl oxygen of the pGlu moiety are 
necessary for hydrogen bond formation within the active site of PAP 1 during catalysis 
(Section 1.3.10.2).
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L-pGlu
H H
2-pyrrolidone 5-oxoproIinaI
H
L -pro line L-hydroxyproline sulphonamido analogue
Figure 1.9 Structural analogues of pGlu
Various structural analogues o f  pGlu. Only those m olecules having a nitrogen at position 1 together with 
a carbonyl oxygen at position 5 can bind into the PAP1 active site. Illustrated using ChemSketch (Section  
2 . 11).
A study using synthetic site-specific inhibitors of PAP 1 (Figure 1.10) was carried out 
(Fujiwara et al., 1981a; 1981b; 1982; Wilk et al.9 1985). These compounds cause rapid 
and complete inhibition of PAP1 activity. That this inhibition was active site-specific 
was demonstrated by prior treatment of PAP 1 with /?-CMB, a thiol-blocking compound 
mentioned in Section 1.3.7. Activity could be completely restored by dialysis with 2- 
ME or DTT containing buffer. Similarly, prior protection of the active site could be 
achieved with pGlu-Val. The rate of inhibition was significantly higher for pGluCK and 
pGluDK than for ZpGluCK and ZpGluDK giving further evidence for the importance of 
the nitrogen and oxygen of the pGlu moiety as mentioned above. Furthermore, the Z-d- 
pGluCK and Z-o-pGluDK optical isomers were inert toward the enzyme due to the 
optical specificity of PAP 1 as mentioned above.
ZpGluCK pGluCK
ZpGluDK pGluDK
Figure 1.10 Active site-directed inhibitors of PAP1
Synthetic active site-directed inhibitors o f  PAP1: L-pGlu chloromethyl ketone (pGluCK), N°- 
carbobenzoxy-L-pGlu chloromethyl ketone (ZpGluCK), L-pGlu diazomethyl ketone (pGluDK) and N a- 
carbobenzoxy-L-pGlu diazomethyl ketone (ZpGluDK). Illustrated using ChemSketch (Section 2.11).
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1.3.9 Characteristics of PAP1
Biochemical studies and characterisation have been carried out on PAP1 enzymes from 
a range of prokaryotic and eukaryotic organisms. Table 1.6 has a summary of the 
reported PAP 1 enzyme characteristics.
The molecular weight of PAP 1 under denaturing and native conditions was determined 
mainly by SDS-PAGE and gel filtration respectively. The subunit size has mostly been 
reported as around 24 kDa, which is in good agreement with the sizes predicted from 
the nucleotide sequences, where available (Tables 1.2 and 1.4). &zwPAPl and 
MjoPAPI were found to be slightly larger, attributed to six additional His residues 
fused to the N-terminal (&zmPAP16h and MwPAPUh, Section 1.3.5). EfaPA?\ and 
5/aPAPl were found to have subunit sizes of around 40 kDa.
The denatured size has been reported for few eukaryotic PAP1 enzymes but considering 
the high similarity in nucleotide sequence length (Tables 1.2 and 1.4) the assumption is 
made that their native sizes reflect monomeric enzymes. The larger native size of 
/tooPAPl and Gga?API, together with the deduced monomeric size of 22.8 kDa for the 
former (Table 1.4) suggests that these enzymes occur in oligomeric form. The 
prokaryotic PAPls seem to be consistently oligomeric.
More than one native size has been reported for Bam?A?\. The 72 kDa size refers to 
the enzyme purified from B. amyloliquefaciens while the size of 51 kDa refers to the 
recombinant enzyme expressed in E. coli. This seems to suggest a difference in 
oligomeric state between wild type and recombinant enzymes. The tertiary structure of 
recombinant Bam?A?\ has been reported as tetrameric (Section 1.3.10.1).
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Table 1.6 Characteristics of various PAPI enzymes
PAPI
(Section 1.3.3)
Denatured
size (Da)
Native 
size (Da)
Optimum
PH
PI Optimum  
Temp. (°C)
Km
(mM)
ttsaPAPl n.d. 24,000 7.0 -  9.5 n.d. 50 0.05 *
BlaPAPi "7 24,000 23,700 8.5 n.d. n.d. 0.015 * ,0 .021b
C/JoPAPI ,7 n.d. 24,000 n.d. n.d. n.d. 0.15 b
OckPAPI " n.d. 33,000 7.5 n.d. n.d. n.d.
Co/PAPl " n.d. 33,000 7.5 n.d. n.d. 0.13 a
ÄnoPAPI 15 n.d. 60,000 8 .0 -8 .4 n.d. n.d. n.d.
GgaPAPl n.d. 86,000 7 .0 -8 .0 5.5 n.d. 0.73 a, 0 .0 4 b
PflPAPI rl5 23,500 41,000 6 .5 -8 .5 4.9 30 0.21 a
äskPAPI rl2 25,200 91,000 6 .8 -7 .5 n.d. n.d. 1.04 a
SpyPAPl rl3 23,500 85,000 7.0 n.d. n.d. 1 .79a
Kc/PAPl a n.d. 74,000 6.0 -  7.5 n.d. n.d. n.d.
EfaPAP\ rl* 40,500 82,000 7.2 -  7.5 4.2 3 5 - 4 5 0.55 a
S/aPAPl r3 42,000 n.d. 7.6 n.d. n.d. 0 .8 6 a
SamPAPl 18,14 24,000 72,000 
or 51,000
oOÓ1o 5.4 45 0.13 a
rap API ,2° 24,000 96,000 7 .0 - 8 .0 n.d. 70 n.d.
PfiiPAPi r” 22,937 96,300 
or 45,643
oo<1©VO n.d. 90 n.d.
SauP A P l« ,'16 30,000 46,000 7.8 n.d. n.d. n.d.
AftoPAPl«, 121 29,000 46,000 n.d. n.d. n.d. n.d.
[n.d. - not determined; a - determined for pGlu-/?-NA; b - determined for pGlu-AMC; r l, Szewczuk and 
Kwiatkowska, 1970; r2, Kwiatkowska et al., 1974; r3, Sullivan et al., 1977; r4, Tsuru et al., 1978; r5, 
Busby et al., 1982; r6, Tsuru et al., 1982; r7, Browne and O’Cuinn, 1983; r8, Tsuru et al., 1984; r9, 
Lauffart and Mantle, 1988; rlO Lauffart et al., 1989; r l l ,  Mantle et al., 1991; rl2, Gonzales and Awad6, 
1992; rl3 , A wade et al., 1992; rl4 , Yoshimoto et al., 1993; rl5 , Gonzales and Robert-Baudouy, 1994; 
rl6 , Patti et al., 1995; rl7 , Cummins and O’Connor, 1996; rl8 , Mineyama and Saito, 1998; rl9 , 
Tsunasawa et al., 1998; r20, Singleton et al., 2000; r21, Kim et al., 2001; r22, Dando et al. 2003]
The two native sizes reported for Pfu?A?\ result from two separate methods for their 
determination. The 96.3 kDa size was determined by analytical ultracentrifugation while 
the 45.6 kDa size was determined by ionspray mass spectrometry. This variation in the 
determination of native size needs to be reflected on regarding all the native size data in 
this section. The tertiary structure of recombinant Pfu?AP\ has been reported as 
tetrameric (Section 1.3.10.1).
The optimal activity for all PAP Is falls into the pH range 6.0 to 9.5, with a mean of 7.5. 
The isoelectric point (pi), where reported, is around 5.0. The physiological temperature 
of 37°C has been widely used as the standard reaction temperature for analysis of 
eukaryotic PAP1. The optimum temperature for activity for mesophilic prokaryotic 
PAP1 has been reported ranging from 30 to 45°C. The two thermophilic enzymes 
77/PAP 1 and Pfu?A?\ exhibit optimum activity at 70 and 90°C respectively. The 
contribution of intersubunit disulphide bridges toward high thermostability is discussed 
in Section 1.3.10.1
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As well as the inhibitory effects of thiol blocking compounds and pGlu analogues 
metioned in section 1.3.8, the inhibition of PAP 1 by many cations such as Hg2+, Zn2+, 
Cu2+, Co2+, Ca2+, Mn2+, Mg2+, Ni2+, Ba2+, Sr2* and Cd2+ has been demonstrated 
(Szewczuk and Mulczyk, 1969; Albert and Szewczuk, 1972; Szewczuk and 
Kwiatkowska, 1974; Kwiatkowska et al., 1974; Prasad and Peterkofsky, 1976; Tsuru et 
al., 1978; Mantle et al., 1991; Awade et al., 1992; Bharadwaj et al., 1992; Patti et al., 
1995; Cummins and O’Connor, 1996; Mineyama and Saito, 1998; Tsunasawa et al.,
1998; Dando et al., 2003).
Two compounds of low anti-microbial value, benarthin and pyrizinostatin, isolated from 
the genus Streptomyces, were found to be inhibitors of BtaPAPX (Aoyagi et al., 1992a; 
Aoyagi et al., 1992b). Also, the inhibitory effect of an oligosaccharide gum from Hakea 
gibbosa on BtaPAP\ activity was reported (Alur et al., 2001).
1.3.10 Structure of PAP1
Recently the three-dimensional structures of four prokaryotic PAP1 enzymes were 
solved using X-ray crystallography. These four structures; for the mesophilic BamPAPX 
(Odagaki et al., 1999) and the thermophillic 77/PAP 1 (Singleton et al., 1999a; 1999b), 
PfuPAP\ (Tanaka et al., 2001) and PhoPAPX (Sokabe et al., 2002) have been deposited 
in the Protein Data Bank (Section 2.11) as structural coordinate files [1 AUG], [1A2Z], 
[1IOF] and [11U8] respectively. Crystals were obtained using the hanging drop vapour- 
diffusion method such as described in Section 2.19.7. The crystals diffracted to a 
resolution of 2.0, 1.73, 2.2 and 1.6 A for BamPAPX, TliPAPX, PfuPAPX and PhoPAPX 
respectively.
1.3.10.1 Quaternary structure of PAP1
The crystal structures of BamPAPX, 77/PAP 1, PfuPAPX and PhoPAPX each have a 
tetrameric arrangement comprising of four identical subunits designated A to D (Figure
1.11). Each monomer of the tetramer makes contact with two other subunit monomers. 
These interfaces are named by using subunit A as a reference. The tetramers are 
approximately 80 A along each side as indicated in Figure 1.11, with the monomers 
being approximately 50 A at the longest axis.
The A-D interface of BamPAPX is illustrated in Figure 1.12. This interaction exists by 
burying 1427 A2 of hydrophobic surface from the surrounding medium, as well as 
having several ionic salt bridges, between each monomer. The A-C interaction (Figure
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1.13) buries 1355 A2 of hydrophobic surface. It does not feature any ionic salt bridges 
and a thin layer of water mediates hydrogen bonds between the subunits. Conflicting 
values for native size of BamPAPX (Section 1.3.9) suggests that one of the above 
interactions may be dominant in solution and the tetrameric form of BamPAPX may 
therefore be an artefact of crystallisation. If this is the case, the extensive A-D 
interaction is more likely to be found in solution.
The 77/PAP 1 tetramer has a central cavity of 6000 A3, which is partially filled by a core 
structure comprised of loops from each subunit. This core structure is maintained by 
hydrophobic interactions involving Phel79, Phel80, Leul81 and Leu 182 of each 
subunit (Figure 1.14). This FFLL motif represents a notable variation from other PAP1 
sequences (Figure 1.23). This hydrophobic core may contribute towards the 
thermostability of 77/PAP 1. The A-B interface has hydrophobic interactions and also 
salt bridges involving Arg81, Asp88, AsplOl and Argll9 (Figure 1.15). The A-C 
interface is formed by an extended loop which folds towards the core structure. A 
disulphide bridge exists between Cysl90 of each monomer (Figure 1.16). Other 
residues along this interface are generally hydrophobic.
The A-C interface of PfuPAPX consists mostly of hydrophobic interactions and no ionic 
interactions are present. The A-D interface consists of both hydrophobic interactions 
and 10 ionic bonds (Figure 1.17).
The A-B interface of the PhoPAPX tetramer has inter-subunit ion bonds and 
hydrophobic interactions (Figure 1.18). The A-C interface of PhoPAPX features 
hydrogen bonds that are entirely mediated by a thin layer of water (not shown). Gel 
filtration suggests that PhoPAPX is a dimer in solution. This dimer is more than likely 
the A-B variation since this interface is more closely held.
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Barn I’AIM 77/PAP1
PfuPAP\ PhoPAPi
Figure 1.11 Tetrameric arrangement of PAP1.
Ribbon diagrams o f  the tetrameric crystal structures o f  ZtamPAPl, 77/PAP 1, PJu?A?\ and Pho?A?\. The 
monomeric subunits are labelled A to D and individually coloured. To give an idea o f  size, the distance o f  
80 A has been indicated for Bam?API. Generated using Deep V iew (Section 2.11).
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Figure 1.12 The A-D interface of BamFXFl.
Ribbon diagram o f  the A-D  interface o f  BamPAPX. The same subunit colour coding as in Figure 1.11 
applies. (1): Residues Ile85, Asn86, Leu87, A lai 11, A lai 12, Trpl 14, T yrl37, T hrl38 and Thrl41 o f  each 
monomer contributing to hydrophobic interactions are shown. Only the residues from subunit A have 
been labelled. (2): Residues Arg82, Glu89 and L ysl20  o f  each monomer involved in ionic interactions are 
shown. For amino acid information see Appendix D. Generated using DeepView (Section 2.11).
Figure 1.13 The A-C interface of Bam?API
Ribbon diagram o f  the A-C interface o f  BamPAPX. The same subunit colour coding as in Figure 1.11 
applies. Residues M et76, I le l31 , Prol32, Prol73, T hrl76, L eu l77 , A la i81, Prol82 and H is l88 
contributing to hydrophobic interactions are shown. Only the residues from subunit A have been labelled. 
For amino acid information see Appendix D. Generated using DeepView (Section 2.11).
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Figure 1.14 Core structure of 77/PAP 1
Ribbon diagram o f  the core structure o f  77/PAP 1. The same subunit colour coding as in Figure 1.11 
applies. The residues P hel79 , P hel80 , Leul81 and L eu l82  involved in the hydrophobic core are shown. 
Only the residues from subunit A have been labelled. For amino acid information see Appendix D. 
Generated using Deep View (Section 2.11).
Figure 1.15 The A-B interface of 77/PAP1
Ribbon diagram o f the A-B interface o f  77/PAP 1. The same subunit colour coding as in Figure 1.11 
applies. Residues involved in ionic interactions are shown. For amino acid information see Appendix D. 
Generated using DeepView (Section 2.11).
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Figure 1.16 The A-C interface of 77/P API
Ribbon diagram o f  the A-C interface o f  77ÎPAP1. The same subunit colour coding as in Figure 1.11 
applies. The disulphide bridge is shown and coloured by CPK colour schem e (C = white, O = red, N = 
blue and S = yellow ). For amino acid information see Appendix D. Generated using DeepView (Section  
2. 11).
Figure 1.17 The A-D interface of/yiiPAPl
Ribbon diagram o f  the A-D  interface o f  PfuPAPX. The same subunit colour coding as in Figure 1.11 
applies. (1): Residues contributing to hydrophobic interactions are shown. Only the residues from subunit 
A have been labelled. (2): Residues Arg80, Asp87, Glu99, AsplOO and L ysl 18 involved in ionic 
interactions are shown. For amino acid information see Appendix D. Generated using DeepView (Section
2 . 11).
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Figure 1.18 The A-B interface of Pho?API
Ribbon diagram o f  the A-B interface o f  PhoPAPX. The same subunit colour coding as in Figure 1.11 
applies. (1): Residues Val78, Val80, Met82, A la l06 , A la l07 , P hel09 , V a ll29  and L eu l30  contributing to 
hydrophobic interactions are shown. Only the residues from subunit A have been labelled. (2): Residues 
Arg77, Asp84, Asp97, A r g ll5  and T yrl32  involved in ionic interactions are shown. For amino acid 
information see Appendix D. Generated using Deep View (Section 2.11).
1.3.10.2 Monomeric structure of PAP1
The subunit monomers ofZtamPAPl, 77/PAP 1, PfuPAPl and PhoPAP\ (Figures 1.19 to 
1.22 respectively) each fold into single a/p globular domains. The active site is located 
within each monomer and faces toward the central channel of the tetrameric structure 
(Figure 1.11). This type of arrangement has previously been described for human p- 
tryptase (Pereira et al., 1998), which is active only in the tetrameric form.
The active site area of each monomer has a central p-sheet surround Id by a-helices. The 
catalytic cysteine is located at the N terminus of an a-helix. It has been speculated that 
the position of an active site nucleophile at the N-terminus of an a-helix can be 
important for catalysis as the helix dipole polarises the amide bond, enhancing reactivity 
(Doran and Carey, 1996). The sulfhydryl side-chain of this cysteine forms a hydrogen 
bond with the imidazolium ring of a histidine located on the p-sheet. The imidazolium 
ring is orientated/stabilised by a hydrogen bond to a glutamic acid residue, which is the 
third member of the Cys-His-Glu catalytic triad. A unique feature of PhoPAPX is that 
the side-chain NH of Arg70 is hydrogen bonded to the triad Glu76 backbone oxygen, 
which in turn bonds to the Hisl63 imidazole ring (Figure 1.22).
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can 175
Figure 1.19 Subunit monomer of BamŸAPI with detail of active site region
Ribbon diagram o f the subunit monomer o f  Bam ?A?\. The entire monomer is shown on the left. On the 
right is a detail o f  the active site region. Residues PhelO, Phe 13, Thr45, Gln71, Ile92, P hel42  and 
V all43  contributing to the hydrophobic pocket are coloured blue. The side-chain o f Gln71 is oriented by 
hydrogen bonding to Gin 175. The catalytic triad is coloured by CPK colour scheme (C = white, O = red, 
N = blue and S = yellow). For amino acid information see Appendix D. Generated using DeepView  
(Section 2.11).
Figure 1.20 Subunit monomer of TliPAPI highlighting active site
Ribbon diagram o f  the subunit monomer o f  77/PAP 1. Residues contributing to the hydrophobic pocket are 
coloured blue w hile the catalytic triad is coloured by CPK colour schem e (C = white, O = red, N  = blue 
and S = yellow). For amino acid information see Appendix D. Generated using DeepView (Section 2.11).
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Figure 1.21 Subunit monomer of PfuPAVi highlighting active site
Ribbon diagram o f the subunit monomer o f  PfuPAPl. Residues contributing to the hydrophobic pocket 
are coloured blue while the catalytic triad is coloured by CPK colour schem e (C = white, O = red, N = 
blue and S = yellow ). For amino acid information see Appendix D. Generated using DeepView (Section  
2 . 11).
Figure 1.22 Subunit monomer of PhoPAPl highlighting active site
Ribbon diagram o f the subunit monomer o f  PhoP A PI. Residues contributing to the hydrophobic pocket 
are coloured blue w hile residues involved in catalysis are coloured by CPK colour scheme (C = white, O 
= red, N = blue and S = yellow). For amino acid information see Appendix D. Generated using DeepView  
(Section 2.11 ).
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In Bam?A?\ a hydrophobic pocket comprising PhelO, Phel3, Thr45, Gln71, Ile92, 
Phel42 and Vail43 is found close to the catalytic triad (Figure 1.19). With the 
exception of Thr45 and Gln71 these residues are conserved or conservatively 
substituted in 77/PAP 1, PfuPA?\ and PhoPAPl (Figure 1.23) and similarly located in 
the active site region (Figures 1.19 to 1.22). The feasibility of this BamPAPl binding 
pocket was investigated by manually placing a pGlu-His model into the pocket 
(Odagaki et al., 1999) using molecular dynamics simulation software (not shown). In 
this simulation, two methylene carbon atoms of the pGlu pyrrolidone ring point inward 
to the hydrophiobic pocket. The pyrrolidone ring itself is held between the aromatic ring 
of Phel3 and the methylene chain of Gln71 while the ring carbonyl points away from 
the pocket. The pGlu main chain carbonyl, the His imidazole nitrogen and the C- 
terminal oxygen of the model form hydrogen bonds within the pocket. There does not 
appear to be any other clearly defined specificity pocket, supporting that PAP1 is not 
selective for residues in the second position.
Bam PA Pl : 
T l iP A P l  : 
P fu P A P l : 
P h o P A P l :
B am PA Pl : 
T l iP A P l  : 
P fu P A P l : 
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domain 2
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Figure 1.23 Amino acid alignment of B am PAPl, 77ÎPAP1, PfuPAPl and PhoPAPl
Alignment was created using MultAlin with B losum 62-12-2 parameters and edited using GenDoc 
(Section 2.11). Sequence homology is represented by grey scale shading, with black being the highest 
homology. The domains introduced in Figure 1.4 are shown. Several functionally relevant residues have 
been marked in red. The FFLL domain specific to 77/PAP 1 is boxed in red (numbering applies to 
BamPAPl). For amino acid information see Appendix D.
The Mechanism of substrate recognition was observed (Ito et al., 2001) by X-ray 
crystallography of the substrate-inhibitor complex of BamPAPl and aldehyde pGlu 
analog 5-oxoprolinal (Figure 1.9). The resulting structure data reveals direct interaction 
of the pyroglutaminal with Cysl44. Two hydrogen bonds are observed between the 
enzyme and the pyrrolidone ring carbonyl and nitrogen of 5-oxoprolinal. These
33
orientate the molecule for nucleophillic attack by Cysl44. Van der Waals interaction 
between the pyrrolidone ring and the hydrophobic pocket contribute also. By comparing 
the wild type enzyme structure with the substrate-inhibitor complex a particularly large 
movement of the Phel3 and Gln71 is observed, acting as an induced fit mechanism. 
While Phel3 is conserved throughout species (Figures 1.4, 1.5, 1.6 and 1.23) Gln71 is 
substituted with leucine in some prokaryotes and valine in eukaryotes. The benzene 
rings of PhelO, Phel3 and Phel42 are almost parallel with the 5-oxoprolinal 
pyrrolidone ring.
As mentioned in Section 1.3.6, no sequence homology is observed with proteins other 
than PAP Is from different organisms. However, an alignment of protein structure 
distance matrices (Odagaki et al., 1999) shows close structural identity with E. coli 
purine nucleoside phosphorylase (ZscoPNP, Figure 1.24). Several structural domains that 
have very similar orientation are represented by colouration. These domains also have 
the same order in the primary sequence. The catalytic domains of the two proteins, 
however, are orientated very differently (not shown). This structural similarity was also 
reported for 77/PAP 1 (Singleton et al., 1999).
Figure 1.24 Structural comparison of BamPAPl with ZscoPNP
Ribbon diagram comparison o f ZtamPAPl (A) and £coPNP (B). Regions o f structural similarity are 
indicated by colouration. Generated using DeepView (Section 2.11).
A similar structural homology is observed with cutinase from Fusarium solani (Odagaki 
et al., 1999), having a catalytic triad Serl20, Hisl88 and Aspl75. Serl20 is in a similar 
position as Cysl44 in PAP1. However, the linear order of the catalytic triad in cutinase 
is Ser-Asp-His as opposed to Glu-Cys-His in PAP1. As discussed by Murzin (1993) the
34
natural evolution of enzymes can lead to new catalytic functions. A new catalytic active 
site can form on the existing protein scaffold in which case the positions of the active 
sites will have no similarity. Alternatively, the existing active site can transform to a 
new catalytic function.
1.3.11 Mutational analysis of PAP1 structure and function
In addition to the mutational analysis carried out to determine the catalytic triad 
(Section 1.3.7), several studies have used site-specific mutagenesis to probe the 
relationship between structure and function of PAP 1.
The three Bam?API residues PhelO, Phel3 and Phel42 contributing to the hydrophobic 
pocket (Section 1.3.10.2) were mutated to Tyr and Ala (Ito et al., 2001). 
ZtamPAPl_F13mY and ¿to/wPAPl_F142mY had kinetic parameters similar to the wild 
type. The Km for TtamPAPlFlOmY was 3.6-fold higher than wild type. The catalytic 
efficiency of both itamPAPl_F13mA and BamPAPI F 142mA decreased more then 
1000-fold while TtamPAPlFlOmA seemed to undergo severe structural change and 
could not be purified. PhelO plays an essential role in the hydrophobic pocket of 
Bam?AP\.
The high thermal stability of 77/PAP 1 (Section 1.3.9) has been attributed to the inter­
subunit disulphide bond formed by Cysl90 (Figure 1.16), which reduces denaturation 
entropy (Singleton et al., 1999). By sequence alignment (Figure 1.23) this residue 
corresponds to Cysl88 in PfuPAPX, Seri81 in PhoPAP\ and Serl85 in BamPAPX. 
Cysl88 of PfuPAPX is located at a similar position to Cysl90 in 77/PAP1 but PfuPAPX 
does not exhibit a disulphide bridge in the crystal structure. However, a disulphide 
bridge in PfuPAPX involving Cysl88 has been shown by differential scanning 
colourimetry (Ogasahara et al., 2001). The denaturation temperature was 10°C higher in 
the presence of this disulphide bridge as shown by comparison with a mutant having 
both Cysl42 and Cysl88 changed to Ser (7ywPAPl_C142,C188mS). PhoPAPX does not 
feature a hydrophobic tetramer core as seen in 77/PAP 1 or a disulphide bridge as seen in 
PfuPAPX and 77/PAP1. The thermostability of PhoAPX owes to other interactions and 
optimal folding conformation (Sokabe et al., 2002).
To investigate the possibility of enhancing the thermal stability of BamPAPX, Seri85 
was changed to Cys by site-specific mutagenesis (/tawPAPl_C185mS, Kabashima et 
al., 2001). By analysing ZtawPAPl_C185mS by SDS-PAGE with and without 2-ME, it 
was confirmed that a disulphide bond had been formed. The mutation did not affect
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catalytic efficiency but thermal stability was increased by 30°C. However, under 
conditions of 1 mM DTT no difference in thermal stability was determined. Therefore, 
the enhanced thermal stability was attributed to the disulphide bond.
The thermal stability of Pfu?A?\ is very high compared to Bam?A?\ and slightly 
higher than for 77/PAP 1 (Section 1.3.9). Comparatively, Pfu?A?\ has more extensive 
ion pairing and more compact hydrophobic interactions than 77/PAP 1 and in turn 
BamPAPX. By stability profiling it was determined that the high stability of TywPAPl is 
due to increased hydrophobic interaction and ion-pairs as well as an improvement of the 
overall conformation (Ogasahara et al., 2001). The conformational structure is superior 
in the combination of positive and negative factors for stabilisation. The denaturation 
temperature of monomeric PfuPAPX at pH 2.5 (at which BamPAPX was completely 
denatured) was similar to that of tetrameric BamPAPX at pH 9.0 indicating that the 
subunit monomer of PfuPAPX has intrinsic enhanced stability. The comparative 
guanidine hydrochloride-induced unfolding and refolding of /ywPAPl_C142,C188mS 
and BamPAPX was carried out using circular dichroism (CD) measurement at 220 nm 
(Ogashara et al., 1998). The rate of unfolding for /ywPAPl_C142,C188mS was seven 
orders of magnitude slower compared to BamPAPX while the refolding rates were 
similar. This slow unfolding rate is a characteristic of the greater stability of Pfu?AP\ .
1.4 PAP2
The Enzyme Commission list (Section 1.3.2) classifies PAP2 as an omega peptidase 
(EC 3.4.19.6). In the alternative MEROPS database (Section 1.3.2) PAP2 has been 
assigned under metallopeptidase clan MA, family Ml. Metallopeptidases are hydrolases 
where the nucleophilic attack is mediated by a water molecule activated by a divalent 
metal cation (Barrett et al., 199). The metal ion (usually zinc) is held in place by three 
amino acid ligands.
The metallopeptidase PAP2, originally purified from the synaptosomal membranes of 
mammalian brain (O'Connor and O'Cuinn, 1984), has been comprehensively reviewed 
(Cummins and O’Connor, 1998; Barrett et al., 1998). In summary, PAP2 is primarily 
located in the mammalian central nervous system with significantly smaller levels 
observed in other tissues. It appears to be associated exclusively with neurons, 
presumably on postsynaptic membranes. It has an absolute specificity toward TRH 
(Section 1.2). Some very closely related peptides (tripeptides, tripeptide amides and 
tetrapeptides commencing with pGlu-His) are also hydrolysed, albeit at a considerably
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reduced rate. This high specificity has resulted in postulation that membrane anchored 
PAP2 is responsible for selectively inactivating neuronally released TRH within the 
extracellular vicinity of target cells, thus defining it as a “neuropeptide-specific 
peptidase”. PAP2 was found to have its active site directed toward the extracellular 
space where TRH would be located when involved in neurotransmission. Inhibition of 
PAP2 specifically increases recovery of TRH released from brain tissue. PAP2 has a 
broad pH optimum in the neutral range and is sensitive to metal chelators such as 
EDTA. It exhibits no sensitivity to sulphydryl-blocking agents or pGluDK, an active 
site directed inhibitor of PAP 1 (Section 1.3.8). PAP2 has a large relative molecular 
mass of 230 kDa and was shown to be composed of two identical 116 kDa subunits, a 
dimeric structure common for membrane anchored ectoenzymes.
The genes for rat and human PAP2 were cloned (Schauder et al. 1994; Schomburg et 
al., 1999). The deduced highly homologous amino acid sequences are consistent with a 
glycosylated, membrane anchored peptidase. The extracellular domain of PAP2 
contains the HEXXH + E motif which is consistent with zinc-dependent 
metallopeptidases where the three zinc ligands (mentioned above) are the two His 
residues and the Glu residue C-terminal to the HEXXH motif.
A serum form of PAP2 of liver origin has been reported, which has the same degree of 
specificity for TRH and identical biochemical characteristics as the membrane-bound 
form (Cummins and O’Connor, 1998). A recent study (Schmitmeier et al., 2002) has 
supported the hypothesis that both forms of PAP2 are derived from the same gene, 
whereby the serum enzyme is generated by proteolytic cleavage of the membrane- 
bound form in the liver.
1.5 Project aims & objectives
The opening objective of this research project was to clone the gene for human PAP1. 
The putative human PAP1 sequence (Hsa-papl, Table 1.4), which became available on 
GenBank as this work began, would provide a suitable starting point for the design of 
oligonucleotide primers to be used in a PCR-based strategy for the amplification of the 
gene from human RNA.
Upon cloning of the gene the project would focus on the development of an expression 
system, capable of producing catalytically active recombinant human PAP1, which had 
heretofore not been reported. If expression of active recombinant human PAP1 was 
possible in a prokaryotic system, this would enable the rapid production of large
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quantities of the enzyme. Alternatively, a mammalian or yeast-based expression system 
would be explored.
Following successful expression of the recombinant enzyme, a strategy would be 
developed to yield highly purified protein. This could be achieved by conventional 
methodology combining ammonium sulphate fractionation, gel filtration, anion 
exchange, hydrophobic interaction and thio 1-affinity chromatography. An alternative 
option is to make use of a recombinant fusion protein tagging system, enabling one-step 
affinity-tag purification. Both of these approaches have been previously reported for 
other PAP1 enzymes, as described in Section 1.3.5.
The availability of purified recombinant human PAP1 would allow a series of detailed 
molecular, biochemical and kinetic studies to be carried out.
Finally, using the recombinant PAP1 expression system, a series of site-specific 
mutagenesis experiments would be carried out, giving valuable insight into the catalytic 
and structural properties of human PAP1 and opening the way for the design of 
inhibitors and pharmacological agents. Such studies would significantly add to the 
growing amount of published data on PAP1 and represent the first detailed study of the 
human form of this unique enzyme.
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2.0 Materials & Methods
2.1 Bacterial strains, primers and plasmids
The bacterial strains, primers and plasmids used in this work are listed in Tables 2.1, 2.2 
and 2.3 respectively.
Table 2.1 Bacterial strains
Strain Genotype Features/Uses Source
Escherichia coli
DH5a F' endA 1 ree A 1 rei A 1 gyrA 96 supE 44 thi-1 
hsdR\7(rK., mK+) 080/acZAM 15 A (laeZYA- 
argF)U169 deoR phoA X
High transformation efficiency Bethesda 
Research Labs
INVaF' F' endA 1 ree A 1 relA 1 gyr A 96 supE44 thi-1 
hsdR\l(rK., mK+) (P80/acZAM15 A (lacZYA- 
argF) U169
High transformation efficiency Invitrogen
XL-10 Gold A(/wcrA)183 A(/wcrCB-/wdSMR-mrr)173 
endA] recA\ relAX gyrA96 supE44 thi-1 lac Hte 
[F' pro AB /acIqZAM 15 ::TnlO(tefR) Amy (camR)]
High transformation efficiency 
Antibiotic resistance 
Expression host
Stratagene
BL21 F" dem ompT /w¿/SB(rB., mB.) gal Protease deficient 
Negative control for Rosetta
No vagen
Rosetta ¥' dem ompT /?sdSB(rB_, mB.)
pRARE[argU argW ileX glyT leuW proL (camR)]
BL21 with pRARE plasmid 
tRNAs for rare codons 
Antibiotic resistance
Novagen
Nova Blue F[proAB lac\qZ m \ 5  ::TnlO(TetR)] endA\ recAX 
rei AX gyr A96 supE44 thi-1 /?S£/R17(rKi2->rciKi2+) lac
Antibiotic resistance 
Expression host 
Negative control for Rosetta 
Blue
Novagen
Rosetta Blue ¥'[proAB /flcIqZAM15 ::TnlO(TetR)] endAX recAX 
relAX gyrA96 supE44 thi-1 /?5i/R17(rKi2-,mKi2+) lac 
pRARE[argU argW ileX glyT leuW proL (camR)]
NovaBlue with pRARE 
plasmid
tRNAs for rare codons 
Antibiotic resistance
Novagen
Table 2.2 Primers (obtained from MWG-Biotech AG)
Name Sequence
(5’ - 3 ’)
Tm
(°C)
Cloning/Analysis
PAPHsA AACAGAAGCAGGTCCGAGG 58.8
PAPHsB CAGGATGAGGTCTTAGGAGA 57.3
PAPHsF ATGGAGCAGCCGAGGAAGGCG 65.7
PAPHsG GAGCGTCCCTCAGTGTTTGTGGC 66
PAPHsH GCCATGGAGCAGCCGAGGAAG 65.7
PAPHsI GGATCCGTGTTTGTGGCAATAGTTGATTTTGCC 61.9
PAPHsK CACACAGGAAACAGAATTCATTAAAG 58.5
PAPHsL CGCGGATCCTTAGTGTTTGTGGCAATAGTTGATTTTG 58.1
PAPHsM ATGGAGCAGCCGAGGAAGGCG 65.7
PAPHsN GTGTTTGTGGCAATAGTTGATTTTGCCC 63.7
PAPHsR CGCGGATCCTTACTCTGACTGCTCCAGGAGGTCC 65.8
PAPHsS CCGCCAA AACAG AAGCTT AGTG ATGG 64.8
PAPHsT CGCGGATCCCTCTGACTGCTCCAGGAGGTCC 65.9
Amp-for GAGTATTCAACATTTCCGTGTCGC 61
Amp-rev CCAATGCTTAATCAGTGAGGCAC 60.7
pKK-testA GTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCG 77.9
Non-binding tags are in bold type. Restriction sites are underlined. 
Tm takes into account only those bases that bind.
Tm = [69.3 + 0.41(%GC)] -  650/length
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Mutagenesis
PAPmR5K6-f CCATGGAGCAGCCGCGTAAAGCGGTGGTAGTGAC 78.2
PAPmR5K6-r GTCACTACCACCGCTTTACGCGGCTGCTCCATGG 78.2
PAPmR5a-f CCATGGAGCAGCCGCGCAAGGCGGTGGTAGTGAC 83.5
PAPmR5a-r GTCACTACCACCGCCTTGCGCGGCTGCTCCATGG 83.5
PAPmR5b-f CCATGGAGCAGCCGCGTAAGGCGGTGGTAGTGAC 82.3
PAPmR5b-r GTCACTACCACCGCCTTACGCGGCTGCTCCATGG 82.3
PAPmF13W-f GTAGTGACGGGATGGGGCCCTTTTGGGGAAC 78.4
PAPmF13W-r
ApaX
GTTCCCCAAAAGGGCCCCATCCCGTCACTAC 78.4
PAPmF13Y-f
Apa\
GTGACGGGATATGGCCCTTTTGGCGAACACACCG 79.9
PAPmF13Y-r
BglX
CGGTGTGTTCGCCAAAAGGGCCATATCCCGTCAC 79.9
PAPmF13L-f
BglX
GT AGTGACGGGATT GGGCCCTTTT GGGG A AC 80.3
PAPmF13L-r
ApaX
GTTCCCCAAAAGGGCCCAATCCCGTCACTAC 80.3
PAPmF13L_F16L-f
Apa\
G AC GGG ATT GGGCCCTTT GGGGGAAC AC AC 78.3
PAPmF13L_F16L-r
ApaX
GTGTGTTCCCCCAAAGGGCCCAATCCCGTC 78.3
PAPmF16Y-f
Apa\
GGATTTGGCCCTTATGGCGAACACACCGTGAACG 78.7
PAPmF16Y-r
BglX
CGTTCACGGTGTGTTCGCCATAAGGGCCAAATCC 78.7
PAPmF16L-f
BglX
GTGACGGGATTTGGCCCTCTGGGCGAACACACCGTGAAC 81.7
PAPmF16L-r
BglX
GTTCACGGTGTGTTCGCCCAGAGGGCCAAATCCCGTCAC 81.7
PAPmD97E-f
BglX
GGGCTGGAGAACTGCCGCTTTTGCCCCGGATCCCAGTGC
Bam HI
86.4
PAPmD97E-r GCACTGGGATCCGGGGCAAAAGCGGCAGTTCTCCAGCCC 
Bam HI
86.4
PAPmN98V-f GGGCTGGACGTCTGCCGCTTTTGCCCCGGATCCCAGTGC
BamHX
84.9
PAPmN98V-r GCACTGGGATCCGGGGCAAAAGCGGCAGACGTCCAGCCC
BamHX
84.9
PAPmN98Q-f GGGCTGGACCAGTGCCGCTTTTGCCCCGGATCCCAGTGC
BamHX
84.9
PAPmN98Q-r GCACTGGGATCCGGGGCAAAAGCGGCACTGGTCCAGCCC
BamHX
84.9
PAPmSIDl 15AYF-f GCGTGGAGGACGGGCCTGAGGCCTATTTCTCCATCATCGACATGGATGC
StuX
77.7
PAPmSIDl 15AYF-r GCATCCATGTCGATGATGGAGAAATAGGCCTCAGGCCCGTCCTCCACGC
Stu\
77.7
PAPmDl 17+GGG-f GGC C T GA A AGC ATT G AC GGC GGC GGATCC ATC ATCG AC AT GG AT G
BamHX
70.2
PAPmD 117+GGG-r CATCCATGTCGATGATGGATCCGCCGCCGTCAATGCTTTCAGGCC
BamHX
70.2
PAPmI120G-f GCCTGAAAGCATTGACTCGATCGGCGACATGGATGCTGTGTGC
Pvwl
81.7
PAPmI120G-r GCACACAGCATCCATGTCGCCGATCGAGTCAATGCTTTCAGGC
Pvu 1
81.7
PAPmY147F-f GCAGGATGCCGGCAGATTTCTCTGCGACTTTACCTAC 82.7
PAPmY147F-r GTAGGTAAAGTCGCAGAGAAATCTGCCGGCATCCTGC 82.7
PAPmC149W-f GATGCCGGCAGATACCTCTGGGACTTTACCTACTACAC 80.1
PAPmC149W-r GTGTAGTAGGTAAAGTCCCAGAGGTATCTGCCGGCATC 80.1
PAPmH168D-f CGGTCGATCGGCCTTCGTCGACGTGCCC
P v m I
79.5
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PAPmH168D-r GGGCACGTCGACGAAGGCCGATCGACCG 79.5
Pvu 1
PAPmQ180E-f CGTACAACGCGGACGAGCTCGGCAGGGCACTG 82.3
Sac\
PAPmQ180E-r CAGTGCCCTGCCGAGCTCGTCCGCGTTGTACG 82.3
Sacl
Mutation-inducing mismatches are in bold type.
Diagnostic restriction sites are underlined.
Tm = [81.5 + 0.41(%GC)] -  675/length - % mismatch
Sequencing
M13rev(-29) CAGGAAACAGCTATGACC (pCR2.1 forward primer, MWG-Biotech)
M13uni(-21) TGT AAAACGACGGCCAGT (pCR2.1 reverse primer, MWG-Biotech)
PQEfor GT ATCACGAGGCCCTTTCGTCT (pQE-60 forward primer, MWG-Biotech)
PQErev CATTACTGGATCTATCAACAGGAG (pQE-60 reverse primer, MWG-Biotech)
PTrcHisrev CTTCTGCGTTCTGATTTAATCTG (pPC225 forward primer, MWG-Biotech)
M13rev(-49) G AGCGG AT AAC AATTTC AC AC AGG (pPC225 reverse primer, MWG-Biotech)
pKK-for CGGCTCGTATAATGTGTGG (pPC225 forward primer, Qiagen)
pKK-rev GAAAATCTTCTCTCATCCGCC (pPC225 reverse primer, Qiagen)
Table 2.3 Plasmids
Plasmid Description Source
Vectors
pCR2.1 TA cloning vector: Plac, ampR, kanR, lacZa, ColEl origin. 
Figure 2.1
Invitrogen
pQE-60 Expression vector: T5 promoter//oc operon, ampR, 6xHis 
sequence at 3 ’ end of MCS, ColEl origin. Figure 2.2
Qiagen
pPC223 Modified derivative o f  pKK223-3 expression vector from 
Amersham Pharmacia: Ptac, ampR, ColEl origin. Elimination of  
BamHl site external to MCS
Clarke (2000)
pPC225 Modified derivative o f pPC223. Insertion of 1800 bp fragment in 
BamHl o f MCS for ease o f cloning. Figure 2.3
Clarke (2000)
pRARE Plasmid carrying genes for tRNAs that recognise codons 
considered rare in E. coli: ileX (AUA), argU (AGG/AGA), 
argW (AGG), glyT (GGA), /ewW (CUA) and proL (CCC). 
camR, p i5a origin. Figure 2.4
No vagen
pUC18 Cloning vector: Plac, ampR, lacZa, ColEl origin. Amersham
Pharmacia
Constructs
pRVl pCR2.1 containing PAP1 ORF This Work
pRV3 pQE-60 containing PAP1 ORF with 3 ’ 6xHis sequence fusion, 
for expression and subsequently purification. (Erroneous 
deletion within promoter sequence).
This Work
pRV8 As pRV3 (without erroneous deletion) This Work
pRV5 pPC225 containing PAP1 ORF with 3 ’ 6xHis sequence fusion, 
sub-cloned from pRV3, for expression and subsequently 
purification
This Work
pRV 5A 6 H Modified derivative of pRV5, deletion of the 3 ’ 6xHis sequence This Work
pRV5 mutant derivatives
pRV5 R5 K6 Silent mutations: R5 (AGG to CGT), K6 (AAG to AAA) This Work
pRV5 R5sa Silent mutation: R5 (AGG to CGC) This Work
pRV5 R5sb Silent mutation: R5 (AGG to CGT) This Work
pRV5 F13mW Mutation: F I3 to W (TTT to TGG) This Work
pRV5_F13mY Mutation: F I3 to Y (TTT to TAT) 
Silent mutation: G17 (GGG to GGC)
This Work
pRV5_F13mY.P175mS Mutation: F13 to Y (TTT to TAT), P175 to S (CCG to TCG) 
Silent mutation: G 17 (GGG to GGC)
This Work
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pRV5_F13mL
pRV 5_F 13mL.F 16mL
pRV5_F16mY
pRV5_F16mL
pRV5_D97mE
pRV 5_D97mE.N98C99mM
pRV5_N98mV 
pRV5_N98mQ 
pRV 5 S ID 115mA YF
pRV5_Dl 17+GGG
pRV5_I120mG
pRV5_Y147mF
pRV5_C149mW
pRV5_H168mD
pRV5_Q180mE
pRV 5_Q 180mE.N 177My
pRV5_A3’
pRV5_A3’A6H
Mutation: F I3 to L (TTT to TTG) This Work
Mutation: F 13 to L (TTT to TTG), F 16 to L (TTT to TTG) This Work
Mutation: F16 to Y (TTT to TAT) This Work
Silent mutation: G17 (GGG to GGC)
Mutation: F 16 to L (TTT to CTG) This Work
Silent mutation: G17 (GGG to GGC)
Mutation: D97 to E (GAC to GAG) This Work
Silent mutation: G 104 (GGC to GGA)
Mutation: D97 to E (GAC to G A A), This Work
N98 and C99 to M (AAC TGC to ATG)
Silent mutation: G 104 (GGC to GGA)
Mutation: N98 to V (AAC to GTC) This Work
Silent mutation: G 104 (GGC to GGA)
Mutation: N98 to Q (AAC to CAG) This Work
Silent mutation: G104 (GGC to GGA)
Mutation: SI 15 to A (AGC to GCC), I I 16 to Y (ATT to TAT), This Work 
D117 to F (GAC to TTC)
Silent mutation: El 14 (GAA to GAG)
Mutation: Addition of GGG (GGC GGC GGA) after D117 This Work 
(GAC)
Mutation: 1120 to G (ATC to GGC) This Work
Silent mutation: SI 18 (TCC toTCG)
Mutation: Y 147 to F (TAT to TTT) This Work
Mutation: C l49 to W (TGC to TGG) This Work
Silent Mutation: Y147 (TAT to TAC)
Mutation: H I68 to D (CAC to GAC) This Work
Silent Mutation: S I64 (TCA to TCG)
Mutation: Q180 to E (CAG to GAG) This Work
Silent mutation: L I81 (CTG to CTC)
Mutation: Q 180 to E (CAG to GAG), N 177 to Y (AAC to TAC) This Work 
Silent mutation: LI 81 (CTG to CTC)
Mutation: Deletion of G201 to H209 This Work
Mutation: Deletion of G201 to H209 This Work
Deletion of the 3’ 6xHis sequence______________________________________
Hindni -1 - A'AGCT T
Figure 2.1 pCR2.1 vector
The 3906 bp TA cloning vector pCR2.1 (Table 2.3). The multiple cloning site (MCS) enzymes are 
indicated. The TA cloning site is situated within the LacZa ORF (green), which is under the control of the 
Piac promoter (yellow). Ampicillin and Kanamycin resistance genes (ampK & kanK) are shown in red. 
Generated using pDRAW32 (Section 2.11).
43
EcoW -1  - G’AATT C
Figure 2.2 pQE-60 vector
The 3431 bp cloning/expression vector pQE-60 (Table 2.3). The multiple cloning site (MCS) enzymes are 
indicated. The 6xHis coding sequence (green) is situated at the 3’ end of the MCS, which in turn is 
situated downstream of the T5 promoter//ac operon (yellow). Ampicillin resistance gene (ampK) is shown 
in red. Generated using pDRAW32 (Section 2.11).
EcoKL -1 - G'AATT C
Figure 2.3 pPC225 vector
The 6392 bp cloning/expression vector pPC225 (Table 2.3). The multiple cloning site (MCS) enzymes 
are indicated. A 1800 bp sequence (white box) is situated within the MCS, which in turn is situated 
downstream of the Ptoc promoter (yellow). Ampicillin resistance gene (ampK) is shown in red. Generated 
using pDRAW32 (Section 2.11).
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Figure 2.4 pRARE vector
The 4694 bp pRARE plasmid (Table 2.3) codes for 6 tRNAs that recognise codons considered rare in E. 
coli. ileX (AUA), argU (AGG/AGA), argW (AGG), g ly l  (GGA), /e«W (CUA) and proL (CCC). 
Chloramphenicol resistance gene (camR) is shown in red. Generated using pDRAW32 (Section 2.11).
2.2 Media, solutions and buffers
All chemicals and reagents were obtained from Sigma-Aldrich unless otherwise stated. 
All chemicals were Analar grade. Microbiological media were obtained from Oxoid. 
Sterilisation was achieved by autoclaving at 121°C and 15 lb/in for 20 min, unless 
otherwise stated.
Luria Bertani broth (LB)
Tryptone 10g/L
NaCl lOg/L
Yeast Extract 5 g/L
Adjusted to pH 7.0 with NaOH. Sterilised by autoclaving. For solid, LB 15 g/L 
Technical Agar No.3 (Oxoid) was included.
SOB broth
Tryptone 20 g/L
NaCl 500 mg/L
Yeast Extract 5 g/L
KC1 2.5 mM
pH 7.0
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After autoclaving, MgCl2 and MgSC>4 were added to 10 mM from sterile 1 M stock 
solutions.
TE buffer
Tris-HCl
Na2-EDTA
pH
TAE buffer (50X)
Tris
Glacial Acetic Acid
EDTA
pH
STET buffer
Sucrose 
Triton X-100 
Tris-HCl 
Na2-EDTA 
pH
Solution 1 of 1-2-3 method
Glucose
Na2-EDTA
Tris-HCl
Solution 2 of 1-2-3 method
NaOH
SDS
Solution 3 of 1-2-3 method
Potassium acetate 
pH
10 mM 
1 mM
8.0
242 g/L
57.1 ml/L
100 ml/L (of 0.5 M stock)
8.0
8% (w/v)
5% (v/v)
50 mM 
50 mM
8.0
(Section 2.4.1.2)
50 mM
10 mM (from 0.5 M stock) 
25 mM (from 1 M stock)
(Section 2.4.1.2)
200 mM
1 % (w/v)
(Section 2.4.1.2)
3 M
4.8
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To 60 ml of 5 M potassium acetate, 11.5 ml of glacial acetic acid and 28.5 ml of dH20  
was added. The resulting solution was 3 M with respect to potassium and 5 M with 
respect to acetate.
TB buffer
Pipes 10 mM
CaCl2 15 mM
KC1 250 mM
pH 6.7
The pH was adjusted with KOH and then MnCl2 was added to 55 mM. The solution was 
filter sterilised through a 0.22 ^m membrane and stored at 4°C.
RF1 buffer
RbCl 100 mM
CaCl2 10 mM
Potassium acetate 30 mM
Glycerol 15% (v/v)
pH (with HC1) 5.8
After the pH had been adjusted MnCl2 was added to 50 mM. The solution was filter 
sterilised through a 0.22 jim membrane and stored at 4°C.
RF2 buffer
RbCl 10 mM
MOPS 10 mM
CaCl2 75 mM
Glycerol 15% (v/v)
pH 6.8
The solution was filter sterilised through a 0.22 \.im membrane and stored at 4°C.
Transfer buffer
Tris-HCl 25 mM
Glycine 150mM
Methano 1 10% (v/v)
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TBS buffer
Tris-HCl 10 mM
NaCl 150 mM
pH 7.5
TBS-Tween/Triton buffer
Tris-HCl 20 mM 
500 mM 
0.05% (v/v) 
0.2% (v/v) 
7.5
NaCl
Tween 20
Triton X-100
pH
Gel loading dye (6X)
Bromophenol Blue 0.25%
Xylene Cyanol 0.25%
Ficoll (Type 400) 15%
Bromophenol Blue and/or Xylene Cyanol were used as appropriate. On a 1% agarose 
gel, bromophenol blue and xylene cyanol migrate approximately with the 300 bp and 
4000 bp fragments respectively.
Ethidium bromide stain
A 10 mg/ml stock solution in dH20  was stored at 4°C in the dark. For the staining of 
agarose gels, 100 |il o f the stock solution was mixed into 1 L of dH20 . The staining 
solution was kept in a plastic tray and covered to protect against light. Used ethidium 
bromide stain was collected and filtered through a deactivating filter (Schleicher & 
Schuell).
2.3 Antibiotics
■ Ampicillin was prepared in dH20  at a concentration of 100 mg/ml and stored at 
-20°C. The working concentration for E. coli was 100 jig/ml.
■ Chloramphenicol was prepared in ethanol at a concentration of 100 mg/ml and
stored at -20°C. The working concentration for E. coli was 25 ng/ml.
■ Tetracycline was prepared in 50 % ethanol at a concentration of 10 mg/ml and
stored at -20°C. The working concentration for E. coli was 10 |ig/ml.
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■ Kanamycin was prepared in dl-hO at a concentration of 100 mg/ml and stored at 
-20°C. The working concentration for E. coli was 30 fag/ml.
2.4 Isolation and purification of DNA and RNA
2.4.1 Isolation of plasmid DNA
Three procedures for the isolation of plasmid DNA were variably employed. The Rapid 
Boiling Method (Section 2.4.1.1) was used for convenient plasmid isolation from large 
numbers of samples, mostly for the purpose of screening. The 1-2-3 Method (Section
2.4.1.2), yielding higher quality DNA than the previous method, was used routinely. 
The Genelute Plasmid Miniprep Kit (Sigma, Section 2.4.1.3) was used to prepare 
consistently pure and supercoiled plasmid DNA, mostly for the purpose of DNA 
sequencing.
2.4.1.1 Rapid boiling method
This method is adapted from the procedure outlined by Holmes and Quigley (1981). 1.5 
ml of a bacterial culture in a microfuge tube was centrifuged at 13,000 rpm for 5 min to 
collect the cells. The supernatant was discarded and the cell pellet re-suspended in 350 
1^ of STET buffer. Alternatively, bacterial growth was taken off an LB agar culture 
plate with a sterile loop and re-suspended in 350 jal of STET buffer. 20 |il of a freshly 
made 10 mg/ml lysozyme solution was added and the microfuge tube was incubated at 
room temperature for 10 min. The microfuge tube was placed in a boiling water bath for 
60 seconds and then centrifuged at 13,000 rpm for 10 min. The supernatant was 
removed to a new microfuge tube. An equal volume of isopropanol was added and 
mixed by inversion. The tube was left at room temperature for 5 min and then 
centrifuged at 13,000 rpm for 20 min to pellet the plasmid DNA. The pellet was washed 
with 70% ethanol and then dried briefly in a Speed Vac (Savant) vacuum centrifuge. The 
plasmid DNA was resuspended in 50 jil o f TE buffer and 1 jal o f Ribonuclease A 
(Section 2.8) was added to digest co-purified RNA. Plasmid DNA was stored at -20°C.
2.4.1.2 1-2-3 method
This method is adapted from the procedure described by Bimboim and Doly (1979). 1.5 
ml of a bacterial culture in a microfuge tube was centrifuged at 13,000 rpm for 5 min to 
collect the cells. The supernatant was discarded and the cell pellet re-suspended in 200 
|il o f Solution 1. Alternatively, bacterial growth was taken off an LB agar culture plate
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with a sterile loop and re-suspended in 200 |il of Solution 1. The re-suspension was left 
for 5 min at room temperature. 200 1^ o f Solution 2 was added, the tube was mixed by 
inversion and placed on ice for 5 min. 200 |il of Solution 3 was added, the tube was 
mixed by inversion and placed on ice for 10 min. A clot of chromosomal DNA was 
collected by centrifugation at 13,000 rpm for 10 min. The supernatant was removed to a 
new microfiige tube with 400 |il o f phenol chloroform isoamylalcohol (25:24:1) and 
mixed by brief vortexing. Upon centrifugation at 13,000 rpm for 5 min the mixture is 
divided into an upper aqueous and lower organic layer. The aqueous layer was removed 
to a new microfuge tube with an equal volume of isopropanol and mixed by inversion. 
The tube was left at room temperature for 5 min and then centrifuged at 13,000 rpm for 
20 min to pellet the plasmid DNA. The pellet was washed with 70% ethanol and then 
dried briefly in a SpeedVac (Savant) vacuum centrifuge. The plasmid DNA was 
resuspended in 50 jil of TE buffer and 1 |il o f Ribonuclease A (Section 2.8) was added 
to digest co-purified RNA. Plasmid DNA was stored at -20°C.
2.4.1.3 GenElute plasmid miniprep kit
The kit was used according to the manufacturer’s instructions: 1.5 ml of a bacterial 
culture in a microfuge tube was centrifuged at 13,000 rpm for 5 min to collect the cells. 
The supernatant was discarded and the cell pellet was completely re-suspended in 200 
|il o f re-suspension solution. 200 |il o f lysis solution was mixed in by inversion to lyse 
the cells. 350 (il neutralisation/binding buffer was added and mixed by inversion to 
precipitate cell debris, lipids, proteins and chromosomal DNA. The precipitate was 
collected by centrifugation at 13,000 rpm for 10 min. The supernatant was transferred to 
a spin column in a microfuge tube and centrifuged at 13,000 rpm for 1 min to bind the 
plasmid DNA. The flow through was discarded and 750 |il o f washing solution was 
added followed by further centrifugation at 13,000 rpm for 1 min. The flow through was 
discarded and the column was centrifuged at 13,000 rpm for 1 min to dry the spin 
column. The spin column was transferred to a fresh microfuge tube and 100 |il TE 
buffer was added. The DNA was eluted by centrifugation at 13,000 rpm for 1 min.
2.4.2 Isolation of DNA from agarose gels
Both the GeneClean method (Section 2.4.2.1) and the PerfectPrep Kit (Eppendorf, 
Section 2.4.2.2) were used to purify DNA from agarose gels, the latter being more 
consistent and reliable.
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2.4.2.1 GeneClean
This method was described by Mather et al. (1993). The DNA band to be isolated was 
excised from the agarose gel using a scalpel. The gel slice was weighed and placed in a 
microfuge tube. Three gel slice volumes of saturated sodium iodide solution were 
added. The tube was incubated at 65°C for 10 minutes to completely dissolve the 
agarose in the chaotropic solution. 2 jil (typically for up to 100 ng DNA) of silica 325 
mesh glass beads were added and mixed by vortexing. The tube was kept at -20°C for 
30 minutes. The beads were collected by centrifugation at 13,000 rpm for 5 seconds. 
The supernatant was discarded and the beads were washed three times with 300 |il 70% 
ethanol. The beads were re-suspended in 15-30 |il TE buffer and incubated at 55°C for 
15 minutes to elute the DNA. The beads were removed by centrifugation at 13,000 rpm 
for 5 seconds and the supernatant was placed in a fresh microfuge tube.
2.4.2.2 PerfectPrep kit
The kit was used according to the manufacturer’s instructions: The desired DNA band 
was excised from the agarose gel using a scalpel. The gel slice was weighed and placed 
in a microfuge tube. The tube was incubated at 65°C for 10 min to completely dissolve 
the agarose in the chaotropic solution. One gel slice volume of isopropanol was added 
and mixed by inversion. The solution was transferred to a spin column in a microfuge 
tube and centrifuged at 13,000 for 1 min to bind the plasmid DNA. The flow through 
was discarded and 750 jil o f washing solution was added followed by further 
centrifugation at 13,000 rpm for 1 min. The flow through was discarded and the column 
was centrifuged at 13,000 rpm for 1 min to dry the spin column. The spin column was 
transferred to a fresh microfuge tube and 30 [i\ TE buffer was added. The DNA was 
eluted by centrifugation at 13,000 rpm for 1 min.
2.4.3 Purification and concentration of DNA samples
The sample containing the DNA to be precipitated was brought to 400 jul with dH20 . 
400 |il of phenol chloroform isoamylalcohol (25:24:1) was added and mixed by brief 
vortexing. Upon centrifugation at 13,000 rpm for 5 min the mixture is divided into an 
upper aqueous and lower organic layer. The aqueous layer was removed to a new 
microfuge tube with an equal volume of chloroform and mixed by brief vortexing. The 
tube was centrifuged at 13,000 rpm for 5 min and the aqueous layer was transferred to a
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new microfiige tube. A 1/10 volume of 3 M sodium acetate was added followed by an 
equal volume of isopropanol and mixed by inversion. The tube was left at room 
temperature for 60 min and then centrifuged at 13,000 rpm for 20 min to pellet the 
DNA. The pellet was washed with 70% ethanol and then dried briefly in a SpeedVac 
(Savant) vacuum centrifuge. The DNA was resuspended in 20-50 [i\ of TE buffer.
2.4.4 Isolation of RNA
RNA was isolated using Trizol Reagent (Invitrogen), a mono-phasic solution of phenol 
and guanidine isothiocyanate. This is an improvement of the method developed by 
Chomczynski and Sacchi (1987). 100 mg of tissue was homogenised in 1 ml o f Trizol 
reagent using a glass-Teflon homogeniser (treated with RNase AWAY, Molecular Bio- 
Products, inc.) and transferred to a microfuge tube. Alternatively, a pellet of cultured 
cells was lysed in 1 ml o f Trizol reagent by repeated pipetting. The sample was 
incubated at room temperature for 5 min to allow complete dissociation of 
nucleoprotein complexes. 200 jil of chloroform was added, mixed by brief vortexing 
and incubated at room temperature for 3 min. The phases were separated by 
centrifugation at 13,000 rpm for 15 min. The upper aqueous layer was transferred to a 
fresh microfuge tube. 500 |il o f isopropanol was added and mixed by inversion. The 
sample was incubated at room temperature for 10 min to precipitate the RNA and then 
centrifuged at 13,000 rpm for 10 min. The supernatant was discarded and the RNA 
pellet was washed with 1 ml of 70% ethanol. The RNA pellet was air-dried and 
dissolved in 30 |il RNase-free water. Any possible DNA contamination was eliminated 
by treatment with Deoxyribonuclease I (Section 2.8).
2.4.5 Quantification of DNA and RNA
Nucleic Acid concentration was quantified by UV spectrometry. A dilution of the 
sample (typically 1/50) in dH20  was measured for absorbance at 260 nm. A reading of 
1.0 corresponds to 50 |ig/ml o f DNA or 40 ¿ig/ml of RNA. The approximate quantity of 
DNA in individual bands on agarose gels (Section 2.5) could be judged by comparing to 
bands of known amounts of linear DNA on a reference gel (Figure 2.5).
2.5 Agarose gel electrophoresis
DNA was analysed by electrophoresing through agarose gels in a BioRad horizontal gel 
apparatus. Agarose was added to TAE buffer to the required concentration (typically
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0.7-2%) and dissolved by boiling. The agarose solution was poured into plastic trays 
and allowed to set with a plastic comb fitted to create sample wells. TAE buffer was 
used as the running buffer. Loading dye was mixed with the DNA samples to facilitate 
loading and to give indication of migration distance during electrophoresis. When RNA 
samples were being analysed 0.1% (v/v) DEPC was included in the TAE buffer. Gels 
were run at 140 volts for 20-40 min depending on size o f gel. Gels were stained for 15 
min by immersion in an ethidium bromide staining solution. Gels were visualised using 
a UV transilluminator coupled with an image analyser to capture the image to a PC. On 
every gel 0.5 jig of 1 Kb Plus DNA Ladder (Invitrogen, Figure 2.5) was run as a 
molecular size marker.
Figure 2.5 Reference DNA gel
1.0% Agarose Gel. Lane 1, 0.5 i^g DNA Ladder (band sizes are indicated); Lanes 2-8, Increasing amounts 
of linear 2686 bp pUC 18 DNA (amounts are indicated); Inset graphically shows increase in band intensity 
as determined by densitometry (Section 2.16.5).
2.6 Competent cells
The two methods used to prepare competent cells were the rubidium chloride method 
(section 2.6.1) and the TB method (section 2.6.2). The former method was favoured for 
its reliability.
2.6.1 Rubidium chloride method
This is an adaptation of the method outlined by Hanahan (1985). Sterile conditions were 
used throughout. 10 ml o f LB broth containing the relevant antibiotics was inoculated
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with a single colony of the desired bacterial strain from a plate stock and cultured 
overnight at 37°C. A 1 L flask with 200 ml of LB broth was inoculated with 2 ml of the 
overnight culture and incubated at 37°C shaking at 225 rpm. When the culture had 
reached an OD600 of -0.5 (early-mid exponential phase) the flask was cooled in ice 
water. All subsequent transactions took place at 4°C. The culture was transferred to a 
sterile centrifuge bottle. The cells were collected by centrifugation at 3,000 rpm for 5 
min (using a Beckman JA-14 rotor). The supernatant was decanted and the cells gently 
re-suspended in 60 ml of chilled RF1 buffer. The suspension was left on ice for 90 min. 
The cells were again collected by centrifugation at 3,000 rpm for 5 min. The supernatant 
was decanted and the cells gently re-suspended in 8 ml o f chilled RF2 buffer. Aliquots 
of 800 |xl were prepared in sterile 1.5 ml microfuge tubes and flash frozen using -70°C 
ethanol. The competent cells were stored at -70°C. Cells were routinely used within a 
few weeks.
2.6.2 TB method
This method was developed by Inoue et al. (1990). Sterile conditions were used 
throughout. 10 ml of LB broth containing the relevant antibiotics was inoculated with a 
single colony of the desired bacterial strain from a plate stock and cultured overnight at 
37°C. A 1 L flask with 200 ml of SOB broth was inoculated with 2 ml o f the overnight 
culture and incubated at 37°C shaking at 225 rpm. When the culture had reached an 
O D 6oo of 0.4, as optimised by Inoue et al. (1990), the flask was cooled in ice water. All 
subsequent transactions took place at 4°C. The culture was transferred to a sterile 
centrifuge bottle. The cells were collected by centrifugation at 3,000 rpm for 5 min 
(using a Beckman JA-14 rotor). The supernatant was decanted and the cells gently re- 
suspended in 80 ml of chilled TB buffer. The suspension was left on ice for 10 min. The 
cells were again collected by centrifugation at 3,000 rpm for 5 min. The supernatant was 
decanted and the cells gently re-suspended in 15 ml o f chilled TB buffer. DMSO was 
added drop-wise to 7% (v/v). The suspension was left on ice for 10 min. Aliquots of 
800 |il were prepared in sterile 1.5 ml microfuge tubes and flash frozen using -70°C 
ethanol. The competent cells were stored at -70°C. Cells were routinely used within a 
few weeks.
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2.6.3 Transformation of competent cells
An aliquot of competent cells was thawed on ice. 200 |il of the cell suspension was 
mixed gently with 1-50 \x\ of plasmid DNA in a sterile 1.5 ml microfuge tube. The 
mixture was left on ice for 30 min. The cells were heat-shocked at 42°C for 30 seconds 
and placed back on ice for 2 min. 800 |il of LB broth was added to the cells followed by 
incubation at 37°C for 60 min. 100 jul of the transformation suspension was spread on an 
LB agar plate containing the relevant antibiotics and incubated at 37°C overnight.
2.6.4 Determining cell efficiency
Competent cell efficiency is defined in terms of the number of colony forming units 
obtained per jig of transformed plasmid DNA. A 10 ng/|il stock of pUC18 plasmid 
DNA was diluted to 1 ng/|il, 100 pg/jal and 10 pg/|al. 1 jul of each dilution was 
transformed as described above. The cell efficiency was calculated from the number of 
colonies obtained, taking into account the dilution factor and the fraction of culture 
transferred to the spread plate.
2.7 Bacterial storage
Bacterial strains were stored as 40% glycerol stocks. 750 jul of an overnight culture was 
mixed with 750 jul sterile 80% glycerol in a microfuge tube. If the bacterial strains 
contained plasmids, the selective antibiotic was included in the culture. Duplicate stocks 
were stored at -20°C and -70°C. Working stocks streaked on LB agar plates, containing 
antibiotics where appropriate, were stored at 4°C. Bacterial samples containing plasmids 
to be sent for commercial DNA sequencing were prepared as stab cultures. 1 ml o f LB 
agar containing the selective antibiotic was added to a microfuge tube and allowed to 
set. The tube was inoculated by stabbing using a sterile pin with bacterial growth taken 
from an LB broth culture.
2.8 Enzymes
All restriction endonucleases and T4 DNA ligase were obtained from Invitrogen Life 
Technologies or New England Biolabs. Deoxyribonuclease I (Ribonuclease free), 
Ribonuclease A (Deoxyribonuclease free), REDTaq and REDAccu7a^ DNA 
polymerases were obtained from Sigman-Aldrich. PfuTurbo DNA polymerase was 
obtained from Stratagene. AMY reverse Transcriptase was obtained from Promega.
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Enzymes were used with their relevant buffers according to the manufacturers 
instructions.
2.8.1 Reverse transcription
1 i^g of RNA was combined with 0.5 ^g oligo(dT)i5 primer (alternatively 1 \i\ of 25 jliM  
specific reverse primer or 1 |il o f 50 |xM random nonamers) and the volume made to 5 
[il with dl-hO. The mixture was incubated at 70°C for 10 min and then placed on ice for 
5 min. To the mixture were added dNTP’s to 500 jiM each, 1 unit AMV reverse 
transcriptase and 2 i^l specific lOx enzyme buffer. The volume was brought to 20 jil 
with dH20 . The first strand was synthesised at 42°C for 60 min followed by inactivation 
of the transcriptase at 95°C for 2 min. 2 jj.1 of the reaction was used as template for PCR.
2.8.2 Polymerase chain reaction
PCR reactions (Mullis and Faloona, 1987) were carried out using a Hybaid PCR 
Express Thermocycler. The standard PCR reaction volume was 50 }j,l containing 1 ¿il 
template (10-100 ng), 1-2.5 mM MgCk, 0.5 \iM of each primer, 200 |iM of each dNTP, 
1 unit REDTaq or REDAccu7a# DNA polymerase and 5 \i\ specific lOx enzyme buffer. 
The standard PCR program was:
Stage 1 Step 1: 95°C for 10 min
Stage 2 (30 cycles) Step 1: 95°C for 1 min
Step 2: Tann for 30 sec
(Tann was routinely 5°C below the Tm of the primers)
Step 3: 72°C for 1 min per Kb to be synthesised 
Stage 3 Step 1: 72°C for 10 min
2.9 Gene manipulation
A variety of plasmid-based gene cloning approaches such as described by Maniatis et 
al. (1982) were used, employing PCR techniques (Section 2.8.2), restriction 
endonucleases and DNA ligase (Section 2.8).
2.9.1 TA cloning of PCR products
PCR products were cloned using the TA cloning vector pCR2.1 (Invitrogen, Table 2.3, 
Figure 2.1). The cloning method using this vector exploits the fact that thermostable
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polymerases such as Taq DNA polymerase leave 3’ A-overhangs due to their lack of 3’- 
5’ exonuclease activity. The pCR2.1 vector is provided with a location in the lacZa 
gene open with 3’ T overhangs (Figure 2.1). PCR products with 3’ A-overhangs can be 
directly ligated into this cloning site. The ligation was transformed into E. coli cells 
(routinely DH5a or INVaF' strains were used, Table 2.1) as described in Section 2.6.3.
100 (il of the transformation reaction was plated on an LB agar plate containing
ampicillin and kanamycin. The agar plate was previously overlaid with 60 jxl o f 40 
mg/ml X-gal to test for a-complementation of p-galactosidase. X-gal stock was 
prepared in DMF and stored in the dark at -20°C. The lacZa gene encodes the a-peptide 
of p-galactosidase, which cleaves the X-gal substrate yielding a blue product. This 
allows for positive selection of transformants harbouring plasmids with PCR product 
inserts. Routinely a small proportion of colonies are blue. It is assumed that these arise 
as a result of re-circularisation of the pCR2.1 vector.
2.9.2 Site-specific mutagenesis
Point mutations were introduced into open reading frames on plasmid constructs by 
PCR amplification using complementary primers carrying the desired mutation. 50 \i\ 
reactions were set up, containing 10-100 ng of plasmid template isolated from dam E. 
coli (e.g. DH5a, INVaF or XL-10 Gold strains, Table2.1), 0.5 jxM of each primer, 200 
|iM of each dNTP, 2.5 units of PfuTurbo DNA polymerase and 5 1^ specific lOx enzyme 
buffer. The particular PCR program used was:
Stage 1 Step 1: 95°C for 1 min
Stage 2(18 cycles) Step 1: 95°C for 50 sec
Step 2: 60°C for 50 sec
Step 3: 68°C for 2 min per Kb of template plasmid
Stage 3 Step 1: 68°C for 7 min
The template DNA was eliminated by digestion with 20 units o f Dpn I restriction 
endonuclease. Dpn I is biased toward a methylated recognition sequence. It selectively 
digests the template DNA from dam+ E. coli strains mentioned above and not the newly 
synthesised DNA. Subsequently the samples were transformed into E. coli XL 10-Gold. 
Transformants were screened by restriction analysis. Where possible, a diagnostic 
restriction site had been created by co-introducing a silent mutation. Potential mutants 
were verified by DNA sequencing.
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2.10 DNA sequencing
Recombinant clones and potential mutants were verified by DNA sequencing. 
Commercial sequencing services were provided by MWG Biotech AG (also Lark 
Technologies Inc. and Qiagen Ltd.). Suitable sequencing primers (Table 2.2) for 
standard vectors were provided as part of the service. Samples were variably sent as 
dried plasmid DNA or as stab cultures.
2.11 Bio-Informatics
Nucleotide and Amino Acid sequences were analysed using a variety of web-based 
tools. The BLAST programs (Altschul et al., 1997) at the National Centre for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov) were used to identify 
homologous sequences deposited in GenBank (Benson et al., 1996). Protein sequences, 
structure files and tools to calculate protein molecular weights and isoelectric points 
were obtained from the Swiss-Prot database (Bairoch and Apweiler, 1996) at 
(http://us.expasy.org) and the Protein Data Bank (PDB, Berman et al., 2000) at 
(http://www.rcsb.org/pdb). Alignments of DNA and Protein sequences were performed 
using the Mult Alin program (Corpet, 1988) available at
(http://prodes.toulouse.inra.fr/multalin/multalin.html) and edited using the GeneDoc 
program (Nicholas et a l , 1997) available for download at
(www.psc.edu/biomed/genedoc). Plasmid maps were constructed using the pDRAW32 
program available for download at (http://www.acaclone.com). Chemical structures 
were drawn using the ACD/Labs ChemSketch program available for download at 
(http://www.acdlabs.com). DNA sequences were analysed for restriction enzyme sites 
using the Webcutter 2.0 tool at (http://ma.lundberg.gu.se/cutter2). Tertiary protein 
structure was predicted by the automated SWISS-MODEL server (Schwede et al., 2003, 
http://swissmodel.expasy.org), subsequently analysed and visualised using the 
DeepView software (Guex and Peitsch, 1997) available for download at 
(http://ca.expasy.org/spdbv). The secondary structure of mRNA was predicted using 
Mfold (Zuker, 2003; http://mfold.bumet.edu.au).
2.12 Protein expression
2.12.1 Standard expression culture
100 ml of LB broth was inoculated with 1 ml o f a stationary phase culture of E. coli that 
had been transformed with an expression plasmid. Selective antibiotics were included in
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the LB broth. The culture was incubated at 37°C, shaking at 220 rpm, until an optical 
absorbance (A600) of 0.3-0.5 was reached. IPTG was added (from 10 mM stock) to a 
final concentration of 50 jiM to induce expression (if required). The culture was allowed 
to incubate for a defined period, sampling 1 ml routinely at hourly intervals. Both these 
samples and the remaining culture were centrifuged at 5,000 rpm for 5 min (using a 
Beckman JA-14 rotor) to pellet the cells. The supernatant was discarded and the pellets 
were stored at -20°C.
2.12.2 Preparation of cleared lysate
A cell pellet from a 100 ml expression culture was washed in potassium phosphate 
buffer, pH 8.0 followed by centrifugation at 4,000 rpm for 5 min (using a Beckman JA- 
20 rotor). The supernatant was discarded and the cells were re-suspended in 10 ml 
Potassium phosphate buffer, pH 8.0. In the case of the 1 ml samples, 100 [i\ of 
potassium phosphate buffer, pH 8.0 was used. The cells were disrupted on ice with a 3 
mm micro-tip sonicator (Sonics & Materials Inc.) using 2.5 sec, 40 kHz pulses for 30 
sec. The cell debris was removed by centrifugation at 4,000 rpm for 20 min at 4°C 
(using a Beckman JA-20 rotor). The cleared lysate was transferred to a fresh universal 
container and stored at 4°C.
2.13 Protein purification
Immobilised Metal Affinity Chromatography (IMAC) was used to purify recombinant 
human PAP1 having a C-terminal 6xHis tag (Table 2.3).
2.13.1 Standard IMAC procedure
1 ml of nickel-nitrilotriacetic acid resin (Ni-NTA, Qiagen) was gently mixed with 10 ml 
of cleared lysate for 60 min at 4°C. The mixture was poured into a 0.7 x 15 cm column, 
allowing the resin to settle. The column was washed three times with 10 ml potassium 
phosphate buffer, pH 8.0 containing 20 mM imidazole and then eluted with 5 ml 
potassium phosphate buffer, pH 8.0 containing 200 mM imidazole. The elute was 
dialised overnight against 1 L potassium phosphate buffer, pH 8.0. Samples taken 
throughout the procedure were analysed by SDS-PAGE (Section 2.16). Protein 
concentration was determined by the standard BCA or Coomassie Plus assay (Section 
2.14) and PAP1 activity was determined by the fluorimetric assay (Section 2.15). The 
purified PAP1 sample was stored at 4°C or -20°C with 40% glycerol.
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2.13.2 Recharging of Ni-NTA resin
This procedure was routinely used before re-using the Ni-NTA Resin. The resin was 
poured into a column and washed with 2 column volumes (2cv) of distilled water 
followed by 2cv 50% ethanol. The resin was stripped with 3cv 100 mM EDTA, pH 8.0. 
The resin was washed with 2cv 500 mM NaCl followed by 2cv distilled water. The 
resin was re-charged with 2cv 100 mM NiSC>4. The resin was washed with 2cv distilled 
water, transferred to a plastic container and stored at 4°C in 20% ethanol.
2.13.3 Preparation of dialysis tubing
The required amount of tubing was placed in a 1 L glass beaker and rinsed thoroughly 
with distilled water. The beaker was filled with distilled water and ~1 g of EDTA was 
added. The beaker was brought to boil and boiled for 2 min. The water was allowed to 
cool and then poured off. The beaker was re-filled with fresh distilled water and boiled 
again for 2 min. The water was allowed to cool and poured off. The tubing was 
thoroughly rinsed with distilled water. The tubing was stored at 4°C in distilled water.
2.14 Protein concentration
2.14.1 Quantitative determination by BCA assay
The Bicinchoninic acid (BCA) assay described by Smith et al. (1985) was used for the 
colorimetric detection and quantification of total protein in the range of 20-2,000 ¿ig/ml. 
All samples were dialysed against dH20  and diluted appropriately to achieve a 
concentration within range of the assay. 100 |il o f sample was added in triplicate to 2 ml 
of BCA reagent (Sigma) and incubated at 37°C for 30 min. Absorbances were read at 
562 nm on a spectrometer blanked with dH20 . Bovine serum albumin (BSA) was used 
as the reference protein. BSA standards (0-2 mg/ml) were prepared in dH20  and 
assayed in triplicate to yield a standard curve (Appendix A). Protein concentration of 
samples was determined from this standard curve.
2.14.2 Quantitative determination by Coomassie assay
The Coomassie Plus assay (Bradford, 1976) was used for the colorimetric detection and 
quantification of total protein in the range of 100-1,500 |ig/ml. All samples were 
dialysed against dH20  and diluted appropriately to achieve a concentration within range 
of the assay. 50 (il of sample was added in triplicate to 1 ml of Coomassie Plus reagent
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(Pierce) and mixed gently. Absorbances were read at 595 nm on a spectrometer blanked 
with dl-hO. Bovine serum albumin (BSA) was used as the reference protein. BSA 
standards (0-2 mg/ml) were prepared in dl-hO and assayed in triplicate to yield a 
standard curve (Appendix A). Protein concentration of samples was determined from 
this standard curve.
2.14.3 Qualitative determination by Coomassie assay
A 96-Well plate version of the Coomassy assay (Section 2.14.2) with a working range 
of 0-25 |ig/ml was used for post column chromatography fractions. 150 jil o f sample 
was added to 150 |xl of Coomassie Plus reagent and read at 595 nm using a Techan 
Spectra Plate Reader. A BSA standard curve (Appendix A) was prepared under the 
same conditions.
2.15 Fluorescence spectrometry
2.15.1 AMC standard curve
A 100 stock of 7-Amino-4-Methyl-Coumarin (AMC) was prepared in 50 mM 
potassium phosphate buffer, pH 8.0 containing 4% (v/v) methanol. This stock solution 
was stored in the dark at 4°C for up to one month. AMC standards were prepared by 
dilution of the stock solution with potassium phosphate buffer, pH 8.0 to the range of 0- 
20 jiM. 500 jil of each standard was incubated in triplicate at 37°C for 15 min followed 
by the addition of 1 ml o f 1.5 M acetic acid. The fluorescence intensities of the 
standards were read using a Perkin Elmer LS50 Fluoresence Spectrophotometer at 
excitation and emission wavelengths of 370nm and 440nm respectively. Excitation slit 
width was lOnm while emission slit width was 2.5nm. This AMC standard curve is 
shown in Appendix A
2.15.2 Quantitative fluorimetric PAP1 assay
Quantitative pGlu-AMC degrading PAP1 activity was determined according to the 
method by Fujiwara and Tsuru (1978), as modified by Browne and O’Cuinn (1983). 
PAP1 sample was suitably diluted in potassium phosphate buffer, pH 8.0. 100 jjJ was 
incubated in triplicate at 37°C for 15 min with 400 ¿il of pGlu-AMC substrate (final 
concentration 250 fiM) in 50 mM potassium phosphate, pH 8.0 containing at final 
concentration 10 mM DTT, 2 mM EDTA and 5% (v/v) DMSO. Blanks were set up by 
substituting 100 jxl 50 mM potassium phosphate buffer, pH 8.0 for PAP1 sample. The
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reaction was terminated by the addition of 1 ml 1.5 M acetic acid. Liberated AMC was 
detected using a Perkin-Elmer LS-50 fluorescence spectrophotometer with excitation 
and emission wavelengths o f 370 and 440 nm, respectively. The fluorescence readings 
were converted to nanomoles o f AMC released per minute by calculations shown in 
Appendix C, using a standard curve of free AMC (Appendix A), prepared as described 
in Section 2.15.1 under identical assay conditions. Units o f PAP 1 activity were defined 
as nanomoles of AMC released per minute at 37°C (unit = nmoles.min'1).
To monitor the effect of temperature on PAP1 activity, the standard assay was carried 
out at a range of temperatures from 4 to 70°C. PAP1 samples were pre-incubated for 5 
min before the addition of the substrate solution.
The stability of PAP 1 at various temperatures was determined by incubating samples at 
a range of 4 to 70 °C. Aliquots were removed at appropriate time intervals for up to 120 
min and assayed under standard conditions at 37°C. The initial activity was compared to 
the residual activity at each temperature.
2.15.3 Qualitative 96-well plate fluorimetric PAP1 assay
A qualitative version of the above assay, for large scale screening of samples was 
carried out on a 96-well plate. 10 |il of sample was incubated in triplicate with 40 jil of 
the substrate solution used in Section 2.15.2 at 37°C for 15 min. The reaction was 
terminated by the addition of 100 |il 1.5 M acetic acid. Liberated AMC was detected 
fluorometrically using a Perkin Elmer LS-50B plate reader attachment with excitation 
and emission wavelengths of 370 and 440 nm, respectively.
2.15.4 Fluorimetric colony assay
Screening for transformants with PAP1 activity was carried out by a fluorimetric plate 
assay similar to that described by Mulczyk and Szewczuk (1970). Selective agar plates 
with colonies from an overnight transformation were flooded with 250 |iM pGlu-AMC 
substrate in 50 mM potassium phosphate, pH 8.0 with 10 mM DTT, 2 mM EDTA and 
5% (v/v) DMSO. After 30 min incubation at 37°C the plates were viewed under UV 
light. A digital camera was used to capture the images to a PC.
2.16 SDS-PAGE
Protein samples were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE), based on the method outlined by Laemmli (1970).
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2.16.1 Preparation of SDS gels
10% and 15% resolving and 4% stacking polyacrylamide gels were prepared as per 
Table 2.4. Gels were cast using an ATTO vertical mini electrophoresis system. Upon 
the addition of the TEMED to the resolving gel it was poured immediately and overlaid 
with 50% ethanol. After polymerisation, the overlay was removed. Upon the addition of 
the TEMED to the stacking gel it was poured immediately and allowed to polymerise 
around a comb placed into the top of the gel liquid to form loading wells.
Table 2.4 Preparation of SDS-PAGE gels
Solution 10% Resolving Gel 15% Resolving Gel 4% Stacking Gel
1.5 M Tris-HCl, pH 8.8 Resolving Gel buffer 1.625 ml 1.625 ml -
0.5 M Tris-HCl, pH 6.8 Stacking Gel buffer - - 0.625 ml
dH20 2.64 ml 1.56 ml 1.538 ml
Acrylamide/Bis-acrylamide 30%/0.8% (w/v) 2.17 ml 3.25 ml 0.335 ml
10% (w/v) Ammonium Persulphate 32.5 til 32.5 [i\ 12.5 Hi
20% (w/v) SDS 32.5 \i\ 32.5 nl 12.5 Hi
TEMED 3.25 nl 3.25 nl 2.5 Hi
2.16.2 Sample preparation
20 |il of sample was added to 5|il solubilisation buffer (5X) consisting of 50% (v/v) 
glycerol, 2% (w/v) SDS, 5% (v/v) 2-mercaptoethanol, 0.1% (w/v) bromophenol blue 
and 62.5 mM Tris-HCl, pH 6.8. Samples were boiled for 3 minutes and stored on ice 
until application.
2.16.3 Sample application
Routinely 25 ¿il of each prepared sample was applied to the SDS PAGE gel. Standard 
loading was achieved using a dilution approach, together with densitometry readings 
(Section 2.16.5) for constitutively expressed standard protein bands.
10 |xl relative molecular weight protein marker (Mr) solution (SigmaMarker, Sigma, 
Figure 2.6) was also applied to the gel consisting of Rabbit Muscle Myosin (205 kDa), 
E. coli P-Galactosidase (116 kDa), Rabbit Muscle Phosphorylase b (97 kDa), Rabbit 
Muscle Fructose-6-phosphate Kinase (84 kDa), Bovine Serum Albumin (66 kDa), 
Bovine Liver Glutamic Dehydrogenase (55 kDa), Chicken Egg Ovalbumin (45 kDa), 
Rabbit Muscle Glyceraldehyde-3-phosphate Dehydrogenase (36 kDa), Bovine 
Erythrocyte Carbonic Anhydrase (29 kDa), Bovine Pancreas Trypsinogen (24 kDa), 
Soybean Trypsin Inhibitor (20 kDa), Bovine Milk a-Lactalbumin (14.2 kDa) and
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Bovine Lung Aprotinin (6.5 kDa). Gels were run at 25 mA for 1-2 hrs at room 
temperature using Running Buffer containing 25 mM Tris-HCl, 192 mM glycine and 
0.1% (w/v) SDS.
Figure 2.6 Relative molecular weight protein marker (Mr)
15% polyacrylamide gel
2.16.4 Gel staining
Polyacrylamide gels removed from the electrophoresis chamber and washed with dH20  
for 5 min. Routinely, gels were stained for 60 min in a 0.25% (w/v) Coomassie blue 
solution containing 10% (v/v) Acetic Acid/45% (v/v) methanol and then de-stained 
overnight using 10% (v/v) Acetic Acid/45% (v/v) methanol. Subsequent soaking in 
dH20  enhanced the protein bands further. If this did not sufficiently stain the gel, the 
more intense silver staining method (Blum et al., 1987) was used as outlined in table
Table 2.5 Silver staining of SDS-PAGE gels
Step Duration Reagent
Fix 60 min 50% ethanol, 12% acetic acid, 0.05% formaldehyde (37% stock)
Wash 3 x 20 min 50% ethanol
Pre-Treat 1 min 200 \i\ of a 5% Na2S20 3 x H20  stock solution in 100 ml dH20
Rinse 2 x 20 sec dH20
Impregnate 20 min 0.1 g AgN03, 70 [i\ formaldehyde in 100 ml dH20
Rinse 2 x 20 sec dH20
Development 10 min (max.) 3g Na2C 0 3, 50 i^l formaldehyde, 4 ^1 Na2S20 3 x H20 stock solution 
in 100 ml dH20
Stop 5 min 0.1 MEDTA
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2.16.5 Gel analysis
Gels were placed between two transparent sheets and scanned using a flatbed scanner, 
allowing the image to be saved to a PC. Analysis and densitometry of gel images was 
performed using the ImageJ program available for download at 
(http://rsb.info.nih.gov/ij). Densitometry values for specific sample bands were 
determined, taking into account relative loadings (Section 2.16.3) and expressed as 
percentages of either total protein or as relative ratios to defined bands used as standards 
(i.e. that have been shown to be constitutively expressed).
2.17 UV Zymography
2.17.1 Native PAGE
A 15% native polyacrylamide gel was prepared as in section 2.16.1 with the omission of 
SDS and set up at 4°C with running buffer as in section 2.16.3 with the omission of 
SDS. 20 [i\ of sample was added to 5 |il non-denaturing solubilisation buffer consisting 
of 50% (v/v) glycerol, 0.0125% (w/v) bromophenol blue and 62.5 mM Tris-HCl, pH 
6.8. The samples were applied directly to the gel. The gel was run at constant 100 V at 
4°C for up to 2.5 hrs.
2.17.2 UV zymogram development
After native PAGE the gel was gently rinsed with ice cold dH20  and then incubated at 
37°C in 20 ml of 5 jiM pGlu-AMC in 50 mM potassium phosphate, pH 8.0 containing 
at final concentration 10 mM DTT, 2 mM EDTA and 5% (v/v) DMSO. After 10-15 min 
the gel was visualised using a UV transilluminator coupled with an image analyser to 
capture the image to a PC.
2.18 Western blotting
An SDS-PAGE gel was run as described in section 2.16. Coloured molecular weight 
markers (CMr, Sigma ColorBurst, Figure 2.7) were included on the gel. 4 pieces of 3 
mm filter paper (Whatman) and 1 piece o f nitrocellulose membrane (Schleicher and 
Schuell) were cut to the size of the gel. The filter paper sheets and the membrane were 
soaked in Transfer Buffer for 10 min. Avoiding air bubbles, 2 sheets of filter paper were 
placed on the cathode of a horizontal semi-dry electro-blotter (ATTO), followed by the 
membrane, the gel, 2 sheets of filter paper and finally the anode. The protein transfer
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was allowed to take place at a constant 20 V for 8 min. To verify protein transfer the 
membrane was incubated in 0.1% Ponceau S (Sigma), 5.0% Acetic Acid staining 
solution with gentle agitation for 2 min followed by de-staining in dl-hO. The 
membrane was washed twice for 10 min with TBS buffer. The membrane was then 
blocked in 30 ml 5% (w/v) Milk Powder in TBS buffer for 60 min followed by 
incubation in 20 ml of Anti-His-HRP conjugate Antibody solution (prepared in blocking 
buffer) for 60 min. The membrane was washed 4 times for 10 min with TBS- 
Tween/Triton buffer. Finally the membrane was incubated briefly with the HRP 
substrate DAB (3,3’-Diaminobenzidine Tetrahydrochloride) until the signal was clearly 
visible. Using a flatbed scanner an image of the blot was saved to a PC.
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Figure 2.7 Coloured molecular weight marker (CMr)
10% polyacrylamide gel
2.19 PAP1 characterisation
A range of biochemical and kinetic properties of recombinant PAP1 were determined 
(Sections 2.19.1 to 2.19.7) including native size, pH optimum, Michaelis constant, 
turnover number, maximal velocity, inhibition constants, effect of inhibitors, isoelectric 
point and crystallisation conditions.
2.19.1 Size exclusion chromatography
The native molecular mass o f recombinant PAP1 under native conditions was 
determined by size exclusion chromatography. A 2.5 x 48 cm Sephadex G-100 gel-
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filtration column (Sigma-Aldrich) was equilibrated with potassium phosphate buffer, 
pH 8.0 containing 100 mM NaCl at 4°C. The void volume of the column was 
determined by eluting 250 jul blue dextran (8 mg/ml) at a flowrate of 0.3 ml/min. 1 ml 
fractions were collected and optical density read at 620 nm. To calibrate the column, 
standard molecular mass markers were applied separately to the column and eluted at a 
flowrate of 0.3 ml/min. The markers applied were: 100 |j.l BSA (66 kDa, 2 mg/ml), 300 
|il Carbonic Anhydrase (29 kDa, 1 mg/ml), and 100 |xl lysozyme (14.2 kDa, 2 mg/ml). 1 
ml fractions were assayed for protein concentration using the Coomassie method 
described in Section 2.14.3. 50 fil of purified PAP1 (250 jig/ml) was applied to the 
column. 1 ml fractions were assayed for activity using the 96-well plate method 
described in Section 2.15.3. A linear plot of log molecular mass versus Ve/VQ was 
constructed. The relative molecular mass o f PAP 1 was estimated using this plot.
2.19.2 Determination of pH optimum
The pH activity profile o f PAP 1 was determined by carrying out the standard activity 
assay as described in Section 2.15.2 at pH range 6.0-10.5. This range was established 
using the following buffers: 50 mM potassium phosphate for pH range 6.0-8.0, 50 mM 
Tris-HCl for pH range 7.5-9.5 and 50 mM NaOH/glycine for pH range 9.5-10.5. PAP1 
samples were pre-incubated in the above buffers for 10 min at 37°C prior to addition of 
the substrate solution, also prepared in the respective buffers.
2.19.3 Determination of Michaelis constant
The Michaelis constant (Km) was determined using a range of concentrations of pGlu- 
AMC (10-500 |iM), prepared in 50mM potassium phosphate, pH 8.0 containing at final 
concentration 10 mM DTT, 2 mM EDTA and 5% (v/v) DMSO. Purified PAP1 activity 
was assayed in triplicate with each concentration as in Section 2.15.2. Km, Vmax 
(maximal velocity) and Kcat (turnover number) values of PAP 1 for the substrate pGlu- 
AMC were obtained by fitting the data to Lineweaver-Burk, Eadie-Hofstee and Hanes- 
Woolf kinetic models (Appendix C).
2.19.4 Determination of dissociation constant
The effect of selected synthetic peptides (TRH, pGlu-His-Gly, pGlu-Ala and pGlu-Val) 
on the kinetic interaction between PAP1 and the substrate pGlu-AMC was determined. 
pGlu-AMC substrate concentrations were prepared (10-500 ¿iM) in 50 mM potassium
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phosphate, pH 8.0 containing at final concentration 10 mM DTT, 2 mM EDTA, 5% 
(v/v) DMSO and 250 |iM peptide. PAP1 activity was assayed in triplicate as outlined in 
Section 2.15.2 in the presence of the above peptides. The data obtained was applied to 
the Lineweaver-Burk, Eadie-Hofstee and Hanes-Woolf kinetic models, whereby the 
dissociation, or inhibition constant ( K j ) ,  and the type of inhibition observed were 
determined as outlined in Appendix C.
2.19.5 Inhibition
A selection of compounds (Table 2.6) were investigated for their effect on the pGlu- 
AMC degrading activity of PAP1. If the effect was inhibitory, the IC50 value was 
determined, the inhibitor concentration resulting in the PAP1 activity being reduced to 
50%. pGlu-AMC (250 (iM) substrate solutions were prepared in 50 mM potassium 
phosphate, pH 8.0 containing, at final concentration, 10 mM DTT, 2 mM EDTA, 5% 
(v/v) DMSO and the compounds summarised in Table 2.6. PAP1 samples were pre­
incubated with the same relevant compound concentration for 10 min at 37°C. PAP1 
activity was assayed in triplicate using these substrate solutions as outlined in Section
2.15.2.
Table 2.6 Compounds tested for inhibition
Inhibitor Assay conc. range (mM)
L -pG lu 0-20
2-pyrrol ¡done 0-20
Iodoacetate 0 -1 .0
1,10-phenanthroline 0-3.5
4,7-phenanthroline 0-5.0
diisopropylfluorophosphate (DFP) 0-5.0
Phenylmethylsulphonyl fluoride (PMSF) 0-5.5
2.19.6 Isoelectric focusing
The Isoelectric point of purified PAP1 was determined by Isoelectric focusing (IEF). A 
1 mm Novex pre-cast IEF gel (Invitrogen) containing a pH 3-10 gradient was used. 
PAP1 samples were dialysed against dH20  and 5 jxl mixed with 5 il of Novex IEF 
sample buffer. 5 |il (50 jig) of standard IEF markers (SERVA) were loaded alongside 
the samples (Figure 2.8). The gel was run at 100 V for 60 min, then 200 V for 60 min 
and finally 500 V for 30 min. The gel was stained and visualised as described in 
Sections 2.16.4 and 2.16.5
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Figure 2.8 IEF Markers
2.19.7 Determination of crystallisation conditions
Preliminary screening was carried out to determine conditions under which recombinant 
PAP1 could form crystals. The sparse matrix screening strategy (Jancarik and Kim, 
1991; Cudney et al., 1994) was employed using Crystal Screen 1 and 2 reagent kits 
(Hampton Research). The kits consist of a panel of reagents combining various salts, 
buffers, précipitants and solvents. The composition of the Screen 1 and Screen 2 
reagents are shown in Tables 2.7 and 2.8 respectively.
Purified PAP1 was dialysed extensively into dH20  and then concentrated to 1.5-12 
mg/ml using a SpeedVac (Savant) vacuum centrifuge. The screening was carried out by 
the hanging drop vapour diffusion method. 1 ml of each Screen reagent was aliquoted 
into a separate reservoir of a 24-Well sample plate. Vaseline was applied around the 
upper edge of each reservoir. 2 jil of reagent was taken from each reservoir and placed 
onto a glass cover slide. 2 |il of PAP 1 sample was mixed with the drop of reagent. The 
slide was inverted and pressed gently over the reservoir, creating a seal with the 
Vaseline and resulting in the drop hanging over the reservoir. dH20  from the dialysis 
reservoir was used as negative control. The drops were monitored daily using a 
microscope (10-100x magnification). Observations were recorded and images 
transferred to a PC using a digital camera attached to the microscope.
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Table 2.7 Crystal screen 1
Reagent Salt Buffer Precipitant
1 0.02 M Calcium chloride dehydrate 0.1 M Sodium acetate trihydrate pH 4.6 30 % v/v 2-methyl-2,4-pentanediol
2 None None 0.4 M Potassium sodium tartrate tetrahydrate
3 None None 0.4 M Ammonium dihydrogen phosphate
4 None 0.1 M Tris hydrochloride pH 8.5 2 M Ammonium sulfate
5 0.2 M tri-Sodium citrate dehydrate 0.1 M Sodium HEPES pH 7.5 30% v/v 2-methyl-2,4-pentanediol
6 0.2 M magnesium chloride hexahydrate 0.1 M Tris hydrochloride pH 8.5 30% w/v polyethylene glycol 4000
7 None 0.1 M sodium cacodylate pH 6.5 1.4 M sodium acetate trihydrate
8 0.2 M tri-sodium citrate dehydrate 0.1 M sodium cacodylate pH 6.5 30% v/v iso-propanol
9 0.2 M ammonium acetate 0.1 M tri-sodium citrate dihydrate pH 5.6 30% w/v polyethylene glycol 4000
10 0.2 M ammonium acetate 0.1 M Sodium acetate trihydrate pH 4.6 30% w/v polyethylene glycol 4000
11 None 0.1 M tri-sodium citrate dihydrate pH 5.6 1 M Ammonium dihydrogen phosphate
12 0.2 M magnesium chloride hexahydrate 0.1 M Sodium HEPES pH 7.5 30% v/v iso-propanol
13 0.2 M tri-Sodium citrate dehydrate 0.1 M Tris hydrochloride pH 8.5 30% v/v polyethylene glycol 400
14 0.2 M Calcium chloride dehydrate 0.1 M Sodium HEPES pH 7.5 30% v/v polyethylene glycol 400
15 0.2 M ammonium sulphate 0.1 M sodium cacodylate pH 6.5 30% w/v polyethylene glycol 8000
16 None 0.1 M Sodium HEPES pH 7.5 1.5 M lithium sulfate monohydrate
17 0.2 M lithium sulfate monohydrate 0.1 M Tris hydrochloride pH 8.5 30% w/v polyethylene glycol 4000
18 0.2 M magnesium acetate tetrahydrate 0.1 M sodium cacodylate pH 6.5 20% w/v polyethylene glycol 8000
19 0.2 M ammonium acetate 0.1 M Tris hydrochloride pH 8.5 30% v/v iso-propanol
20 0.2 M ammonium sulphate 0.1 M Sodium acetate trihydrate pH 4.6 25% w/v polyethylene glycol 4000
21 0.2 M magnesium acetate tetrahydrate 0.1 M sodium cacodylate pH 6.5 30% v/v 2-methyl-2,4-pentanediol
22 0.2 M sodium acetate trihydrate 0.1 M Tris hydrochloride pH 8.5 30% w/v polyethylene glycol 4000
23 0.2 M magnesium chloride hexahydrate 0.1 M Sodium HEPES pH 7.5 30% v/v polyethylene glycol 400
24 0.2 M Calcium chloride dehydrate 0.1 M Sodium acetate trihydrate pH 4.6 20% v/v iso-propanol
25 None 0.1 M imidazole pH 6.5 1 M Sodium acetate trihydrate
26 0.2 M ammonium acetate 0.1 M tri-sodium citrate dihydrate pH 5.6 30% v/v 2-methyl-2,4-pentanediol
27 0.2 M tri-Sodium citrate dehydrate 0.1 M Sodium HEPES pH 7.5 20% v/v iso-propanol
28 0.2 M sodium acetate trihydrate 0.1 M sodium cacodylate pH 6.5 30% w/v polyethylene glycol 8000
29 None 0.1 M Sodium HEPES pH7.5 0.8 M Potassium sodium tartrate tetrahydrate
30 0.2 M ammonium sulphate None 30% w/v polyethylene glycol 8000
31 0.2 M ammonium sulphate None 30% w/v polyethylene glycol 4000
32 None None 2 M Ammonium sulfate
33 None None 4 M Sodium formate
34 None 0.1 M sodium acetate trihydrate pH 4.6 2 M Sodium formate
35 None 0.1 M Sodium HEPES pH 7.5 0.8 M Sodium dihydrogen phosphate 
0.8 M potassium dihydrogen phosphate
36 None 0.1 M Tris hydrochloride pH 8.5 8% w/v polyethylene glycol 8000
37 None 0.1 M Sodium acetate trihydrate pH 4.6 8% w/v polyethylene glycol 4000
38 None 0.1 M Sodium HEPES pH 7.5 1.4 M tri-sodium citrate dihydrate
39 None 0.1 M Sodium HEPES pH 7.5 2% v/v polyethylene glycol 400 
2 M ammonium sulfate
40 None 0.1 M tri-sodium citrate dihydrate pH 5.6 20% v/v iso-propanol
20% w/v polyethylene glycol 4000
41 None 0.1 M Sodium HEPES pH 7.5 10% v/v iso-propanol
20% w/v polyethylene glycol 4000
42 0.05 M mono-Potassium dihydrogen Phosphate None 20% w/v polyethylene Glycol 8000
43 None None 30% w/v polyethylene glycol 1500
44 None None 0.2 M magnesium formate
45 0.2 M Zinc acetate dehydrate 0.1 M sodium cacodylate pH 6.5 18% w/v polyethylene glycol 8000
46 0.2 M calcium acetate hydrate 0.1 M sodium cacodylate pH 6.5 18% w/v polyethylene glycol 8000
47 None 0.1 M Sodium acetate trihydrate pH 4.6 2 M Ammonium sulfate
48 None 0.1 M Tris hydrochloride pH 8.5 2 M Ammonium di hydrogen phosphate
49 1 M Lithium sulfate monohydrate None 2% w/v polyethylene glycol 8000
50 0.5 M lithium sulfate monohydrate None 15% w/v polyethylene glycol 8000
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Table 2.8 Crystal screen 2
Reagent Salt Buffer Precipitant
1 2.0 M sodium chloride None 10%w/v PEG 6000
2 0.01 M Hexadecyltrimethylammonium Bromide None 0.5 M sodium chloride
0.01 M magnesium chloride hexahydrate
3 None None 25% v/v ethylene glycol
4 None None 35% v/v dioxane
5 2.0 M ammonium sulfate None 5% v/v iso-propanol
6 None None 1.0 M imidazole pH 7.0
7 None None 10% w/v polyethylene glycol 1000 
10% w/v polyethylene glycol 8000
8 1.5 M sodium chloride None 10% v/v ethanol
9 None 0.1 M sodium acetate trihydrate pH 4.6 2.0 M sodium chloride
10 0.2 M sodium chloride 0.1 M sodium acetate trihydrate pH 4.6 30 % v/v MPD
11 0.01 M cobaltous chloride hexahydrate 0.1 M sodium acetate trihydrate pH 4.6 1.0 M 1,6 hexanediol
12 0.1 M cadmium chloride dehydrate 0.1 M sodium acetate trihydrate pH 4.6 30% v/v polyethylene glycol 400
13 0.2 M ammonium sulfate 0.1 M sodium acetate trihydrate pH 4.6 30% w/v polyethylene glycol monomethyl ether 2000
14 0.2 M potassium sodium tartrate tetrahydrate 0.1 M tri-sodium citrate dihydrate pH 5.6 2.0 M ammonium sulfate
15 0.5 M ammonium sulfate 0.1 M tri-sodium citrate dihydrate pH 5.6 1.0 M lithium sulfate monohydrate
16 0.5 M sodium chloride 0.1 M tri-sodium citrate dihydrate pH 5.6 2% w/v ethylene imine polymer
17 None 0.1 M tri-sodium citrate dihydrate pH 5.6 35% v/v tert-butanol
18 0.01 M ferric chloride hexahydrate 0.1 M tri-sodium citrate dihydrate pH 5.6 10% v/v jeffamine M-600
19 None 0.1 M tri-sodium citrate dihydrate pH 5.6 2.5 M 1,6 hexanediol
20 None 0.1 M MES pH 6.5 I .6M magnesium sulfate heptahydrate
21 0.1 M sodium dihydrogen phosphate 
0.1 M potassium dihydrogen phosphate
0.1 M MES pH 6.5 2.0 M sodium chloride
22 None 0.1 M MES pH 6.5 12% w/v polyethylene glycol 20,000
23 1.6 M ammonium sulfate 0.1 M MES pH 6.5 10% v/v dioxane
24 0.05 M cesium chloride 0.1 M MES pH 6.5 30% v/v jeffamine M-600
25 0.01 M cobaltous chloride hexahydrate 0.1 M MES pH 6.5 1.8 M ammonium sulfate
26 0.2 M ammonium sulfate 0.1 M MES pH 6.5 30% w/v polyethylene glycol monomethyl ether 5000
27 0.01 M zinc sulfate heptahydrate 0.1 M MES pH 6.5 25% v/v/ polyethylene glycol monomethyl ether 550
28 None None 1.6 M tri-sodium citrate dihydrate
29 0.5 M ammonium sulfate 0.1 M HEPES pH 7.5 30% v/v MPD
30 None 0.1 M HEPES pH 7.5 10% w/v polyethylene glycol 6000 
5% v/v MPD
31 None 0.1 M HEPES pH 7.5 20% v/v jeffamine M-600
32 0.1 M sodium chloride 0.1 M HEPES pH 7.5 1.6 M ammonium sulfate
33 None 0.1 M HEPES pH 7.5 2.0 M ammonium formate
34 0.05 M cadmium sulfate hydrate 0.1 M HEPES pH 7.5 1.0 M sodium acetate
35 None 0.1 M HEPES pH 7.5 70% v/v MPD
36 None 0.1 M HEPES pH 7.5 4.3 M sodium chloride
37 None 0.1 M HEPES pH 7.5 10% w/v polyethylene glycol 8000 
8% v/v ethylene glycol
38 None 0.1 M HEPES pH 7.5 20% w/v polyethylene glycol 10000
39 0.2 M magnesium chloride hexahydrate 0.1 M tris pH 8.5 3.4 M 1,6 hexanediol
40 None 0.1 M tris pH 8.5 25% v/v tert-butanol
41 0.01 M nickel (11) chloride hexahydrate 0.1 M tris pH 8.5 1.0 M lithium sulfate monohydrate
42 1.5 M ammonium sulfate 0.1 M tris pH 8.5 12% v/v glycerol anhydrous
43 0.2 M ammonium dihydrogen phosphate 0.1 M tris pH 8.5 50% v/v MPD
44 None 0.1 M tris pH 8.5 20% v/v ethanol
45 0.01 M nickel (II) chloride hexahydrate 0.1 M tris pH 8.5 20% w/v polyethylene glycol monomethyl ether 2000
46 0.1 M sodium chloride 0.1 M bicine pH 9.0 20% w/v polyethylene glycol monomethyl ether 550
47 None 0.1 M bicine pH 9.0 2.0 M magnesium chloridc hexahydrate
48 2% v/v Dioxane 0.1 M bicine pH 9.0 10% w/v polyethylene glycol 20000
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3.0 Cloning, expression and purification of recombinant human PAPI
3.1 Overview
This chapter describes cloning of the human PAPI gene from eDNA and the subsequent 
development of a recombinant expression system, capable o f producing catalytically 
active recombinant human PAPI at high levels, which could be isolated to a high purity. 
Various biochemical, kinetic (Chapter 4) and functional studies (Chapter 5) were then 
carried out.
3.2 Cloning of human PAPI gene
Cell pellets (~1 x 107 cells) o f two human cancer cell lines, SW620 and Hs 578T 
(American Type Culture Collection No. CCL-227 and HTB-126 respectively), were 
obtained from workers in the laboratory of Dr. Susan McDonnell (DCU, Ireland). 
SW620 is derived from a metastatic lymph node colorectal adenocarcinoma. Hs 578T 
was derived from a carcinoma of the breast. The SW620 cells (suspended in 1 ml of 50 
mM potassium phosphate buffer, pH8.0) were found to be positive for PAPI activity 
(2.8 units/ml) as determined by the method described in Section 2.15.2. In contrast, the 
Hs 578T cells registered a negligible 0.08 units/ml by equivalent analysis. Total RNA 
was isolated from a fresh SW620 cell pellet as described in Section 2.4.4. Figure 3.1 A 
shows analysis of this RNA by agarose gel electrophoresis (Section 2.5). Sharp, clear 
28S and 18S ribosomal RNA (rRNA) bands were an indication that the RNA 
preparation had not been degraded to any significant extent.
The sequence for putative human PAPI mRNA (AJ278828, Table 1.4, Figure 3.2) was 
obtained from GenBank (Benson et al., 1996). This putative sequence was confirmed 
during the progression of this work (Dando et al., 2003). The 707 bp sequence contains 
a 630 bp open reading frame (ORF) for human PAPI (Hsa-papl). Primers PAPHsA and 
PAPHsB (Table 2.2) were designed external to this ORF to amplify the putative PAPI 
gene (Figure 3.2) as a 698 bp fragment. cDNA was generated from the SW620 RNA 
using the specific reverse primer PAPHsB as described in Section 2.8.1. The cDNA was 
used as template for PCR (Section 2.8.2) using primers PAPHsA and PAPHsB. The 
resulting RT-PCR product, analysed by agarose gel electrophoresis (Section 2.5), is 
shown in Figure 3 .IB. A band corresponding to the expected size of 698 bp was 
obtained. Some non-specific bands were also present. Several attempts were made to 
eliminate these bands by increasing the annealing temperature during the PCR reaction 
(data not shown). However, these attempts were unsuccessful.
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The RT-PCR products shown in Figure 3 .IB were cloned into the TA cloning vector 
pCR2.1 (Table 2.3, Figure 2.1) as described in Section 2.9.1. Several white colonies 
were purified and plasmid DNA was isolated (Section 2.4.1). Screening for a TA clone, 
having the desired -700 bp recombinant Hsa-papl insert (rHsa-papl), was carried out 
by enzymatic restriction analysis with EcoRX (Section 2.8). EcoR\ specifically cuts the 
TA insert out of the pCR2.1 vector. A candidate clone was identified and further 
analysed by PCR using PAPHsF and PAPHsG (Figure 3.2). A band corresponding to 
the expected 638 bp rHsa-papl product was obtained, as shown in Figure 3.1C.
A restriction digest of this clone (pRVl) analysed by agarose gel electrophoresis is 
shown in Figure 3.3. Restriction with EcoRX produces a band corresponding to the 
expected 713 bp fragment containing the rHsa-papl sequence. The EcoRW restriction 
resulted in a band corresponding to 492 bp, suggesting that the rHsa-papl sequence had 
inserted in the opposite orientation to the lacZa ORF of pCR2.1 (a band corresponding 
to 245 bp would have indicated the same orientation as lacZa). The Nco\ restriction 
similarly supported this opposite orientation. Single restriction with HindXW and BamW\ 
produced bands corresponding to the expected 4603 bp linearised plasmid. The 
successful cloning of rHsa-papl was confirmed by DNA sequencing (Section 2.10). 
The sequencing data is given in Appendix B. A map of pRVl is shown in Figure 3.4.
A  1 2 3 B 1 2 C J ___ 2_
Figure 3.1 Cloning of human PAP1 gene
1% agarose gels. (A): Lane 1, DNA Ladder (not quantifying for RNA); Lane 2, RNA isolated from 
SW620 cells (Section 2.4.4) treated with Ribonuclease A (Section 2.8); Lane 3, RNA isolated from 
SW620 cells. Prominent 18S and 28S rRNA bands are indicated (B): Lane 1, DNA Ladder (sizes as in 
Figure 2.5); Lane 2, product of RT-PCR (Section 2.8.1 & 2.8.2) on SW620 RNA using primers PAPHsA 
and PAPHsB (Table 2.2, Figure 3.2). The band corresponding to the expected 698 bp PAP1 product is 
indicated by red arrow, while non-specific bands are indicated by black arrows. (C): Lane 1, DNA 
Ladder; Lane 2, product of PCR (Section 2.8.2) on pRVl using primers PAPHsF and PAPHsG (Table 
2.2). The band corresponding to the expected 638 bp PAP1 product is indicated by red arrow.
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A J 2 7 0 B 2 8  : AGTCGCAACAGAAGCAGGTCCGAGGCACAGCCCGATCCCGCCAIGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTITGGGGAACACAC : 1 0 1  
PAPHsA ”  PA PH* F
A J 2 7 8 8 2 8  : CGTGAACGCCAGTIGGATTGCAGTTCAGCAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAG : 2 0 2
A J 2 7 8 8 2 8  : TCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCACGCATGGCGACCACAGTCACACTGGAGAAATGT : 3 0 3
A J 2 7 8 8 2 8  : GGACACAACAAGGGCTACAAGGGQCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGA : 4 0 4
Eco  RV
A J 2 7 B 8 2 0  : CATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACA : SOS
A J 2 7 8 3 2 8  : CCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCATC : 6 0 6
A J 2 7 8 8 2 B  : ATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAACACTGAGGGACGCTCAGGTCTCCTAAGACCTCATCCTGCTC : 7 0 7
** PÂPHsü-----------------  '  PAPHsB
Figure 3.2 Human PAP1 putative mRNA sequence
Nucleotide sequence AJ278828: human putative PAP1 mRNA. ORF is highlighted in blue. Binding 
locations of primers PAPHsA, PAPHsB, PAPHsF and PAPHsG (Table 2.2) are indicated. Restriction 
sites are marked in red. Illustrated using GenDoc (Section 2.11).
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Figure 3.3 Verification digest of pRVl
Restriction digest of pRVl clone analysed on 1% agarose gel (Section 2.5): Lane 1, DNA Ladder (sizes 
as in Figure 2.5); Lane 2, //m dlll; Lane 3, BamWX ; Lane 4, Nco\ \ Lane 5, £cc>Rl; Lane 6, fcoRV; Lane 
7, uncut (prominent covalently closed and open circular bands are visible as well as a fainter linear band).
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HiKdm -1  - A'AGCT_T
Figure 3.4 pRVl plasmid map
The rHsa-papl gene fragment (blue) is inserted in opposite orientation relative to the LacZa ORF (green), 
which is under the control of the Plac promoter (yellow). Ampicillin and kanamycin resistance genes 
(ampR & kanR) are shown in red. Some restriction sites are indicated with position and sequence. See 
Figure 2.1 for map of parent vector pCR2.1. Illustrated using pDRAW32 (Section 2.11).
3.3 Choice of expression host for recombinant human PAP1
The Gram-negative bacterium E. coli is one of the most commonly used host of 
recombinant heterologous protein expression (Baneyx, 1999). It grows rapidly at high 
density on inexpensive substrates. It has well-characterised genetics and many variable 
strains are available, as well as a broad range of compatible cloning and expression 
vectors. The major drawbacks of E. coli as an expression system, especially for 
recombinant eukaryotic proteins, include the inability to perform many of the post- 
translational modifications necessary for eukaryotic proteins, in particular 
glycosylation; and a limited ability to facilitate extensive disulphide bond formation 
(Makrides, 1996).
Studies to date on the native mammalian PAP1 enzymes indicate that the active forms 
are not glycosylated. A close sequence identity, as well as very similar biochemical and 
catalytic properties between eukaryotic and prokaryotic PAP1 enzymes, has been 
reported in Chapter 1. Active recombinant forms of several prokaryotic PAP1 enzymes 
have been successfully expressed in E. coli (Section 1.3.5), which has no endogenous 
PAP1 activity (Section 1.3.3). Thus, although there was some probability that
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catalytically active recombinant human PAP1 (r/fctfPAPl) would not be expressed in E. 
coli, it was decided to investigate this possibility.
3.4 Construction of E. coli expression system for recombinant human PAP1
In order to create a potential system for the expression of rHsaPAPX in E. coli, the 
rHsa-papl sequence (Section 3.2) was sub-cloned into E. co//-compatible expression 
plasmids. The plasmids pQE-60 and pPC225 were used, as presented in Sections 3.4.1 
and 3.4.2. The resulting constructs had introduced 6 consecutive His codons (6xHis) as 
a 3’ extension to the rHsa-papl ORF. This His-tag would benefit protein purification 
(Section 3.7), assuming it did not interfere with catalytic activity. A construct lacking 
the 6xHis sequence was also created to provide the means of expressing non His-tagged 
rHsa?A?\ (Section 3.4.3).
3.4.1 Sub-cloning of human PAP1 gene into E. coli expression vector pQE-60
The vector pQE-60 (Table 2.3, Figure 2.2) features an optimised hybrid promoter- 
operator element (Bujard et al., 1987) consisting of the phage T5 transcriptional 
promoter and a lac operator sequence, which increases lac protein (LacI) binding, 
enabling repression of this strong promoter. Associated with this operator region is a 
synthetic ribosome binding site (RBS) designed for high translation rates. The /?- 
lactamase gene conferring resistance to ampicillin (ampK) is present on the vector. Most 
significantly, the vector has six consecutive His codons (6xHis) followed by a stop 
codon, at the 3’ end of the multiple cloning site (MCS). This enables translation of a 
fusion protein having a C-terminal His-tag, which can be exploited during protein 
purification (Section 3.7).
The rHsa-papl sequence was sub-cloned from pRVl into pQE-60 by the strategy 
outlined in Figure 3.5. The pQE-60 MCS conveniently has an Nco\ site as the 5’ 
insertion point. As can be seen in Figure 3.2 the rHsa-papl sequence already features 
this site within the mRNA. rHsa-papl was amplified by PCR with primers PAPHsH 
and PAPHsI (Table 2.2) and ligated into vector pCR2.1 as described in section 2.9.1. 
PAPHsH was designed to include the Nco\ site at the 5’ end of rHsa-papl (Figure 3.2) 
and PAPHsI to tag a BamHX site at the 3’ end, replacing the stop codon. rHsa-papl was 
excised from this intermediate clone by an NcoX/BamWX restriction and ligated into 
pQE-60, which had been opened by an NcoMBglU restriction. BamHX and Bgl\\ sites
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have compatible ends which, when fused, eliminate the restriction site. The cloning of 
rHsa-papl into pQE-60 thus results in a 3’ 6xHis fusion to the ORF.
Figure 3.6 shows a verification digest o f this construct, pRV3. The Ncol/Hindlll 
restriction resulted in a band corresponding to the expected 654 bp fragment containing 
the rHsa-papl-6xHis fusion. EcoRX, Nco\ , Hind III and EcoKV single restrictions 
produced bands corresponding to the expected 4046 bp linearised plasmid.
DNA sequencing of pRV3 (Section 2.10; Appendix B) revealed a 32 bp deletion (Figure 
3.7), upstream of the EcoR\ site within the vector sequence, affecting critical elements 
of the pQE-60 T5 promoterI lac operator. Other workers in the laboratory subsequently 
confirmed the presence of identical deletions in their pQE-60 constructs, indicating this 
deletion was carried forward from the original laboratory plasmid stock. Consequently, 
a new sample of pQE-60 was obtained from Qiagen and the cloning procedure in Figure
3.5 was repeated, yielding the construct pRV8, which was confirmed by DNA 
sequencing (Appendix B).
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Figure 3.5 Cloning strategy for pRV3 (pRV8)
Outline of sub-cloning strategy from pRVl to generate pRV3 (pRV8). PCR (Section 2.8.2) on pRVl 
using primers PAPHsH and PAPHsl (Table 2.2) generates product containing rHsa-papl without stop 
codon and having Nco\ and BamYi\ site tags, which is ligated into pCR2.1. rHsa-papl is excised from 
intermediate clone by NcoMBamHX restriction and ligated into pQE-60 (Table 2.3, Figure 2.2), which has 
been opened with NcoMBgtft restriction. Resulting construct, pRV3, has 6xHis sequence cloned to 3’ end 
of rHsa-papl followed by stop codon. Restriction sites are indicated with positions (and sequence for 
final construct). Illustrated using pDRAW32 (Section 2.11).
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Figure 3.6 Verification digest of pRV3
Restriction digest of pRV3 construct analysed on 1% agarose gel (Section 2.5): Lane 1, DNA Ladder 
(sizes as in Figure 2.5); Lane 2, EcoKl; Lane 3, Nco\\ Lane 4, Nco\/Hind\l\; Lane 5, Hind III; Lane 6, 
£coRV; Lane 7, uncut (prominent covalently closed and open circular bands are visible). Due to lack of 
RNase treatment, significant RNA levels are visible at lower end of gel.
pRV3 : AATTTAt M B M t GTGAGCGGATAACAAt B ---------------------------------------------------------- TC : 3 3
e x p e c t e d  : AAT T T AtH H ^  GT GAGCGGAT AACAAt M B B t a GAT T C A |t  TGT GAGCGGAT AACAATT TC : 65
-35 -10 +1
transcription start
£ cpR 1 ______________________ jVco»
pRV3 : ACACAGAAT T C A T T TAACC^KGAGCAGCCGAGGAAGGCGGT GGTAGTGACG : 98
e x p e c t e d  : a r.a r.a g a a t t c a t t a t t a a c c & ~ ;a»-■ r a g c c g a g g a a g g c g g t g g t A G T g a c g  : 1 3 0
RBS rHsa-papl
start codon
Figure 3.7 Deletion within pRV3
Alignment of the actual pRV3 sequence (Appendix B) with the expected sequence. Promoter region is 
highlighted in red with -35 box, -10 box and transcription start site indicated. Ribosome binding site 
(RBS) is highlighted in black. rHsa-papl ORF is highlighted in blue. EcoRl and Nco\ restriction sites 
are marked. The 32 bp deletion encompasses the transcription start site and the -10 box. Illustrated using 
GenDoc (Section 2.11).
3.4.2 Sub-cloning of human PAP1 gene into E. coli expression vector pPC225
While awaiting the arrival o f another sample o f pQE-60 vector for the construction of 
pRV8 (Section 3.4.1), rHsa-papl was sub-cloned from pRV3 into the vector pPC225 
(Table 2.3, Figure 2.3) as outlined in Figure 3.8. pPC225 features the tac transcriptional 
promoter (Ptac). Ptac is a hybrid promoter consisting of the -35 region from the trp 
promoter fused to the -10 region (Pribnow box), operator and RBS (Shine-Dalgamo 
sequence) from Plac. DeBoer et al. (1983) reported on the high efficiency of Ptac in 
expressing foreign genes in E. coli as opposed to the parental promoters. Ptac can be 
repressed by the LacI protein. pPC225 contains ampR and another useful feature, noted 
during cloning, was that the 1800 bp fragment within the MCS (Figure 2.3) allowed for 
easy differentiation of linear from uncut vector.
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An £,coRl////«dIII restriction enabled the entire rHsa-papl-6xHis fusion to be 
transferred from pRV3 to pPC225, which had been opened with EcoRl/Hindlll. Figure
3.9 shows a restriction digest of this construct, pRV5. The EcoR\/Hind\l\ restriction 
produced a band corresponding to the expected 680 bp fragment containing the rHsa- 
papl-6xH\s fusion. EcoRM, Ncol, EcoR\ and Hindlll single restrictions produced 
bands corresponding to the expected 5235 bp linearised plasmid. 
pRV5 was subsequently verified by DNA sequencing (Appendix B). Figure 3.10 details 
the rHsa-papl region of pRV5 showing the promoter elements, translated sequence, 
restriction sites and the 6xHis tag.
Æcaül • 1
Figure 3.8 Cloning strategy for pRV5
Outline of sub-cloning strategy from pRV3 to generate pRV5. The rHsa-papl-6xHis fusion is excised 
from pRV3 by restriction with EcoRl and Hindlll. This 680 bp fragment is ligated into pPC225, which 
has been opened with EcoRl and Hindlll. Resulting construct, pRV5, has rHsa-papl-6xHis fusion under 
control of Ptac promoter. Restriction sites are indicated with positions (and sequences for final construct). 
Illustrated using pDRAW32 (Section 2.11).
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Figure 3.9 Verification digest of pRV5
Restriction digest of pRV5 contruct analysed on 1% agarose gel (Section 2.5): Lane 1, DNA Ladder 
(sizes as in Figure 2.5); Lane 2, EcoRV; Lane 3, Nco 1; Lane 4, EcoR\; Lane 5, £coRl///mdIII; Lane 6, 
HindlU; Lane 7, uncut (prominent covalently closed and open circular bands are visible as well as a 
fainter linear band).
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pRV5 : TCTGAAATGAGCTGjBBBATTAATCATCGGCTCGBmiGTGTGGB ATTGTGAGCGGATAACAATTTCACACBEBSAACA : 5235 bP 
-35 -10 +1 transcription start  RBS______
Nco 1
Eco R1 M E Q P R K A V V V T G F G P F G E H  : I9AA
pRV5 : GAATTCATTgHSEEBffi^^TTAACcHBGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACA : 83 bp 
RBS rH sa-papl start codon
— pswkr:----- ^
Stu\
T V N A S W I A V Q E L E K L G L G D S V D L H V Y E  : 46AA 
pRV5 : CACCGTGAACGCCAGT T GGAT T GCAGT T CAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGT GGACCT GCAT GT GTACGAGA =166 bp
r  P V E Y Q T V Q R L I  P A L W E K H S  P Q L V V H V G :  74AA 
pRV5 : TTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGG :249bp
V S G M A T T V T L E K C G H N K G Y K G L D N C R F C  :102AA 
pRV5 : GT GT CAGGCAT GGCGACCACAGT CACACT GGAGAAAT GT GGACACAACAAGGGCT ACAAGGGGCT GGACAACT GCCGCT T T T G : 332 bp
P G S Q C C V E  D G P E  S I D S I I D M D A V C K R V  : 129 AA 
pRV5 : CCCCGGCT CCCAGT GCT GCGT GGAGGACGGGCCT GAAAGCAT T GACT CCAT CAT CGACAT GGATGCT GT GT GCAAGCGAGT CA =415 bp
Eco RV
T T L G L D V S V T I S Q D A G R Y L C D F T Y Y T  S L  : 157 AA 
pRV5 : CCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTG : 498 bp
Y Q  S H G R  S A F V H V P  P L G K  P Y N A D Q L G R A L : 1 8 5 A A  
pRV5 : TACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACT : 581 bp
R A I I E E M L D L L E Q S E G K I N Y C H K H G S  H :212AA
pRV5 : GAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAACACGGATCTHffli = 664 bp
linker
PAPHsL \AA~Bar>A  11 —c la m p
H H H H H ///»dill : 217 AA
pRV5 : T GGCT GT T T T GGCGGAT GAGAGAAGAT T T T CAGCCT GATACAGAT TAAAT CAGAACGCAGAAG : 747 bp
6x1 lis stop codon
Figure 3.10 pRV5 sequence detail
The rHsa-papl (blue) and Ptac promoter (red) regions of pRV5 are shown in detail. The translation of 
rHsa-papl is shown in blue above the ORF. The 6xHis tag sequence is shown in green, joined to rHsa- 
papl by a Gly-Ser linker. Two ribosome binding sites (RBS, black) are shown. The first RBS upstream 
from the rHsa-papl start codon was subcloned from pRV3 (Figure 3.5) while the second RBS was 
present on pPC225 associated with the Ptac promoter. Restriction enzymes and primers PAPHsK &
PAPHsL (Table 2.2) are marked in red. For amino acid information see Appendix D. Illustrated using 
GenDoc (Section 2.11).
3.4.3 Construction of human PAP1 expression plasmid without His-tag
A strategy to sub-clone rHsa-papl from pRV5 is shown in Figure 3.11. PCR was 
performed on pRV5 using primers PAPHsK and PAPHsL (Table 2.2, Figure 3.10). This 
resulted in a product encompassing the EcoKl site upstream from rHsa-papl and the 
6xHis being replaced with a stop codon followed by a BamWX site with restriction 
clamp. The use of this clamp allowed the PCR product to be restricted directly without 
the need of an intermediate clone such as was used in a previous strategy (Figure 3.5).
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The PCR product was restricted by EcoRl/BamHl and ligated into pPC225, which had 
been opened by EcoRHBamWl.
Figure 3.12 shows a restriction digest of the resulting construct, pRV5_A6H. The 
EcoRl I BamHl restriction produced a band corresponding to the expected 658 bp 
fragment containing the rHsa-papl sequence. EcoRl, BamW 1, EcoRV and Hind III 
single restrictions produced bands corresponding to the expected 5233 bp linearised 
plasmid. pRV5_A6H was verified by DNA sequencing (Appendix B). The pRV5_A6H 
construct is identical to pRV5 except that the 6xHis sequence has been deleted.
EcoRl - 1
Figure 3.11 Cloning strategy for pRV5_A6H
Outline of sub-cloning strategy from pRV5 to generate pRV5_A6H. PCR (Section 2.8.2) on pRV5 using 
primers PAPHsK and PAPHsL (Table 2.2) generates product with EcoRl site upstream from rHsa-papl 
and having the 6xHis fusion replaced by stop codon followed by BamHl tag with clamp. Fragment is 
restricted with EcoRl and BamHl and then ligated into pPC225, which has been opened with EcoRl and 
BamHl. pRV5_A6H has rHsa-papl (without 6xHis) under control of P tac promoter. Restriction sites are 
indicated with positions (and sequences for final construct). Illustrated using pDRAW32 (Section 2.11).
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Figure 3.12 Verification digest of pRV5_A6H
Restriction digest ofpRV5_A6H contruct analysed on 1% agarose gel (Section 2.5). Lane 1, DNA Ladder 
(sizes as in Figure 2.5); Lane 2, EcoKl; Lane 3, EcoRMBamHl; Lane 4, BamHl; Lane 5, EcoRV; Lane 6, 
Hindlll; Lane 7, uncut (covalently closed and open circular bands are visible).
3.5 Preliminary characterisation of recombinant human PAP1
The effort of constructing E. coli expression systems for recombinant human PAP1 
(Section 3.4) was justified by the successful expression of catalytically active native 
(r//swPAPl) and His-tagged (rHsaPAP 1 6h) enzyme.
The r/fctfPAPl expression plasmid pRV5_A6H (Section 3.4.3), as well as the 
r//stfPAPl6H expression plasmids pRV5 (Section 3.4.2) and pRV8 (Section 3.4.1), were 
transformed into E. coli XL 10-Gold (Table 2.1) by the method described in Section 
2.6.3. The plasmid vector pPC223 (Table 2.3), which serves as a negative control to 
pRV5 and pRV5_A6H, was also transformed.
Expression cultures were prepared by the methodology described in Section 2.12. 
Samples were taken 4 hrs after induction with 50 jliM  isopropyl-P-o- 
thiogalactopyranoside (IPTG, Section 3.8). Cleared lysate samples obtained from 
rHsaPAP 1 and rHsaPAP 16H expression cultures (using pRV5_A6H and pRV5, 
respectively), as well as a negative control (using pPC223) were analysed for PAP1 
activity as outlined in Section 2.15.2. The rHsaPAPX sample measured an activity o f
2894.7 units/mg, while the r/fctfPAPl6H sample measured 2057.7 units/mg. The 
negative control measured 0.01 units/mg. Figure 3.13A shows SDS-PAGE analysis 
(Section 2.16) of these samples. Prominent protein bands are evident, running between 
the 20 and 24 kDa markers. The molecular weights of rHsaPAP] and r/fcaPAPl6H are
23,138 (Table 1.4) and 24,105 respectively, as deduced from their amino acid 
sequences. A subtle size difference of about 1 kDa is observed between rHsa?AP\ and 
r/fctfPAPlóH, which is attributed to the His-tag and linker amino acid residues (Figure 
3.10). Comparative kinetic analysis o f the two forms of recombinant human PAP1 
within cleared lysate is presented in Section 4.2.
Samples from rHsa?A?\eH expression cultures using pRV5 and pRV8 were analysed 
by SDS-PAGE (Figure 3.13B). Both expression systems gave comparable levels of  
recombinant protein. This recombinant protein expression was not observed from 
expression cultures with pRV3 (data not shown), attributed to the deletion within the 
promoter sequence (Figure 3.7).
Zymogram analysis (Section 2.17) of a r/fcaPAPUn cleared lysate sample provided a 
correlation between the prominent protein band and PAP1 activity (Figure 3.14). 
Further zymography, of purified rHsa?A?\en, can be seen in Figure 3.34. Confirmation 
that the His-tag is fused to the protein of expected size for human PAP1 was obtained 
by western blotting (Section 2.18) with anti-His antibody (Figure 3.15). Further western 
blot verification, including pPC223 and pRV5_A6H as negative controls, can be seen in 
Figure 5.19.
Figure 3.13 Expression of rHsaPAPl and r//saPAPl6H in E. coli
Analysis of cleared lysate samples by 15% SDS-PAGE (Section 2.16). (A): Lane 1, Mr (sizes as in Figure 
2.6); Lane 2, E. coli XL 10-Gold cultured with pPC223 (Table 2.3); Lane 3, r//saPAPl (expressed from 
pRV5_A6H in E. coli XL 10-Gold as outlined in Section 2.12); Lane 4, r//s<2PAPl6H (expressed from 
pRV5 in E. coli XLIO-Gold). (B): Lane 1, Mr (sizes as in Figure 2.6); Lane 2, rHsaPAPlm (expressed 
from pRV5 in E. coli XL 10-Gold); Lane 3, xHsa?API6H (expressed from pRV8 in E. coli XL 10-Gold).
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Figure 3.14 Zymogram analysis of r//vaPAPl()1i
Zymogram analysis (Section 2.17) of cleared lysate sample from E. coli XLIO-Gold culture expressing 
(Section 2.12) iHsa?AP16H from pRV5 (Figure 3.8). Lane 1, 1/10 dilution; Lane 2, 1/100 dilution; Lane 
3, 1/1000 dilution. The fluorescence corresponds to the prominent protein bands visible after coomassie 
staining (data not shown).
Figure 3.15 Western blot analysis of r/faaPAPl6H
Western blot (Section 2.18) analysis, using anti-His antibodies, of cleared lysate sample from E. coli 
XLIO-Gold culture expressing (Section 2.12) r//sflPAPl6H from pRV5 (Figure 3.8). Lane 1, CMr (sizes 
given in Figure 2.7); Lane 2 cleared lysate.
3.6 Optimisation of recombinant human PAP1 expression in E. coli 
The merits of different E. coli genotypes for the expression of vHsa?API6h were 
investigated. The expression plasmid pRV5 (Section 3.4.2, Figure 3.8) was transformed 
into various E. coli strains, namely DH5a, lNVaF', BL21, Nova Blue, XLIO-Gold, 
Rosetta and RosettaBlue (Table 2.1), by the method described in Section 2.6.3.
The very similar DH5a and INVaF' strains are used routinely in this work for the 
cloning and propagation of plasmid constructs. BL21 is a strain deficient in the OmpT
30,000 Da
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protease, purportedly allowing higher recovery of heterologous recombinant proteins. 
The Nova Blue and XL 10-Go Id strains contain F factors, which carry the lac\q allele. 
The laclq allele is a promoter mutation that expresses the LacI repressor protein at high 
levels, resulting in strong repression o f the Ptac promoter (Section 3.4.2) unless the 
inducer 1PTG is added, which binds and inactivates LacI and thus induces transcription 
from Ptac.
Genes in both prokaryotes and eukaryotes exhibit a non-random usage of synonymous 
codons (A codon table is given in Appendix D). This means there is a bias toward one 
or two codons in most degenerate codon families. The frequency of codon usage is 
usually reflected by the abundance of the associated tRNAs in different cell 
backgrounds. This implies that recombinant heterologous genes enriched with codons 
rarely used in E. coli may experience poor translation efficiency (Makrides, 1996). 
Figure 3.16 shows the nucleotide sequence coding for r/fcaPAPUH, as it is found on the 
pRV5 construct (Figure 3.8). Codons of optimal and minimal usage in E. coli have been 
indicated, according to international DNA sequence databases (Nakamura et al., 2000). 
E. coli Rosetta and RosettaBlue are derivatives of the strains BL21 and NovaBlue, 
respectively, carrying the pRARE plasmid (Table 2.3, Figure 2.4). pRARE (Novy et al., 
2001) encodes genes for six tRNAs that recognise codons considered rare in E. coli. The 
use of pRARE during the expression of heterologous proteins is one strategy to 
overcome a possible codon bias o f E. coli. Those codons, which are compensated for by 
the pRARE system, have been marked in Figure 3.16. It should be noted this system 
does not provide for all the rare codons.
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M E  Q P R  K A V V V T  G F G P P  G E  H T V N A S  W I  A  V : 28 AA
Q E L B K L G L G D 3 V D L  H V  Y E I  P  V  E Y Q T V Q : 55 AA 
p R V S  : T H B G A G f l B H B A A G f l |H |C T T H ( S A C B H |G A C M H H H |T A C G A G C H n G T T G A G T A C C A A f l § ^ T c |H | |  : 1 6 6  b p* *
R L I  P A L W  E K H  8 P Q L V V H V G V S G M A T T V T  : 8 3 A A  
p R V 5 : GACT CATCCCCGCCCTGTGGGASAAGCACAGTCCACAGCTGGTGGTGCATGTQGGGGTGTCAGGCATGGCGACCACA ST I'ACA =249 bp
* *
L E  K C G H N  K G Y K G L D N C R  F C P G  S Q C C V E  D : I II  AA 
p R V S  : H § G A G M T G T B ^ A C ^ B A A G B B T A C A A G H H B G A C ® C rr G C C G C T T T T G C C C C G G C T r- r C A G T G C T G C G i|G A G G A  : 332 bp
G P E S I D 3 I I D M D A V C K R V T T L G L D V S V  :138AA 
p R V 5  : cB W C C T G A A A G C A T T G A C T C C A T C A T C G A C ® H H <3 C T B | H B AAGS B GTCB B k CGTTG<sG C C T G G A T G T < S T C G H B | :415 bp
T I  S Q D A  G R Y L C D  F  T Y Y T 3 L Y Q 3 H G R 3 A  F  :166AA 
p R V 5  : B a t c t c g c a g g a t g c c g g c a g a t a t c t c B B g a c J B B B t a c t a c S B t c t t t g t a c H ^ - g t c a c g g t c g a t c a g c c t t c  : 498 bp
V H V P P L S K P Y N A D Q L G R A 1 . R A I I E  E M L D :194AA 
p R V 5  : G T C C A C | H H | H | H | B A A G | | T A C f l M M G A C | H i H H H GCAM H H H A': r c I H GAG G A G H 9 rT G G A  ¡581 bp
*  *  *
L L  E Q S E G K I  W Y C H K H G S H H H H H H  :217AA
p R V 5 : CCTcBBGAGCAGTCAGAGGGCAAAATCAACTAlTGCCACAAACACGGATCTCATCACCATCACCATCACgB! ¡654 bp
Figure 3.16 E. coli codon bias relative to rHsa-papl
Nucleotide sequence coding for r//saPA Pl6H5 as found on pRV5 (Figure 3.8). Amino acids corresponding 
to each codon are specified. Codons of optimal usage in E. coli are highlighted green. Codons considered 
rare in E. coli are highlighted red. Those codons whose corresponding tRNAs are encoded on the pRARE 
plasmid (Table 2.3, Figure 2.4) are marked by red stars. For amino acid information see Appendix D. 
Illustrated using GenDoc (Section 2.11).
Expression of r//stfPAPl6H was carried out by the methodology outlined in Section 
2.12. The growth curves of these expression cultures, measured by optical absorbance at 
600 nm (A6oo), are shown in Figures 3.17 and 3.22. Growth rates, during exponential 
phase, are expressed as the increase in A6oo per hour. The strains had comparable 
growth rates, although some took longer to reach the exponential growth phase. One 
reason for this may be slightly different inoculation concentrations. However, repeated 
experiments with consistent results (data not shown), conclude that some E. coli strains, 
especially DH5a, exhibit a longer lag phase.
The cleared lysate samples obtained from these expression cultures were analysed by 
SDS-PAGE (Section 2.16), shown in Figure 3.18 (DH5a and INVaF'), Figure 3.19 
(BL21 and Rosetta), Figure 3.20 (Nova Blue and RosettaBlue) and Figure 3.23 (XL10- 
Gold). Also, Figure 3.21 shows samples taken from expression cultures in Nova Blue, 
RosettaBlue and XL10-Gold (induced with 50 IPTG), compared to non-induced 
cultures. r/fctfPAPl6H activity was determined for each sample as outlined in Section
2.15.2. Using densitometry (Section 2.16.5) the percentage of total protein attributed to
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the rHsaPAPleu band was approximated. In Figure 3.21 a discrepancy is observed 
between the ratios of densitometry and activity values comparing induced to non­
induced samples. It is likely that this discrepancy is the result of underestimation in the 
densitometry readings obtained from the SDS gel. Irrespective of which set of data is 
taken, E. coli XL 10-Gold was considered to give the optimal expression level.
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Figure 3.17 Growth curves for expression of r//saPAPl6H in E . coli
Log absorbance readings at 600nm (Log A 6oo) taken during expression (Section 2.12) of r//saPA Pl6H in 
E. coli DH5a and INVaF' (Figure 3.18); BL21 and Rosetta (Figure 3.19); Nova Blue and RosettaBlue 
(Figure 3.20). Induction of Nova Blue and RosettaBlue with 50 |iM IPTG as indicated by arrows. Growth 
rates (increase of A 6oo per hour) during exponential phase are given in red.
- o -  BL21 (0.47)
—x -  Rosetta (0.38) 
Nova Blue (0.35)
—0 -  RosettaBlue (0.39) 
- + -  DH5ct (0.48)
_ a_  INVaF (0.36)
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Figure 3.18 Expression of r//snPAPl6H in E. coli DH5a and ENTVaF'
Analysis of i7/saPAPl6H expression in E. coli (Section 2.12) from pRV5 (Figure 3.8) by 15% SDS-PAGE 
(Section 2.16). r//5flPAPl6H given as percentage of total protein, as determined by densitometry (Section 
2.16.5). Growth curves shown in Figure 3.17. (A) DH5a: Lane 1, Mr (sizes given in Figure 2.6); Lane 2, 
5.5 hrs (8%); Lane 3, 6.5 hrs (11%); Lane 4, 7.5 hrs (11.9%); Lane 5, 8.5 hrs (13.3%); Lane 6, 9.5 hrs 
(13.7%). (B) INVaF: Lane 1, Mr; Lane 2, 3.5 hrs (6%); Lane 3, 4.5 hrs (9.4%); Lane 4, 5.5 hrs (11.3%); 
Lane 5, 6.5 hrs (11.2%); Lane 6, 7.5 hrs (11.8%).
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Figure 3.19 Expression of rHsaPAPlm in E. coli BL21 and Rosetta
Analysis of r//stfPAPl6H expression in E. coli (Section 2.12) from pRV5 (Figure 3.8) by 15% SDS-PAGE 
(Section 2.16). r//5aPAPl6H given as percentage of total protein, as determined by densitometry (Section 
2.16.5). Growth curves shown in Figure 3.17. (A) BL21: Lane 1, Mr (sizes given in Figure 2.6); Lane 2 ,2  
hrs (4.6%); Lane 3, 3 hrs (6.8%); Lane 4, 4 hrs (3.8%); Lane 5, 5 hrs (5.4%); Lane 6, 6 hrs (5.5%). (B) 
Rosetta: Lane 1, Mr; Lane 2, 4.5 hrs (10.5%); Lane 3, 5.5 hrs (12.2%); Lane 4, 6.5 hrs (13%); Lane 5, 7.5 
hrs (13.2%); Lane 6, 8.5 hrs (14.2%).
xHsaVm
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Figure 3.20 Expression of rtfsaPAPl6H in E . coli Nova Blue and RosettaBlue
Analysis of r//5aPAPl6H expression in E. coli (Section 2.12) from pRV5 (Figure 3.8) by 15% SDS-PAGE 
(Section 2.16). r//saPA Pl6H given as percentage of total protein, as determined by densitometry (Section 
2.16.5). Growth curves shown in Figure 3.17. (A) Nova Blue: Lane 1, Mr (sizes given in Figure 2.6); 
Lane 2, 3.5 hrs (0%) -  point of induction with 50 mM IPTG; Lane 3, 4.5 hrs (3.7%); Lane 4, 6.5 hrs 
(10.2%); Lane 5, 7.5 hrs (10.2%); Lane 6, 8.5 hrs (11.4%). (B) RosettaBlue: Lane 1, Mr; Lane 2, 4.5 hrs 
(0%) -  point of induction with 50 mM IPTG; Lane 3, 5.5 hrs (10.6%); Lane 4, 6.5 hrs (13.5%); Lane 5, 
7.5 hrs (13.5%); Lane 6, 8.5 hrs (13%).
Figure 3.21 Expression control in E. coli Nova Blue, RosettaBlue and XLIO-Gold
(A): Analysis of rHsaPAPl6H expression in E. coli (Section 2.12) from pRV5 (Figure 3.8) by 10% SDS- 
PAGE (Section 2.16). Samples taken 4 hrs after induction with 50 mM IPTG. Lane 1, Mr (sizes given in 
Figure 2.6); Lane 2, Nova Blue (non-induced); Lane 3, Nova Blue (induced); Lane 4, RosettaBlue (non­
induced); Lane 5, RosettaBlue (induced); Lane 6, XL 10-Gold (non-induced); Lane 7, XL 10-Gold 
(induced). (B): r//saPA Pl6H activity (units per mg total protein) of each sample (Section 2.15.2). 
r//5tfPAPl6H given as percentage of total protein, as determined by densitometry (Section 2.16.5).
3.6.1 Expression of recombinant human PAP1 in E.coli XL 10-Gold
Of the various E. coli strains investigated (Section 3.6) for the expression of  
recombinant human PAP1 from pRV5 (Figure 3.8), XL10-Gold was considered the 
most efficient. The growth curve of an E. coli XL 10-Gold culture, expressing (Section
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2.12) rHsa?A?\en is shown in Figure 3.22. The culture was induced with 50 jiM IPTG 
when the A6oo had reached 0.5. The specific vHsa?AP\en activity (units per mg of total 
protein) of hourly samples was calculated by the method outlined in Section 2.15.2, 
using protein concentrations determined by methods described in Section 2.14. Also 
shown in Figure 3.22 are growth curves o f two E. coli XLIO-Gold control cultures, one 
with pRV5 which was not induced with IPTG, the other with the negative control 
plasmid pPC223. Figure 3.23 shows the SDS-PAGE analysis (Section 2.16) of the 
vHsaPA? 1 6h expression run. The prominent protein band, attributed to vHsaPA? 1 6h, is 
estimated as percentage of total protein as determined by densitometry (Section 2.16.5). 
Figure 3.24 is an SDS-PAGE analysis comparing samples taken from an induced (50 
jiM IPTG) and a non-induced cultures expressing vHsa?A?\en in E. coli XL 10-Gold.
To optimise the induction with IPTG, cultures of E. coli XL10-Gold containing the 
r//stfPAPl6H expression construct pRV5, similar to those described above, were induced 
with various concentrations of IPTG (up to 1 mM), at A6oo of 0.3. The SDS-Page 
analysis of these cultures is shown in Figure 3.25.
In order to investigate what consequences, if any, the time of induction has on 
expression, cultures of E. coli XL 10-Gold containing the rHsaFAFlen expression 
construct pRV5 were induced (with 50 jaM IPTG) at various times from A6oo of 0.3 to 
0.5. The SDS-PAGE analysis of samples, taken 4 hrs after induction, is shown in Figure
3.26.
The length of sonication time used in the preparation of cleared lysate (Section 2.12.2) 
was optimised. Several samples from a culture of E. coli XL10-Gold expressing 
r//stfPAPl6H from the construct pRV5 were subjected to increasing times of sonication 
from 15 to 180 sec. SDS-PAGE analysis of this trial is shown in Figure 3.27A. The 
rHsa?AP\en activities of the resulting cleared lysate samples (units per mg total 
protein) are shown in Figure 3.27B.
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Figure 3.22 Growth curve for expression of r//saPAPl6H in E. coli XLIO-Gold
Log absorbance readings at 600nm (Log A600) taken during expression of r//saPA Pl6H in E. coli XL 10- 
Gold from pRV5 with (O) and without (O) induction using 50 jiM IPTG (indicated by red arrow). A 
culture with the vector pPC223 (A) served as a negative control for expression. Growth rates (increase in 
A6oo per hour) during exponential phase were of 0.27 for 0 , 0.19 for O and 0.22 for A. Specific activity of 
r//saPA Pl6H (units per mg of total protein) shown by bar chart.
r//jflPAPl6H
Figure 3.23 Expression of rHsaPAPleu in E. coli XL10-Gold
Analysis of rHsa?A?\6U expression in E. coli XLIO-Gold (Section 2.12) from pRV5 (Figure 3.8) by 15% 
SDS-PAGE (Section 2.16). r//5tfPAPl6H given as percentage of total protein, as determined by 
densitometry (Section 2.16.5). Growth curve shown in Figure 3.22. Lane 1, Mr (sizes given in Figure 2.6); 
Lane 2, 5.5 hrs (0%) -  point of induction with 50 mM IPTG; Lane 3, 6.5 hrs (8.7%); Lane 4, 7.5 hrs 
(13.2%); Lane 5, 8.5 hrs (16.7%); Lane 6, 9.5 hrs (16.3%); Lane 7, 10.5 hrs (16.7%); Lane 8, 11.5 hrs 
(17.2%); Lane 9, 12.5 hrs (16.4%); Lane 10, 13.5 hrs (17.9%); Lane 11, 14.5 hrs (15.5%); Lane 12, 15.5 
hrs (17.6%).
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Figure 3.24 Expression control of rH saPAPlm  in E. coli XLIO-Gold
Analysis of r//saPA Pl6H expression in E. coli XLIO-Gold (Section 2.12) from pRV5 (Figure 3.8) by 15% 
SDS-PAGE (Section 2.16). Induction with 50 jiM IPTG at A600 of 0.5. Lane 1, Mr (sizes given in Figure 
2.6); Lane 2, point of induction; Lane 3, non-induced for 1 hr; Lane 4, induced for 1 hr; Lane 5, non­
induced for 3 hrs; Lane 6, induced for 3 hrs; Lane 7, non-induced for 4 hrs; Lane 8, induced for 4 hrs.
Figure 3.25 Effect of IPTG on r//saPAPl6H expression in E. coli XLIO-Gold
Analysis of r//saPA Pl6H expression in # , coli XLIO-Gold (Section 2.12) from pRV5 (Figure 3.8) by 15% 
SDS-PAGE (Section 2.16). Induction at A600 of 0.3 with 0 jiM (A), 1 (B), 5 jiM (C), 50 |iM (D), 500
jiM (E) and 1000 jiM (F) IPTG. Lane 1, Mr (sizes given in Figure 2.6); Lane 2, point of induction; Lane 
3, 1 hr induction; Lane 4, 2 hrs induction; Lane 5, 3 hrs induction; Lane 6, 4 hrs induction. Location of 
r//saPA Pl6H is indicated by red arrows.
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Figure 3.26 Effect of induction time on rH saPAPlm  expression
Analysis of r//stfPAPl6H expression in E. coli XLIO-Gold (Section 2.12) from pRV5 (Figure 3.8) by 15% 
SDS-PAGE (Section 2.16). Induction with 50 jiM IPTG at various A6Go points, samples taken 4 hrs after 
induction. r//saPA Pl6H given as percentage of total protein, as determined by densitometry (Section 
2.16.5). Lane 1, Mr (sizes given in Figure 2.6); Lane 2, A600 of 0.3 (14.8%); Lane 3, A600 of 0.378 
(15.6%); Lane 4, A^ oo of 0.409 (15.4%); Lane 5, A600 of 0.449 (16.7%); Lane 6, Am  of 0.505 (16.7%).
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Figure 3.27 Effect of sonication time on lysis
Identical samples taken from E. coli XL 10-Gold culture, expressing (Section 2.12) r//saPA Pl6H from 
pRV5 (Figure 3.8), after 4 hrs induction with 50 jiM IPTG. Lysis carried out by various times of 
sonication. (A): Analysis of cleared lysate samples by 15% SDS-PAGE (Section 2.16). Lane 1, Mr (sizes 
given in Figure 2.6); Lane 2, 15 sec; Lane 3, 30 sec; Lane 4, 60 sec; Lane 5, 90 sec; Lane 6,120 sec; Lane 
7, 180 sec. (B): r//saPA Pl6H activity (units per mg total protein) of each cleared lysate sample.
3.6.2 Addressing codon bias of E. coli by site-specific mutagenesis
As described in Section 3.6, the effect that codon bias may have on the expression of 
r/ZsaPAPl6H was addressed using the pRARE plasmid system, supplementing limiting 
tRNAs to the E. coli phenotype. It was decided to complement this study with an 
alternative approach: using site-specific mutagenesis to substitute rare codons, in 
particular those at the 5’ end of the gene, for those more commonly used in E. coli 
(Baneyx, 1999). It is known that the presence of rare codons near the 5’ end of a
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transcript can affect translational efficiency (Makrides, 1996; Hannig and Makrides, 
1998) and it has been shown that 5’ codon substitutions in a recombinant gene can 
improve heterologous protein expression (Nilsson and Mannervik, 2001).
At the 5’ end of the sequence coding for rHsaPAPleu (Figure 3.16), Arg5[AGG] is the 
first codon considered rare in E. coli. It is followed by Lys6[AAG] which, while not 
considered a rare codon, is not the Lys codon optimally-used in E. coli. It was decided 
to create a mutant (Section 2.9.2) which has the wild-type Arg5 and Lys6 codons 
substituted with [CGT] and [AAA] respectively (mutant construct pRV5_R5sK6s, 
Table 2.3). This was achieved using primers PAPmR5K6-f & PAPmR5K6-r (Table
2.2). To confirm successful mutagenesis, prior to DNA sequencing, gradient PCR was 
used to differentiate between pRV5 and pRV5_R5sK6s (Figure 3.28), as described by 
Padmakumar and Varadarajan (2003). This screening method utilises the forward 
mutagenesis primer, together with a reverse primer specific to ampK common to both 
plasmids. The differential hybridisation of the mutagenesis primer at higher 
temperatures provided an effective means of identifying the pRV5_R5sK6s plasmid. 
The DNA sequencing (Section 2.10) data for pRV5_R5sK6s is given in Appendix B. 
Standard cultures of E. coli XL 10-Gold, transformed with both pRV5 and 
pRV5_R5sK6s, were carried out as described in Section 2.12.1. SDS-PAGE (Section 
2.16) analysis of these expression cultures is shown in Figure 3.29. Compared to the 
prominent r//s£*PAPl6H band visible for the pRV5 culture, the yield of r/fcaPAPUH was 
greatly reduced for pRV5_R5sK6s.
Two further mutant derivatives of pRV5 were created, having only the Arg5 codon 
changed to each of the two optimally-used Arg codons in E. coli, namely: [CGC] 
(pRV5_R5sa) and [CGT] (pRV5_R5sb) (Table 2.3). The primer sets used were 
PAPmR5a-f/PAPmR5a-r and PAPmR5b-f7PAPmR5b-r respectively (Table 2.2). The 
DNA sequencing data for pRV5_R5sa and pRV5_R5sb is given in Appendix B. 
Expression cultures were analysed as before and the mutant constructs were found to 
yield less r//5^PAPl6H product than obtained from pRV5 (Figure 3.30). These results 
were contrary to an anticipated increase (or even no change) in protein yield. To 
determine if this drop in protein yield was due to a decrease in stable mRNA, RT-PCR 
analysis (Sections 2.8.1 and 2.8.2) was performed on samples taken from each 
expression culture four hours after induction with 50 juM IPTG. As can be seen in 
Figure 3.31, the level o f stable r//saPAPl6H mRNA obtained from both pRV5_R5sa and
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pRV5_R5sb was comparable to that from pRV5. Such analysis was also carried out on 
pRV5_R5sK6s, with similar results (data not shown). It may be that the reduction in 
r/ZstfTPAPl6H yield is due to adverse folding of the mRNA, leading to retarded 
translation.
1 2 3  4 5 6 7 8 9
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Figure 3.28 Confirmation of pRV5_R5 K6 by gradient PCR screening
Differentiation between templates pRV5 and pRV5_R5sK6s using PCR (Section 2.8.2), analysed by 0.7% 
agarose gel electrophoresis (Section 2.5). Primers PAPmR5K6-f & pKKtestA (Table 2.2), giving 
expected product of 1458 bp, with 100 ng template, 15 cycles and increasing T*,,,. Lane 1, DNA Ladder 
(sizes as in Figure 2.5); Lane 2, template 1 56.1°C; Lane 3, template 2 56.1°C; Lane 4, template 1 68.8°C; 
Lane 5, template 2 68.8°C; Lane 6, template 1 69.9°C; Lane 7, template 2 69.9°C; Lane 8, template 1 
70.3°C; Lane 9, template 2 70.3°C.
A 1
24.000 Da
20.000 Da
B 1 2 3
r//sijPA Pl6H
Figure 3.29 Effect of Arg5/Lys6 codon substitution on rHsaPXPUu expression
Analysis of r//saPA Pl6H (indicated by arrow) expression in E. coli (Section 2.12) from pRV5 (A, Figure 
3.8) and pRV5_R5sK6s (B, Table 2.3) by 15% SDS-PAGE (Section 2.16). Lane 1, Mr (sizes given in 
Figure 2.6); Lane 2, time of induction with 50 |iM IPTG; Lane 3, 1 hr, Lane 4, 2 hrs; Lane 5, 3 hrs; Lane 
6 ,4  hrs.
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Figure 3.30 Effect of Arg5 codon substitution on r//saPAPl6H expression
Analysis of i7/saPAPl6H expression in E. coli (Section 2.12) from pRV5 (A, Figure 3.8), pRV5_R5sa (B, 
Table 2.3) and pRV5_R5sb (C, Table 2.3) by 15% SDS-PAGE (Section 2.16). Lane 1, Mr (sizes given in 
Figure 2.6); Lane 2, time of induction with 50 |iM IPTG; Lane 3, 1 hr, Lane 4, 2 hrs; Lane 5, 3 hrs; Lane 
6 ,4  hrs.
Figure 3.31 Level of transcription from pRV5, pRV5_R5sa and pRV5_R5sb
(A): RT-PCR analysis (Sections 2.8.1 to 2.8.2) of RNA isolated (Section 2.4.4) from E. coli XLIO-Gold 
cultures harbouring pRV5, pRV5_R5sa and pRV5_R5sb (Table 2.3). rHsa-papl specific primers 
PAPHsM & PAPHsN (627 bp product) and amp specific primers Amp-for & Amp-rev (856 bp product) 
were used (Table 2.2). Negative controls carried out by omitting RTase. Lane 1, DNA Ladder (sizes as in 
Figure 2.5); Lane 2, pRV5; Lane 3, pRV5 -ve control; Lane 4, pRV5_R5sa; Lane 5, pRV5_R5sa -ve 
control; Lane 6, pRV5_R5sb; Lane 7, pRV5_R5sb -ve control. Ratios of rHsa-papl to ampR product, 
determined by densitometry (Section 2.16.5), are shown in bar chart (B).
3.7 Purification of recombinant human PAP1
Optimisation of the expression system for recombinant human PAP1 in E. coli is 
described in Section 3.6. Since the addition of the His residues to the C-terminal end of 
the enzyme did not appear to alter its catalytic properties, it was decided to scale-up the 
production in order to carry out a detailed biochemical and kinetic study (Chapter 4) of 
the recombinant forms of the enzyme, both with (r/fctfPAPl6H) and without
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(r/fctfPAPl) the addition of the His-tag. rHsa?A?\eu could be purified by single-stage 
immobilised metal affinity chromatography (IMAC).
1MAC was traditionally used with the chelating ligand iminodiacetic acid, charged with 
metal ions such as Ni2+, Zn2+ or Cu2+ (Porath et al., 1975). This ligand, however, only 
has three metal chelating sites, leading to weak binding and frequent leaching of the 
ions, resulting in impurity and metal-ion contamination. Nitrilotriacetic acid (NTA) is a 
tetradentate chelator, allowing it to occupy four of the six ligand binding sites in the 
coordination sphere of Ni2+, therefore binding the metal ion far more stably, retaining it 
even under stringent wash conditions. In the Ni-NTA resin, two ligand binding sites of 
each Ni2+ are free to interact with the six consecutive imidazole groups of a 6xHis tag. 
Ni-NTA was used in this work to purify r/fcaPAPUH as reported in the following 
Section 3.7.1.
3.7.1 IMAC purification of recombinant human PAP1
The standard procedure to purify rHsaPAPleu from cleared lysate, obtained from E. coli 
cultures expressing r/fcaPAPUH from the construct pRV5 (Section 3.6), using Ni-NTA 
is described in Section 2.13.1. Both washing and elution was carried out using free 
imidazole. In order to determine the elution profile within the standard buffer of 50 mM 
potassium phospate at pH 8.0, a series of small-scale elutions were set up. Following the 
mixing of 200 |il cleared lysate with 50 |il of Ni-NTA, the resin was collected by 
centrifugation and then mixed with 200 |il buffer containing increasing concentrations 
of imidazole (up to 250 mM). The rHsa?AP\6n activity within each elution was 
determined as described in Section 2.15.2. The resulting imidazole elution profile is 
shown in Figure 3.32.
Figure 3.33A shows the SDS-PAGE analysis (Section 2.16) of a routine IMAC 
purification of rHsa?A? 1 6h, using two 20 mM imidazole washes and two 200 mM 
imidazole elutions. By densitometry (Section 2.16.5) it was determined that 
r/fatfPAPl6H was more than 90% pure in both elutions. The protein concentration and 
specific activity values for the initial cleared lysate and both elutions are given in Figure 
3.33B. Zymogram analysis (Section 2.17) was carried out on purified r/ZraPAPUH, 
shown in Figure 3.34.
To determine suitable storage conditions for purified r/fcaPAPUH, aliquots of purified 
enzyme (250 jig/ml) were stored at both 4°C and -20°C. Additional samples were stored
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at -20°C with 10% and 40% glycerol. Samples were assayed for enzyme activity 
(Section 2.15.2) over the course of ten days. The samples stored at -20°C without 
glycerol suffered extreme precipitation. The accumulated storage profile data is 
presented in Figure 3.35. A similar sample o f purified r/ftaPAPUH, which was stored 
for two months at -20°C with 40% glycerol, retained almost two thirds of its original 
activity (data not shown).
imidazole (tnM)
Figure 3.32 Imidazole elution profile
r//saPA Pl6H activity of samples eluted from Ni-NTA resin by 50 mM potassium phosphate, pH 8.0 
containing increasing concentrations of imidazole.
CL El E2
Figure 3.33 Purification of rHsaPAPUn
(A): Analysis by 15% SDS-PAGE (Section 2.16), of rHsaPAP16H purification using IMAC (Section 
2.13.1). Lane 1, Mr (sizes given in Figure 2.6); Lane 2, cleared lysate; Lane 3, flow-through; Lane 4, first 
wash; Lane 5, second wash; Lane 6, first elution; Lane 7, second elution. (B): Protein concentration 
(mg/ml) and specific activity (units/mg) of cleared lysate (CL), first elution (E l) and second elution (E2).
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Figure 3.34 Zymogram analysis of purified r//saPAPl6H
Native PAGE (A) and subsequent zymogram analysis (B, Section 2.17) of purified r//5aPAPl6H. Lane 1, 
Mr(Figure 2.6); Lanes 2 & 3, purified r//saPA Pl6H (20 jil of 0.195 mg/ml).
□  -20°C
Figure 3.35 Storage profile of r//sdPAPl6H
Profile of rHsaPAP16H activity (units/ml) in samples stored for up to 10 days at both 4°C and -20°C. 
Samples stored at -20°C with and without 10% and 40% glycerol.
3.8 Discussion
The human PAP1 gene was successfully cloned from human mRNA (plasmid pRVl, 
Section 3.2). Although many mammalian proteins cannot be expressed in an active form 
in E. coli, our hope was that, since human PAP1 shared many biochemical 
characteristics and sequence homology with its prokaryotic counterparts (Chapter 1), E. 
coli could be used successfully to express active recombinant human PAP1. As outlined 
in Section 3.5, E. coli could indeed be used as host, expressing catalytically active
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recombinant human PAP1. Significant quantities of enzyme were produced as shown in 
Figure 3.13 and using zymography (Figure 3.14) PAP1 activity was correlated to this 
protein band.
To achieve this expression in E. coli, the recombinant human PAP1 gene (rHsa-papl) 
was cloned within a suitable expression vector. The rHsa-papl sequence was sub­
cloned into the pQE-60 vector to yield the construct pRV8 (Section 3.4.1), and into the 
pPC225 vector to yield the constructs pRV5 (Section 3.4.2) and pRV5_A6H (Section 
3.4.3). pQE-60 features the phage T5 transcriptional promoter and a lac operator 
sequence while pPC225 features Ptac, a hybrid of the trp and lac promoters. Both are 
strong promoter systems that can be repressed by the LacI protein.
Both of these expression vectors provide ribosomal binding sites (RBS). As a result of 
the cloning strategy used to create pRV5 (Figure 3.8), there are two RBS downstream of 
Ptac in this construct (Figure 3.10). One of the two RBS is separated from the rHsa- 
papl start codon by 9 nucleotides, while the other is about 20 nucleotides further 
upstream. It has been reported that the optimal distance between a RBS and the start 
codon is seven plus or minus two nucleotides (Kozak, 1983). At least one of these RBS 
is functionally relevant in pRV5.
Using E. coli XL10-Gold as expression host, the pRV5 and pRV8 expression constructs 
produced similar quantities of r/fctfPAPl6H (Figure 3.13B). pRV5 was chosen for 
optimisation of expression conditions and to establish an efficient host-vector 
combination, to determine if some genotypes are more suitable for expression of this 
particular recombinant protein. Several E. coli strains were transformed with pRV5 to 
express r//^PA Pl6H (Section 3.6).
In addition to investigating the merit of different E. coli host strains (Table 2.1), the 
effect codon bias may have on recombinant human PAP1 expression was considered. 
As described in Section 3.6, E. coli Rosetta and RosettaBlue (derivatives o f BL21 and 
NovaBlue, respectively) carry the pRARE plasmid (Table 2.3, Figure 2.4). The pRARE 
system represents a possible strategy to overcome E. coli codon bias, by raising the 
concentration of the tRNAs that complement rare codons (Novy et al., 2001). The data 
presented in Figure 3.19 would suggest that the pRARE strategy indeed improves 
r/fctfPAPl6H expression. A distinctly greater yield of r//^PA Pl6H was obtained in E. 
coli Rosetta than in BL21. However, this effect is not so evident from the data presented 
in Figure 3.20, where rHsaPAPX^u yield is only slightly more efficient in E. coli 
RosettaBlue than Nova Blue. By comparison, expression in E. coli DH5a and INVaF'
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(Figure 3.18), not harbouring the pRARE plasmid, was relatively good. Furthermore, 
the data presented in Figure 3.21 shows an even greater expression level was achieved 
by E. coli XL10-Gold, a strain also lacking any additional tRNA genes. It should be 
noted that the transcriptional repression in XL 10-Gold was more effective than in Nova 
Blue or RosettaBlue.
Although the supplementation of limiting tRNAs can improve heterologous 
recombinant protein expression to some extent, it is only one aspect of choosing a 
suitable expression host. It would appear that the gain achieved by using a system such 
as pRARE can be made somewhat obsolete by using a more efficient E. coli expression 
strain. It was decided to employ the XL 10-Go Id strain for all subsequent rHsa?AP\6H 
expression. The production of functionally active enzyme was very satisfactory and 
justified the choice o f using E. coli as expression host for this eukaryotic enzyme.
An alternative strategy to overcome the codon bias of E. coli would be to use site- 
specific mutagenesis to replace rare codons with E. coli optimally-used counterparts 
(Baneyx, 1999). This approach was undertaken, as is reported in Section 3.6.2. 
However, this resulted in a decrease in protein yield, rather than an anticipated increase. 
Replacing of the first rare codon Arg5[AGG] with [CGT], together with changing 
Lys6[AAA] to the more optimally-used codon [AAA], resulted in reduced yield of 
r/fctfPAPUH protein, as seen in Figure 3.29. Focusing only on the Arg5 codon (Figure 
3.30), lower levels of r/&tfPAPl6H were obtained in the case of both optimal E. coli 
codons [CGT] and [CGC]. RT-PCR analysis (Figure 3.31) showed that the level of 
transcription obtained for pRV5_R5sa and pRV5_R5sb, were comparable to wild type 
(pRV5), indicating that the reduced yield in protein for these two mutants is not a result 
of reduced message. One possibility is that making the above nucleotide substitutions 
has resulted in a change in mRNA structure. Such an alteration in the mRNA secondary 
structure, although not obviously affecting RNA stability, may be affecting the 
efficiency of translation. A software package which calculates possible secondary 
structures of single stranded nucleic acids (Mfold, Section 2.11) was used to predict 
how the mRNA coding for r//sdPAPl6H might fold (Figure 3.36). For each mRNA 
sequence, up to 35 possible structures were calculated. Figure 3.36 shows those 
structures which had the lowest calculated free energy (AG), therefore being the most 
likely structures. These three structures varied from one another only in the region of 
the translational start. It is possible that ribosome binding may be affected by this 
structural variation, causing retarded translation.
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Figure 3.36 Potential structure of mRNA from pRV5, pRV5_R5sa and pRV5_R5sb
Possible secondary structures of mRNA, predicted using Mfold (Section 2.11), coding for rZ/jaPAPl^H, 
transcribed from pRV5 (Figure 3.10). Substitution of Arg5 codon on pRV5_R5sa and pRV5_R5sb (Table 
2.3) causes change in structure at translation start site (insets). (A): pRV5 (Arg5 AGG). (B): pRV5_R5sa 
(Arg5 AGG to CGC). (C): pRV5_R5sb (Arg5 AGG to CGU). Calculated free energy (AG) is given for 
each structure. Translation start indicated by *. Arg5 codon indicated by *. The predicted structures 
contained a small number of mismatched U-C and U-G base pairs. The validity of such pairing has been 
supported by a study of water-mediated U-C pairings in RNA structures (Brandi et al., 1998).
While the pRV5_A6H construct was created for the expression of native recombinant 
human enzyme (r/fatfPAPl), the pRV5 and pRV8 constructs were designed to express a 
His-tagged enzyme (r/fctfPAPl6H), having a six histidine peptide (6xHis) fused to the 
C-terminal of the protein to aid in purification. A short Gly-Ser codon linker sequence 
(Figure 3.10) exists between rHsa-papl and 6xHis, a result of the BamHMBglU iusion 
(Figure 3.5). Since there was a possibility that such a peptide iusion would affect
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enzyme structure and/or activity (Ledent et al.9 1997), the C-terminal location was 
chosen, it being the terminal o f human PAP1 which exhibits the least homology with its 
prokaryotic counterparts (Figure 5.6). The hope was that this end o f the protein is less 
likely to involve critical regions of the enzyme. As this C-terminal tag did not interfere 
with r/fcaPAPl6H activity (Section 3.5), one-step purification by metal affinity 
chromatography was possible, as reported in Section 3.7. The application of a Strep-tag 
for affinity purification (Skerra and Schmidt, 1999), as an alternative to the His-tag, was 
considered but not carried out in this work.
The analysis o f r/fctfPAPl6H expression in E. coli XL 10-Gold, shown in Figures 3.22 
and 3.23, shows clearly the production of recombinant enzyme. Upon induction with 50 
|iM IPTG, the level o f r//saPAPl6H rises rapidly until it constitutes 15-18% of total 
protein. The increase continues for 4 hrs at which time it levels off, approximately 
matching the progression into stationary phase for the culture. Interestingly, and 
somewhat unexpected in the context of expressing recombinant proteins, the presence of 
the human PAP1 gene results in a higher cell density (Figure 3.22). The effectiveness of 
transcriptional repression shown in Figure 3.21 can again be seen in Figure 3.24. This 
repression is attributed to the lac\q allele, part of the XL 10-Go Id genotype, resulting in 
high levels o f LacI repressor protein (Section 3.6). A study to determine the optimal 
concentration of IPTG used for induction (Figure 3.25) shows that this is a very 
important parameter to consider. Very low levels of recombinant protein were obtained 
when using 0.5 or 1 mM IPTG. 50 p,M IPTG was deemed the most suitable 
concentration. Similar expression was obtained when inducing at various times during 
early exponential phase (A6oo of 0.3 to 0.5) as shown in Figure 3.26. The standard 
induction parameters used in this work were 50 fiM IPTG at A6oo of 0.3.
The effect of sonication was dramatically demonstrated by the analysis shown in Figure
3.27. Sonication of longer than 30 sec resulted in a sharp reduction of rHsa?A?\eu 
activity. This reduction in activity correlates with a reduction in the amount of 
t/Z^PAPUh present. It is assumed that prolonged sonication denatures the protein 
sufficiently to be susceptible to rapid proteolysis. The standard sonication time used in 
this work was 30 sec.
The imidazole elution profile (Figure 3.32) was used to establish suitable concentrations 
of imidazole for the washing and elution steps during IMAC purification of 
r//^PA Pl6H (Section 2.13.1). Since it was desirable to maximise the yield of pure
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enzyme, a concentration of 20 mM imidazole was used for washing. 200 mM imidazole 
was used for elution, ensuring greatest recovery from the Ni-NTA resin.
SDS-PAGE analysis of the standard IMAC purification procedure employed in this 
work (Figure 3.33A) shows that exceptionally pure r//stfPAPl6H was obtained. The 
enzyme had in excess of 90% purity, demonstrating the benefit of this one-stage method 
of protein purification. The purified protein was confirmed as rHsa?A?\sH by 
zymography (Figure 3.34) and western blotting (Figure 5.19). Even with added wash 
steps and/or increased imidazole concentrations, very small amounts of contaminating 
proteins of about 45,000 and 66,000 Da were routinely observed (see also Figure 5.15). 
The increase in specific activity correlating to the purification can be seen in Figure 
3.33B, r/fc#PAPl6H having a specific activity o f around 7000 units/mg. By the standard 
expression (Section 2.12.1) and purification (Section 2.13.1) procedures, r/ZstfPAPl6H 
concentrations of around 500 |ig/ml were routinely achieved in the first 5 ml elution. 
Therefore, by scaling the expression culture up to 1 L, yields of up to 25 mg pure 
enzyme could be achieved.
Suitable storage conditions for purified rHsaPAPlen were investigated as shown in 
Figure 3.35. Storage at -20°C without glycerol resulted in almost complete loss of 
activity, correlating to the substantial precipitation observed. Inclusion of glycerol at 
this temperature protected the protein from precipitating. When using 10% glycerol the 
activity initially dropped to half its original value but did not decrease further during the 
ten-day trial. Using 40% glycerol proved even more preservative, conserving almost 
80% of activity. Even after two months o f storage, two thirds of activity remained. In 
contrast, storage (without glycerol) at 4°C resulted in a less immediate but more 
constant drop in activity, falling below the value retained by -20°C/40% glycerol 
storage, by the end of the ten-day study. When samples o f pure enzyme were to be used 
for various procedures within a few days, storage at 4°C was usually satisfactory. Some 
stock sample was habitually stored at -20°C with 40% glycerol.
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4.0 Characteristics of recombinant human PAPI
The successful cloning and expression of catalytically active, recombinant human PAP1 
(rifotfPAPl) and the purification of the His-tagged enzyme (rHsa?AP\6ii), is reported in 
Chapter 3. Subsequently, a range of studies to determine the biochemical (Section 4.1) 
and kinetic (Section 4.2) characteristics of rHsa?AP\ew were carried out. A preliminary 
study was carried out to establish conditions under which r/fetfPAPl6H would form 
protein crystals (Section 4.3).
4.1 Biochemical properties of recombinant human PAP1
4.1.1 Relative molecular mass
As outlined in Section 2.19.1, 50 jllI of purified rHsa?A?\6u, at a concentration of 250 
jig/ml, was analysed by size exclusion chromatography. Figure 4.1 shows the protein 
concentration profile corresponding to the elution of r/fotfPAPl6H and the protein 
standards BSA, Carbonic Anhydrase and Lysozyme. Also shown is the profile o f PAP 1 
activity corresponding to the elution of r//s£/PAPl6H- The inset in Figure 4.1 shows a 
plot of elution volume over void volume (Ve/V0) versus the log of molecular weight. 
From this plot the relative molecular weight of r/fctfPAPl6H was determined as 24.5 
kDa.
volume (ml)
Figure 4.1 Determination of rHsaPAPlm  native size
Size exclusion chromatography (Section 2.19.1) of r//saPA Pl6H. Void volume of 34 ml was ascertained 
using blue dextran. Elution of r//sflPAPl6H at 73 ml was determined using PAP1 activity assay (Section 
2.15.3) and is represented by fluorescent intensity, shown in red. Elution volumes of molecular weight 
standards BSA (45 ml), Carbonic Anhydrase (65 ml) and Lysozyme (91 ml), were determined by protein 
assay (Section 2.14.3) and used to construct a plot of V/Vo versus log MW (inset). This plot was used to 
establish the relative molecular weight of r//$aPAPl6H to be 24.5 kDa.
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The isoelectric points of rHsaPAPl and r/fctfPAPl6H were predicted as 5.54 and 5.97 
respectively, using online tools (Section 2.11). To determine the isoelectric point of 
rHsa?AP\en experimentally, the isoelectric focusing (IEF) procedure described in 
Section 2.19.6 was carried out on extensively dialysed, purified r/fctfPAPUH* Figure 
4.2A shows the IEF gel stained by the coomassie blue method (Section 2.16.4). By this 
method of staining an extremely faint band was detectable corresponding to the 6.9 pi 
marker. The gel was additionally treated by the silver staining method (Section 2.16.4), 
resulting in Figure 4.2B. By now the faint band, attributed to r/foaPAPUH had been 
significantly over-stained. As an estimation, the pi of r/fcaPAPUH was taken to be 6.9.
4.1.2 Isoelectric point
A B
1 2  3 1 2  3
Figure 4.2 Iso-electric point of r//saPAPl6H
Isoelectric focusing (IEF) of purified r//5flPAPl6H as described in Section 2.19.6. Gel visualised after 
both coomassie (A) and silver staining (B) as described in Section 2.16.4. Lane 1, IEF markers (sizes as 
in Figure 2.8); Lane 2, 5 ^1 purified rHsaVAPl6H (150 jJtg/ml); Lane 3, 2.5 i^l purified rHsaPAPl6H (150 
jig/ml).
4.1.3 Influence of pH
The influence of pH on the activity o f r//stfPAPl and rHsaPAFXen was investigated as 
outlined in Section 2.19.2. Figure 4.3 shows the pH profile for purified r//stfPAPl6H 
which is compared to that of both rHsa?A?\ and rHsaPAPl6h in cleared lysate. The 
three profiles are consistent across the range except at pH 8.5, where purified 
rHsa?AP\eu shows optimum activity.
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Figure 4.3 Influence of pH on rHsaPXPl and r//saPAPl6H activity
Relative enzyme activity over pH range 6.0 to 10.5. Different buffers used for specific ranges as 
described in Section 2.19.2. Both iHsa?A PI and r//sflPAPl6H in cleared lysate (Section 3.5) are 
compared to purified r//saPA Pl6H (Section 3.7.1).
4.1.4 Influence of temperature
The influence of temperature on the activity of r/fctfPAPl6H was investigated. As 
outlined in Section 2.15.2, the standard activity assay was carried out at a range of 
temperatures. The resulting 15 min temperature profile is shown in Figure 4.4. Maximal 
activity was observed at 50°C.
The temperature stability o f ri/stfPAPl6H is illustrated in Figure 4.5, showing the effect 
that pre-incubation of r/ZswPAPUH has on its activity, which was subsequently 
determined using the standard assay (Section 2.15.2) at 37°C.
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Figure 4.4 Influence of temperature on r//saPAPl6H activity
The effect of temperature on the activity of rHsaPAP\6H activity was determined by carrying out the 
standard assay (Section 2.15.2) at 4 to 70T  for 15 min.
r/fo/PAPIfcH (purified) 
rH sa PAP 1*h (lysate) 
r Aba PA PI (lywie)
111
■  4X ’
Time (min)
Figure 4.5 Temperature stability of r//saPAPl6H
The effect of pre-incubating r//saPA Pl6H at a range of temperatures (4 to 60°C). Activity determined by 
standard assay at 37°C (Section 2.15.2).
4.1.5 Influence of DTT and EDTA
DTT and EDTA are essential components of the standard PAP1 activity assay (Section
2.15.2). In order to optimise the assay concentrations, their effect on r//saPAPl6H 
activity was determined. Figures 4.6 and 4.7 show the influence of DTT and EDTA, 
respectively, on vHsa?APUh activity. The optimal DTT concentration for activity was 
found to be 10 mM, while EDTA had only a marginal positive effect on activity as the 
concentration was increased to 20mM.
[DTT] (mM)
Figure 4.6 Influence of DTT on ri/saPAPl6H activity
The effect of DTT concentration on the activity of rHsaPAPlm activity was determined by carrying out 
the standard assay (Section 2.15.2) using a range of DTT concentrations up to 20 mM.
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[EDTA] (mM)
Figure 4.7 Influence of EDTA on rHsaPAPUu activity
The effect of EDTA concentration on the activity of rHsaPAPlm activity was determined by carrying out 
the standard assay (Section 2.15.2) using a range of EDTA concentrations up to 20 mM.
4.1.6 Inhibition
A selection of compounds were investigated for their possible inhibitory effect on the 
pGlu-AMC degrading activity of r//saPAPl6H (Section 2.19.5).
The thiol-blocking compound iodoacetate caused complete inhibition of activity at a 
concentration of 100 [iM (data not shown), consistent with the literature as described in 
Section 1.3.7.
The inhibition caused by free L-pGlu and the substrate analogue 2-pyrrolidone (Section
1.3.8) is shown in Figures 4.8 and 4.9. IC50 values of 2.75 and 1.0 mM, respectively, 
were determined. IC50 being the inhibitor concentration resulting in a 50% loss in 
enzymatic activity.
The broad spectrum serine protease inhibitor diisopropyl fluorophosphate (DFP) had no 
discemable inhibitory effect on activity (Figure 4.10). Phenylmethylsulphonyl fluoride 
(PMSF), which inhibits serine and some cysteine proteases, had an IC50 of 4.1 mM 
(Figure 4.11).
The compound 1,10-phenanthroline was inhibitory with an IC50 of 2.6 mM (Figure 
4.12) while 4,7-phenanthroline was found to exert no inhibitory effect (Figure 4.13).
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L-pGhi] (itiM)
Figure 4.8 Effect of L-pGIu on r/fsaPAPliH activity
The effect of L-pGlu on the activity of r//saPA Pl6H was determined by the procedure outlined in Section 
2.19.5, using L-pGlu at concentration range up to 20 mM.
P-pynolidone] (mM)
Figure 4.9 Effect of 2-pyrrolidone on r/ZsaPAPUn activity
The effect of 2-pyrrolidone on the activity of r/f^aPAPUH was determined by the procedure outlined in 
Section 2.19.5, using 2-pyrrolidone at concentration range up to 20 mM.
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Figure 4.10 Effect of DFP on r//saPAPl6H activity
The effect of DFP on the activity of r//s£*PAPl6H was determined by the procedure outlined in Section 
2.19.5, using DFP at concentration range up to 5 mM.
[PMSF] (mM)
Figure 4.11 Effect of PMSF on r//saPAPl6H activity
The effect of PMSF on the activity of rHsaPAP\6li was determined by the procedure outlined in Section 
2.19.5, using PMSF at concentration range up to 5.5 mM.
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[1,10-phenanthioline] (mM)
Figure 4.12 Effect of 1,10-phenanthroline on r//saPAPl6H activity
The effect of 1,10-phenanthroline on the activity of r//saPA Pl6H was determined by the procedure 
outlined in Section 2.19.5, using 1,10-phenanthroline at concentration range up to 3.5 mM.
[4,7-pherianthroline] (mM)
Figure 4.13 Effect of 4,7-phenanthroline on r//saPAPl6H activity
The effect of 4,7-phenanthroline on the activity of rHsaPAP 1 6h was determined by the procedure outlined 
in Section 2.19.5, using 4,7-phenanthroline at concentration range up to 5 mM.
4.2 Kinetic parameters of recombinant human PAP1
Purified rHsa?AP\6u needed to be diluted to a concentration of 1-5 |ig/ml to ensure the 
fluorescent intensity values fell within the measurable range of the Perkin-Elmer LS-50 
fluorescence spectrophotometer used in this work (Section 2.15.2).
The procedure to assay PAP1 activity at various pGlu-AMC concentrations, as outlined 
in Section 2.19.3, was carried out with purified rHwPAPUH (Section 3.7.1), as well as
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with r/fcaPAPl and r//stfPAPl6H in cleared lysate (Section 3.5). The resulting 
Michaelis-Menten curve for purified rHsa?AP\eu is shown in Figure 4.14 and the 
curves for rHsaPAPleu and r/fctfPAPl in cleared lysate are shown in Figure 4.15.
The data sets from Figures 4.14 and 4.15 were applied to the three kinetic models 
described in Appendix C, namely: Lineweaver-Burk (Figures 4.16 and 4.17), Eadie- 
Hofstee (Figures 4.18 and 4.19) and Hanes-Woolf (Figures 4.20 and 4.21). From these 
plots the maximal enzyme velocity (Vmax) and the Michaelis constant (Km) were 
determined, which are given in Table 4.1. Also given in Table 4.1 is the turnover 
number (kcat) for purified r/fcaPAPUH, which was determined as described in Appendix 
C.
[pOlu-AMC] (mM)
Figure 4.14 Michaelis-Menten curve for purified rH saP \P l6u
Plot of substrate concentration ([pGlu-AMC]) versus reaction rate, represented by fluorescence intensity 
(Fi), for purified r//saPA Pl6H diluted to 2.5 jig/ml. Data obtained by the procedure described in Section 
2.19.3.
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[pGlu-AMC] (inM)
Figure 4.15 Michaelis-Menten curve for rHsaPAPlm and rHsaPAPl in lysate
Plot of substrate concentration ([pGlu-AMC]) versus reaction rate, represented by fluorescence intensity 
(Fi), for both rHsaPAPl (blue) and vHsa?API6U (black) in lysate. Data obtained by the procedure 
described in Section 2.19.3.
1 /[pGlu-AMC]
Figure 4.16 Lineweaver-Burk plot for purified rHsaPAPUu
Data from Figure 4.14 fitted to the Lineweaver-Burk model for the determination of kinetic parameters, 
as outlined in Appendix C. Equation and regression are shown. Km and Vmax values given in Table 4.1.
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l/[pGlu-AMC]
Figure 4.17 Lineweaver-Burk plot for r//saPAPl6H and r//saPAPl in lysate
Data from Figure 4.15 (same colour association) fitted to the Lineweaver-Burk model for the 
determination of kinetic parameters, as outlined in Appendix C. Equation and regression are shown. Km 
and Vmax values given in Table 4.1.
Fi/[pGh>AMC]
Figure 4.18 Eadie-Hofstee plot for purified r/ZsaPAPUn
Data from Figure 4.14 fitted to the Eadie-Hofstee model for the determination of kinetic parameters, as 
outlined in Appendix C. Equation and regression are shown. Km and Vmax values given in Table 4.1.
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Fi/[pGlu-AMC]
Figure 4.19 Eadie-Hofstee plot for r//saPAPl6n and ri/saPAPl in lysate
Data from Figure 4.15 (same colour association) fitted to the Eadie-Hofstee model for the determination 
of kinetic parameters, as outlined in Appendix C. Equation and regression are shown. Km and Vmax values 
given in Table 4.1.
[pGlu-AMC] (niM)
Figure 4.20 Hanes-Woolf plot for purified r//$aPAPl6H
Data from Figure 4.14 fitted to the Hanes-Woolf model for the determination of kinetic parameters, as 
outlined in Appendix C. Equation and regression are shown. Km and Vmax values given in Table 4.1.
120
0.003 T
[pGlu-AMC] (mM)
Figure 4.21 Hanes-Woolf plot for r/fsaPAPl6H and rHsaPAPl in lysate
Data from Figure 4.15 (same colour association) fitted to the Hanes-Woolf model for the determination of 
kinetic parameters, as outlined in Appendix C. Equation and regression are shown. Km and Vmax values 
given in Table 4.1.
Table 4.1 Kinetic parameters for r//sflPAPl6H and rHsaPXPX
Sample Lineweaver-Burk Eadie-Hofstee Hanes-Woolf Average
r//stfPAPl6H (purified)
Km OiM)
47.6 57.9 50 51.8
r//saPA Pl6H (lysate) 42.6 53.4 69.8 55.3
rHsaPAP1 (lysate) 45.5 65.4 45.5 52.1
rHsaPAP 1 6h (purified)
Vmas (units/ml)
15.1 15.9 15.8 15.6
r//saPA Pl6H (lysate) 6.7 7.1 7.4 7.1
r/ZsaPAPl (lysate) 14.4 14.6 14.4 14.5
r//saPA Pl6H (purified)
K»t (s*1) 
2.43 2.56 2.54 2.51
[Km and values obtained from Figures 4.16 to 4.21. kcat calculated as outlined in Appendix C].
4.2.1 Competitive inhibition of recombinant human PAP1 by pGlu-peptides
The competitive influence of selected peptide substrates pGlu-Ala, pGlu-Val, pGlu-His- 
Gly and pGlu-His-Pro-NH2 (TRH) on the pGlu-AMC degrading activity o f vHsa?API6h 
was investigated as described in Section 2.19.4. The resulting data sets were applied to 
the aforementioned kinetic models: Lineweaver-Burk (Figure 4.22), Eadie-Hofstee 
(Figure 4.23) and Hanes-Woolf (Figure 4.24). From these plots the apparent Km (Kmapp) 
was determined in the presence o f each peptide. These Kmapp values were used to 
calculate the dissociation constants (Kj) as outlined in Appendix C, which are given in 
Table 4.2. For example the average Kmapp for TRH, from the three kinetic models 
(Figures 4.22 to 4.24), was 370.1 juM. Using the formula described in Appendix C the 
K, was calculated to be 40.7 ¿iM.
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l/[pG!u-AMC]
Figure 4.22 Kj determination for selected peptides using Lineweaver-Burk plot
Data from peptide competition assays (Section 2.19.4) fitted to Lineweaver-Burk model, as outlined in 
Appendix C, for the determination of apparent Kra (Kmapp). Peptides used: pGlu-His-Pro-NH2 (TRH), 
pGlu-Ala, pGlu-His-Gly and pGlu-Val. Non-inhibited data plotted in black. Equations are shown. Kj 
values given in Table 4.2.
Fi/[pGlu-AMC]
Figure 4.23 Kj determination for selected peptides using Eadie-Hofstee plot
Data from peptide competition assays (Section 2.19.4) fitted to Eadie-Hofstee model, as outlined in 
Appendix C, for the determination of apparent Km (Kmapp). Peptides used: pGlu-His-Pro-NH2 (TRII), 
pGlu-Ala, pGlu-His-Gly and pGlu-Val. Non-inhibited data plotted in black. Equations are shown. K* 
values given in Table 4.2.
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[pGlu-AMC] (mM)
Figure 4.24 Kj determination for selected peptides using Hanes-Woolf plot
Data from peptide competition assays (Section 2.19.4) fitted to Hanes-Woolf model, as outlined in 
Appendix C, for the determination of apparent Km (Km“1’1'). Peptides used: pGlu-His-Pro-NH2 (TRH), 
pGlu-Ala, pGlu-His-Gly and pGlu-Val. Non-inhibited data plotted in black. Equations are shown. Ki 
values given in Table 4.2.
Table 4.2 Ki values for selected peptides
Peptide Kmapp ( ia M ) Average Ki (uM)
Lineweaver-Burk Eadie-Hofstee Hanes-Woolf
None 47.6 57.9 50 51.8 -
pGlu-His-Pro (TRH) 545.5 287 277.8 370.1 40.7
pGlu-Ala 111.1 104.9 100 105.3 242.1
pGlu-His-Gly 117.7 95.9 100 104.5 245.7
pGlu-Val 105.3 74.5 47.6 76.1 532.9
[Kmapp values obtained from Figures 4.22 to 4.24. Ki calculated as outlined in Appendix C].
4.3 Determining crystallisation conditions for recombinant human PAP1
A preliminary study was carried out to determine conditions under which r/&aPAPl6H 
could form protein crystals. The methodology of sparse matrix screening (Jancarik and 
Kim, 1991; Cudney et al., 1994) was employed as outlined in Section 2.19.7. Purified 
r/fctfPAPl6H (Section 3.7.1), which has been extensively dialysed, was used at various 
concentrations from 1.5 up to 12 mg/ml. Crystals were routinely observed after 48 hrs, 
in Screen 1 reagents 1, 24 and 45 (Table 2.7). Figure 4.25 shows typical examples of 
these crystals. Reagent 1 crystals were usually of a multiple slate morphology, while 
Reagent 24 crystals were also slates but seemed to be composed of several fused layers. 
Reagent 45 crystals had a star morphology, with multiple shards joining centrally.
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In a collaboration, these crystals were initially analysed, using X-ray diffraction, by Dr. 
John Gallagher (DCU, Ireland) during his time at the Department of Structural Biology 
and Biochemistry, Howell Laboratories, Hospital for Sick Children, Toronto, Canada. 
Crystals were manipulated into capillary tubes and placed in an X-ray beam, resulting in 
a diffraction pattern. Unfortunately, preliminary reports show that these diffraction 
patterns are typical of mixed salt and protein crystals. Despite the extensive dialysis 
carried out on the rifcaPAPlôH samples, conditions of even lower salt content would 
have to be achieved. Screening for further crystallisation conditions is ongoing.
Figure 4.25 Crystals observed while attempting crystallisation of r//siiPAPl6H
Typical examples of crystals observed during the study to determine crystallisation conditions for 
r//stfPAPl6H (Section 2.19.7). Crystals were observed within 48 hrs in Screen 1, reagent 1 (A), reagent 24 
(B) and reagent 45 (C) for r//stfPAPl6H concentrations ranging from 1.5 to 12 mg/ml. Images viewed at 
lOx magnification.
4.4 Discussion
The catalytically active r/fctfPAPl6H was shown to have a relative molecular mass of
24.5 kDa (Section 4.1.1). This value correlates very well with the molecular weight of 
24,105, deduced from the amino acid sequence for rHsaPAP1 6h  as mentioned in Section 
3.5. An independent study (Dando et al., 2003), published shortly after this experiment 
was completed, reported that the non His-tagged, catalytically active, recombinant 
human PAP1 has a relative molecular mass of 24 kDa. The size difference attributed to 
the His-tag is merely ~1 kDa as shown in Section 3.5 (Figure 3.13A). This combined 
data concludes that recombinant human PAP1 is active as a monomeric enzyme in both 
the native and His-tagged form. This is in agreement with the findings (Table 1.6) that 
eukaryotic PAP1 is generally monomeric.
The isoelectric point (pi), the pH at which the protein has an equal number of positive 
and negative charges, was predicted as 5.97 for r//sY7PAPl6H (5.54 for r/fcaPAPl) using
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online tools (Section 2.11). As shown in Section 4.1.2 (Figure 4.2) the experimentally 
determined isoelectric point for r/fctfPAPl6H lies between 6.0 and 6.9. The pi for PAP1 
enzymes has previously been reported within the range of 4.9 to 5.5 (Table 1.6).
The pH profiles in Figure 4.3 show that both vHsaPAPX and vHsaPAPleu have a pH 
optimum between 8.0 and 9.5. The samples in cleared lysate correlate very closely, 
while the purified r/fcaPAPUH shows a particular peak of activity at pH 8.5. 
Throughout this work, enzymatic analysis was carried out at pH 8.0, being a 
compromise between the physiological pH 7.4 and the optimum determined in the 
above study. pH optima for various eukaryotic and prokaryotic PAP Is have been 
published (Table 1.6), falling in the range of 6.0 to 9.5.
The activity o f r/fctfPAPl6H was shown to increase with temperature, having an 
optimum at 50°C (Figure 4.4), for a 15 min assay. Above 50°C however, activity was 
dramatically reduced. A similar 50°C optimum has been reported for non His-tagged, 
recombinant human PAP1 (Dando et al., 2003). Throughout this work, activity assays 
were carried out at the physiological temperature of 37°C. Even though higher activity 
was achieved at 50°C, this corresponds to a short 15 min assay and is not necessarily 
reflective of the true physiological optimum. This was supported by the thermal stability 
of rHsaPAPlm, which was shown to be robust up to 40°C (Figure 4.5) for two hours. 
Above this temperature the activity rapidly declined. At 60°C the activity had reduced to 
about 30% after 20 min and was almost completely lost after 60 min. 
r/ZstfPAPl6H was shown have an absolute requirement for a thiol reducing agent (Figure 
4.6). This cysteine protease characteristic of PAP 1 has been widely reported (Section
1.3.7). The optimum concentration of DTT, used throughout this work, was 10 mM. 
The thiol-dependent nature of r/fctfPAPl6H was further demonstrated by the complete 
inhibition of activity by 100 |iM of the thiol-blocking agent iodoacetate (Section 4.1.6). 
In contrast, the serine inhibitor DFP had no effect on activity (Figure 4.10). Another 
serine inhibitor PMSF, known to inhibit some cysteine proteases, exhibited inhibition 
with an IC50 of 4.1 mM (Figure 4.11).
The chelating agent EDTA, although not a requirement for PAP1 activity (Figure 4.7), 
was routinely included in the standard PAP1 activity assay (Section 2.15.2), as a 
protective agent for DTT, according to the modified method described by Browne and 
O’Cuinn (1983).
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The inhibitory effect by L-pGlu (IC50 = 2.75 mM, Figure 4.8) and substrate analogue 2- 
pyrrolidone (IC50 = 1.0 mM Figure 4.9) on the pGlu-AMC degrading activity of 
rHsa?A?\6H is due to the competitive binding into the catalytic site, as described in 
Section 1.3.8.
The chelating agent 1,10-phenanthroline caused inhibition with an IC50 of 2.6 mM 
(Figure 4.12) while the structurally similar, yet non-chelating, 4,7-phenanthroline did 
not affect activity (Figure 4.13). It is not known why 1,10-phenanthroline caused 
inhibition. These results would suggest that inhibition is caused by its chelating 
property. This is unlikely however, given the lack of inhibition by the chelator EDTA 
(Figure 4.7). Rather, inhibition may be due to some structural property which 1,10- 
phenanthroline does not share with 4,7-phenanthroline.
The Michaelis-Menten curves (Figures 4.14 and 4.15) show that up to about 200 yM  
pGlu-AMC, the PAP1 substrate concentration is limiting to the enzymatic reaction. For 
this reason, the standard activity assay used in this work (Section 2.15.2) used 250 jaM 
pGlu-AMC, ensuring a substrate excess.
The kinetic data in Table 4.1 shows that relatively little variance was observed between 
the three kinetic models plotted in Figures 4.16 to 4.21. The average Km determined for 
purified rifctfPAPl6H was 51.8 [iM (Table 4.1). The average Km determined for 
rHsa?A?\eu and vHsa?A?\ in cleared lysate were 55.3 and 52.1 |iM respectively. The 
presence of the His-tag clearly did not affect the Km of recombinant human PAP1. A Km 
of 50 ^M for the same substrate was independently reported for non His-tagged, 
recombinant human PAP1 (Dando et al., 2003). Similar values for Km were determined 
for various eukaryotic PAP1 enzymes, as listed in Table 1.6.
As can be seen in Table 4.1, a higher Vmax was observed for r/fctfPAPl than 
rHsa?A?\eu in cleared lysate. This was due to different concentrations of enzyme in the 
samples. While the Km is independent of enzyme concentration, Vmax increases the more 
enzyme is present. Since the concentration of purified r/ZsaPAPUH was known, the 
turnover number (kcat), the number of substrate molecules converted into product by one 
enzyme molecule per second, could be calculated as 2.51 s'1.
The Kj values (Table 4.2) exhibited by r/fctfPAP 1 6h for the selected peptide substrates, 
pGlu-Ala, pGlu-Val, pGlu-His-Gly and pGlu-His-Pro-NH2 (TRH), give an indication of 
their ability to act as competitive inhibitors. With the exception of TRH, the values are 
in agreement with the reported preference PAP1 has for the residue directly adjacent to
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pGlu (Section 1.3.8), namely: Ala>His»Val (Kj: 242.1<245.7«532.9 jiM). The Kj for 
TRH (pGlu-His-Pro-NH2) was 40.7 |iM, indicating r//raPAPl6H has a relatively higher 
specificity for this than the other pGlu peptides. This increased specificity is probably 
not simply due to TRH being a tripeptide (considering the Kj for pGlu-His-Gly), but 
rather the identity o f the third residue: pro line.
The crystallisation work carried out in this thesis was unable to provide protein crystals 
which would be suitable for X-ray diffraction analysis. However, this study is currently 
ongoing in Dr. Brendan O’Connor’s Neuroscience laboratory, DCU, Ireland. It is hoped 
that human PAP1 protein crystals of the required quality will soon be available. X-ray 
diffraction is a critical step towards elucidating the three-dimensional structure of a 
protein. Once the structure of human PAP1 has been determined, it will be of great 
benefit to further work, as discussed in Section 5.3.1.
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5.0 Structural analysis of recombinant human PAPI
5.1 Modelling the structure of human PAP1
To date, there has been no publication of the three-dimensional (3D) structure of human 
or other eukaryotic PAP1 enzymes. However, the 3D structures of four prokaryotic 
PAP1 enzymes have recently been solved using X-ray crystallography. These PAP1 
structures, namely for B. amyloliquefaciens (BamPAP1), T. litoralis (77/PAP 1), P. 
furiosus (PfuPAP 1) and P. horikoshii (PhoPAP]) are described in detail in Section 
1.3.10. /fctfPAPl has considerable homology to prokaryotic PAP1 enzymes, exhibiting 
greatest homology with ¿tamPAPl, as shown in Figure 1.6. Based on this homology a 
3D structure model of /fttfPAPl was created, using the prokaryotic structures as 
templates. The amino acid sequence for human PAP1 (HsaPAP 1, Figure 3.10) was 
submitted to the SWISS-MODEL web server (Section 2.11), which provides an 
automated protein homology-modelling service (Guex and Peitsch, 1997; Schwede et 
al., 2003). In short, SWISS-MODEL performs a search of the Protein Data Bank (PDB, 
Berman et al., 2000) for primary sequence homology to the target (/fctfPAPl). The PDB 
archive contains all known 3D protein crystal structures. If sufficient homology is found 
with one or more primary sequences in the archive, the 3D structure of the target is 
predicted by using the structures corresponding to the homologous sequences as a 
template. The resulting 3D model is returned by e-mail as a structural coordinate file. In 
the case of HsaPAP], SWISS-MODEL automatically selected the PDB entries for 
BamPAP], 77/PAP 1 and PfuPAPl as template structures.
A ribbon diagram of the ifoaPAPl 3D structure model is shown in Figure 5.1, in 
comparison to the three template structures. The a-helices and P-strands in the model 
have been indicated by colouration. The structural pattern of HsaPAP\ closely 
resembles the three prokaryotic structures. The structure is a single a/p globular domain, 
having a central P-sheet surrounded by a-helices. The location of these structural 
features on the primary sequence are indicated on an alignment of HsaPAP] with 
BamPAPl, 77/PAP1 and PfuPAP] (Figure 5.2). The same alignment, showing primary 
sequence homology, is given in Figure 5.3. Homology domains indicated on alignments 
of prokaryotic and eukaryotic PAP1 sequences in Section 1.3.6 (Figures 1.4 to 1.6), 
have again been indicated in Figures 5.2 and 5.3.
SWISS-MODEL excluded three N-terminal and twenty-four C-terminal residues from 
the /fctfPAPl model. These residues are indicated in Figures 5.2 and 5.3. The C- 
terminal region is where the least homology is observed (Figure 5.3). In the prokaryotic 
enzymes the C-terminal region contributes greatly toward interactions between
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monomeric subunits resulting in a tetrameric arrangement, as reported in Section
1.3.10.1. Experimental evidence so far to date (Section 1.3.9), including data presented 
in this thesis (Section 4.1.1), supports a monomeric structure for active eukaryotic PAP1 
enzymes. This would be in keeping with the observed divergence of sequence 
homology between prokaryotic and eukaryotic PAP1 enzymes at the C-terminal.
Hsa PAP1
N - te rm in a l
BamPA?\ 77/PA PIP/i/PA PI
Figure 5.1 HsaPAPl 3D model compared with structural templates
Ribbon diagram of the 3D Hsa?A?\ model, which was predicted using the SWISS-MODEL server 
(Section 2.11), taking the structures of Bam?A?\, Pfu?A?\ and 77/PAP 1 (Section 1.3.10) as templates, a 
-helices are coloured red and p-strands are coloured blue. 3 N-terminal and 24 C-terminal Hsa?A?\ 
residues were excluded from the model. The residues of Bam?A?\, Pfu?A?\ and 77/PAP 1 correlating to 
the excluded C-terminal residues form a-helices, indicated by arrows. Generated using Deep View 
(Section 2.11).
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Figure 5.2 Primary sequence alignment showing structural features
Alignment of HsaPAPl with BamPAPl, TliPAPl and PfuPAPl, identical to the homology alignment in 
Figure 5.3. Residues forming a-helices and p-strands (as shown in Figure 5.1) are coloured red and blue 
respectively. Residues which are not included in the HsaPAP 1 model are marked by black line. 
Homology domains reported in Figures 1.4 to 1.6 are indicated in red. For amino acid information see 
Appendix D. Created using MultAlin with Blosum62-12-2 parameters and edited using GenDoc (Section 
2.11).
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Figure 5.3 Primary sequence homology alignment
Homology alignment of HsaPAPl with BamPAPl, 77/PAP 1 and PfuPAPl. Sequence homology is 
represented by grey scale shading, with black being the highest homology. Residues which are not 
included in the HsaPAPl model are marked by black line. Homology domains reported in Figures 1.4 to 
1.6 are indicated in red. Catalytic triad residues Glu85, Cysl49 and Hisl68 are marked in blue 
(numbering applies to HsaPAPl). For amino acid information see Appendix D. Created using MultAlin 
with Blosum62-12-2 parameters and edited using GenDoc (Section 2.11).
5.1.1 Validation of the human PAP1 structure model
As described in Section 1.3.7 the catalytic triad of prokaryotic PAP1 enzymes was 
shown to consist of Glu-Cys-His. By primary sequence alignment (Figure 5.3) these 
residues correspond to Glu85, Cysl49 and His 168 in //saPAPl. Strikingly, in the 
HsaPAPl model of Figure 5.1, the orientation of these residues relative to each other is 
very similar to that observed for BamPAPl, 77/PAP 1 and PfuPAPl (see Figure 5.4).
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If these residues constitute the catalytic site o f HsaPAP 1, one would expect the enzyme 
activity to be affected dramatically by introducing miss-sense mutations into the codons 
for these amino acids. Using a site-specific mutagenesis approach Cysl49 and His 168 
were substituted with tryptophan and aspartic acid respectively (Figure 5.5). This was 
carried out as described in Section 2.9.2, using primers listed in Table 2.2. Codon 
changes to the recombinant human PAP1 DNA sequence (rHsa-papl) were made on the 
r//saPAPl6H expression plasmid pRV5 (Figures 3.8 and 3.10), as it had been 
demonstrated that the His-tag does not affect the kinetic parameters of the enzyme 
(Table 4.1). The choice of these amino acid replacements was based on radically 
altering the side-chains. The resulting mutant constructs are listed in Table 5.1. Both 
mutations caused a complete loss o f activity, supporting the catalytic significance of  
these residues and also lending support for the HsaPAPl 3D structure (Figure 5.1) 
obtained via SWISS-MODEL.
BamPAPl 77/PAP1
PfuPAPl HsaPAPl
Figure 5.4 Comparison of PAP1 active sites
The side-chain orientation of the catalytic residues Glu, Cys and His for BamPAPl, 77/PAP 1, P/mPAP1 
and the HsaPAPl model. Hydrogen bonds are indicated by broken lines. Colouration of residues by CPK 
colour scheme (C = white, O = red, N = blue and S = yellow). For amino acid information see Appendix 
D. Generated using Deep View (Section 2.11).
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Figure 5.5 Substitution of HsaPAPl residues Cysl49 and Hisl68
Amino acid side-chains of the active site residues Cysl49 and Hisl68, which were substituted with 
tryptophan and aspartic acid respectively. For amino acid information see Appendix D. Illustrated using 
ChemSketch (Section 2.11).
5.2 Functional analysis of recombinant human PAP1
Continuing to use the 3D structure model of HsaPAPl produced by SWISS-MODEL 
(Section 5.1), further residues of the enzyme (Section 5.2.1 to 5.2.3) were targeted for 
functional analysis using site-specific mutagenesis. Figure 5.6 shows the location of 
these residues on a primary sequence alignment and Figure 5.7 shows how these 
residues are positioned in the HsaPAPl model. As with the catalytic residue mutants 
(Section 5.1.1) the codon changes were introduced on the expression plasmid pRV5 
(Figures 3.8 and 3.10) by the method described in Section 2.9.2, using primers listed in 
Table 2.2. Table 5.1 gives a list of all mutant pRV5 constructs as well as names of the 
corresponding mutant r/fctfPAPl6H enzymes.
Where possible, silent mutations were co-introduced to create a diagnostic restriction 
site. The silent mutations introduced in each construct are listed in Table 2.3 and the 
diagnostic restriction sites are indicated in Table 2.2. These restriction sites allowed for 
verification of mutant pRV5 constructs prior to DNA sequencing. For example, with the 
creation of pRV5_I120mG (Table 5.1), having the I lei 20 codon changed to a Gly codon 
(Section 5.2.2), a Pvul site was introduced (see Figure 5.8B). The pRV5 construct 
already has one Pvul site within ampR. A  Pvul restriction of pRV5_I120mG gave a 
1237 bp band, whereas pRV5 was linearised (see Figure 5.8A). Obtaining a band of the 
expected size confirmed successful mutagenesis.
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However, this approach may need to be reassessed in light of some of the data presented 
in Section 3.6.2, where silent codon mutations were found to result in a significant drop 
in recombinant protein production.
HsaPAPl
BamPAPl
TliPAPl
PfuPAPl
HsaPAPl
BamPAPl
TliPAPl
PfuPAPl
PI 73 ___  — ■■ PYKADOgGRA--i3M-8EE-l-iÿPlgEQSEGKlNYCHKH ; 209
 SAjm- LDHI T^BkKA-ItaAV^ DDI E T GGGE L- H : 215
FLLGKNTy^ CLEAE^ HEBvKisgDYgSKDRDDIKIPl— : 220
gkgqvp-^BcyemeSieH rE ieIajIeeSl-------------- : 208
Figure 5.6 Primary sequence alignment showing residues targeted for mutagenesis
Homology alignment of 7/saPAPl with BamPAPl, 77/PAP 1 and P/wPAPl. Sequence homology is 
represented by grey scale shading, with black being the highest homology. Residues which were targeted 
for site-specific mutagenesis are marked in red. Residues affected by unintentional mutagenesis are 
marked in black. For amino acid information see Appendix D. Created using MultAlin with Blosum62- 
12-2 parameters and edited using GenDoc (Section 2.11).
9-|hg-----
E1HRHH PHI
f -I k i e g y p : 
h -Ba t k g y p k m s
Figure 5.7 HsaPAPl 3D model showing residues targeted for mutagenesis
Ribbon diagram of the 3D HsaPAPl model. Residues targeted for site-specific mutagenesis are visualised 
in red. Residues affected by unintentional mutagenesis are marked in green. For amino acid information 
see Appendix D. Generated using DeepView (Section 2.11).
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Table 5.1 Mutant derivatives of r//sflPAPl6H
Mutation Plasmid Enzyme
Wild Type pRV5 tHsa? APIsh
C149 to W pRV5 C149mW rHsa?A?\ C149mW6H
HI 68 to D pRV5 H168mD rHsa?A?\ H168mD6H
F13 to W PRV5 F13mW r/ta P A P l F13mW6H
F13 to Y pRV5 F 13m Y r/ta P A P l F13mY6H
F I3 to Y, P I75 to S pRV5 F13mY.P175mS iHsa?A?\ F13mY.P175mS6H
F I3 to L pRV5 F13mL rHsaPA? 1 _F 13mL6H
F13 to L,F16 to L pRV5 F13mL.F16mL rHsaPAPl F13mL.F16mL6H
F16 to L pRV5 F16mL rHsaPA? 1 _F 16mL6H
F16 to Y pRV5 F16mY r/f.w/PAPl F16mY6H
Y147 to F pRV5 Y147mF rHsa?A?\ Y147mF6H
D97 to E pRV5 D97mE rHsaPAPl D97mE6H
D97 to E, N 98& C 99 toM pRV5 D97mE.N98C99mM tHso?A?\ D97mE.N98C99mM6H
N98 to Q pRV5 N98mQ rHsa?A?\ N98mQ6H
N98 to V pRV5 N98mV r//saPAPl N98mV6H
SI 15 to A, 1116 to Y ,D 117 to F pRV5 SID115mAYF rHsaPAPl SID115mAYF6H
GGG added after D 117 PRV5 D117+GGG rHsaPA? 1 _D 117+GGG6H
1120 to G PRV5 I120mG tH saPAP 1 _1120mG6H
Q180 toE pRV5 Q180mE rHsa?AP\ Q180mE6H
Q180 toE ,N 177 to Y pRV5 Q180mE.N177mY rHsaPAP 1 _Q 180mE.N 177m Y6H
C-terminal deletion: G201 to H209 pRV5_A3’ r/f^aPAPl AC6H
(pRV5 A3’A6H - without 6xHis) (rHsa?AP\ AC)
[On three occasions, unintended mutations (indicated in red) were obtained alongside the planned 
substitutions. For amino acid information see Appendix D. The DNA sequencing data for all mutant 
constructs is given in Appendix B.]
12,000 bp B
3.000 bp
2.000 bp 
1,650 bp
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Wild type
\AGCATTGACTCCATCATCGACATGG;
Ile i 20
Mutant Pvu\
\AGCATTGACTCGATCGGCGACATG G
Gly120
Figure 5.8 Verification of mutation using diagnostic restriction analysis
(A): Restriction digests of pRV5 and pRV5_I120mG (Table 2.3) using Pvu\, analysed on 0.7% agarose 
gel (Section 2.5). pRV5 has single Pvu\ site, within ampR (Figure 3.8). A second Pvu 1 site was 
introduced into pRV5_I120mG by mutation (B). A band of 1237 bp is expected from a Pvu 1 restriction of 
pRV5_I120mG. Lane 1 , pRV5 (uncut); Lane 2, pRV5_I120mG (uncut); Lane 3, pRV5 ( P v m I ) ;  Lane 4 ,  
pRV5_I120mG (Pvt/1); Lane 5, DNA Ladder (sizes as in Figure 2.5).
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5.2.1 Substrate binding pocket residues of human PAP1
A common feature of peptidases is a hydrophobic ‘binding pocket’ that typically 
surrounds the catalytic residues. This type of binding pocket is known to help orientate 
the substrate for hydrolysis. The //saPAPl residues Phel3, Phel6 and Tyrl47 (Figure
5.7) correspond to the Bam?API residues Phe 10, Phel3 and Phel42 respectively 
(Figure 5.6). A recent mutational analysis study has highlighted the essential role these 
residues have within the substrate binding pocket of BamPAPX (Section 1.3.11). In the 
present study Phel3 and Phel6 of HsaPAPl were changed to Leu (both separately and 
simultaneously), thereby keeping the hydrophobic property but replacing the large 
aromatic structure with a smaller side-chain. Both residues were also changed to Tyr, 
conserving the aromatic structure but introducing a polar property. More dramatically, 
Phel3 was changed to Trp, having an even larger aromatic side-chain. Tyrl47 
(/fctfPAPl) is commonly substituted with Phe in prokaryotic PAP1 enzymes. Therefore 
Tyr 147 was changed to introduce the triple Phe arrangement to /feaPAPl. The side- 
chain structure changes of these substitutions are shown in Figure 5.9.
As shown in Figure 5.7, Asp97 and Asn98 are located at the outer edge of the binding 
pocket. While Asp97 is highly conserved (Figures 1.4 to 1.6 and 5.4), Asn98 is 
substituted with various residues in some of the lower eukaryotes (Figure 1.5). The 
charged Asp97 was conservatively changed to Glu. The polar Asn98 was conservatively 
changed to Gin and more dramatically to the hydrophobic Val. The side-chain structure 
changes of these substitutions are shown in Figure 5.10. Analysis of these mutants is 
presented in Section 5.2.4.
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Figure 5.9 Substitution of HsaP API residues Phel3, Phel6 and Tyrl47
Amino acid side-chains of the substrate binding pocket residues Phel3, Phel6 and Tyrl47, which were 
substituted variably with leucine, tyrosine and tryptophan. For amino acid information see Appendix D. 
Illustrated using ChemSketch (Section 2.11).
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Figure 5.10 Substitution of//saPAPl residues Asp97 and Asn98
Amino acid side-chains of the substrate binding pocket residues Asp97 and Asn98, which were 
substituted variably with glutamic acid, and glutamine or valine respectively. For amino acid information 
see Appendix D. Illustrated using ChemSketch (Section 2.11).
5.2.2 Extended loop residues of human PAP1
On an extended outer loop of //stfPAPl (Figure 5.7) the motif Seri 15-Ilel 16-Asp 117 
was changed to Ala-Tyr-Phe, the latter three amino acids being commonly found in 
prokaryotic PAP1 enzymes (Figure 1.4). In addition to this mutation, an insertion of 
three Gly residues was introduced at A spll7 to further address the structural 
significance of the loop. The position occupied by I lei 20 in HsaPAP1 is conserved as 
hydrophobic in most PAP1 enzymes (Figures 1.4 and 1.5). This Ilel 20 residue in 
HsaPAP1 is positioned at the junction between the extended loop and an a-helix. To
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address its importance at the N-terminal o f an a-helix (Figure 5.5), it was changed to 
Gly. Analysis of these mutants is presented in Section 5.2.4.
5.2.3 C-terminal residues of human PAP1
The striking lack of homology between the human PAP1 sequence, at the C-terminal 
end, when compared with the prokaryotic sequences (Figures 1.4 to 1.6 and 5.4), is 
particularly interesting in the proposed structure for HsaPAPl, in which the terminal 24 
residues have been excluded from the model. In order to test the role, if any, in the 
catalytic activity and/or stability o f the enzyme, of these terminal residues, a number of 
additional mutations were made. These included a deletion mutation (spanning the 
terminal nine residues) and a substitution involving residue Glnl80. The strategy used 
to create the C-terminal deletion is outlined in Figure 5.11. Analysis of these mutants is 
presented in Section 5.2.4.
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Figure 5.11 Cloning strategies for 3’ deletion constructs
(A): PCR (Section 2.8.2) on pRV5 using primers PAPHsK and PAPHsR (Table 2.2) generates product 
with EcoRX site upstream from the rHsa-papl having nine 3’ codons deleted and the 6xHis fusion 
replaced by stop codon, followed by BamHX tag with clamp. Fragment is restricted (EcoRX/BamHX) and 
ligated into pPC225 (opened with EcoRX/BamHX). pRV5_A3’A6H has rHsa-papl (3’ deletion and 
without 6xHis) under control of Ptac promoter. (B): PCR on pRV5 using primers PAPHsK and PAPHsT 
(Table 2.2) generates product with EcoRX site upstream from the rHsa-papl having 3’ deletion and 6xHis 
fusion replaced by BamHX site with clamp. Fragment is restricted (EcoRX/BamHX) and ligated into pQE- 
60 (opened with EcoRX/BglXX). Restriction (EcoRX/HiruWW) on intermediate clone results in fragment 
having rHsa-papl with 3’ deletion, fused to 6xHis, which is ligated into pPC225 (opened with 
EcoRX/HindlU). pRV5_A3’ has rHsa-papl (with 3’ deletion and 6xHis) under control of Ptac promoter. 
Restriction sites are indicated with positions (and sequences for final constructs). Illustrated using 
pDRAW32 (Section 2.11).
139
5.2.4 Analysis of recombinant human PAP1 mutants
The mutant plasmid derivatives o f pRV5 (Table 5.1) were transformed into E. coli 
XL 10-Gold as described in Section 2.6.3. Standard expression cultures were prepared as 
outlined in Section 2.12. Cleared lysate samples were assayed for PAP1 activity 
(Section 2.15.2). As reported in Section 5.1.1, no activity was detected for the putative 
catalytic triad mutants r/fcflPAPl_C149mW6H and r//.«jPAPl_H168mD6H. Nor was 
there any activity for r//stfPAPl_F13mW6H, r//stfPAPl_F13mL.F16mL6H, 
r/&tfPAPl_I120mG6H or rHsa?A?\_D\ 17+GGG6H-
All mutant proteins were found to be expressed at high levels comparable to 
r/fctfPAPl6H, except r/&tfPAPl_Dl 17+GGG6H. No significant protein band of the 
expected molecular weight of 24,277 (deduced from amino acid sequence) could be 
seen for the latter. Figure 5.12 shows SDS-PAGE analysis (Section 2.16) of some 
cleared lysate samples from expression cultures, including from an 
rHsa?A?\_D\ 17+GGG6h culture. RT-PCR analysis (Sections 2.8.1 and 2.8.2) was 
performed on r/ZrarPAPlDl 17+GGG6H expression culture samples and a few control 
samples, similar to the approach in Section 3.6.2. As can be seen in Figure 5.13, the 
amount of mRNA being produced for r//súrPAPl_Dl 17+GGG6H was comparable to that 
of rHsa?A?\6U. Thus, the most likely explanation for the lack of appearance of a 
protein band for r//s«PAPl_Dl 17+GGG6H is either due to adverse folding of the 
mRNA, leading to inefficient translation of protein, or, unstable conformation of protein 
structure which is particularly susceptible to degradation.
SDS-PAGE analysis (Figure 5.14) shows clearly the expected size difference between 
r/fctfPAPl6H and the mutant r/ftorPAPlAC, having nine C-terminal residues (and the 
His-tag) removed.
All mutants showing activity were purified according to the standard IMAC procedure 
outlined in Section 2.13.1 (Figure 5.15), except for rHsa?A?\_AC, which is lacking the 
His-tag necessary for IMAC purification. Purified, active rHsa?A?\eH mutants were 
investigated for their kinetic parameters by the same procedures as used in Section 4.2. 
A summary of these parameters is given in Table 5.2, while graphical comparisons are 
given in Figures 5.16 to 5.18. Western blot analysis (Section 2.18) of r//saPAPl6H and 
selected mutants, in cleared lysate, is shown in Figure 5.19. Figure 5.20 shows 
Zymogram analysis (Section 2.17) of r//stfPAPl6H and selected mutants in cleared 
lysate.
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Figure 5.12 Expression of r//saPAPl6H mutants
Analysis o f r//saPA Pl6H mutant expression in E. coli XL10-Gold (Section 2.12) by 15% SDS-PAGE 
(Section 2.16). Samples taken 4 hrs after induction with 50 |iM IPTG. Lane 1, Mr (sizes given in Figure 
2.6); Lane 2, r//saPAPl_SIDl 15mA YF6H; Lane 3, r//saPAPl_D117+GGG6H; Lane 4, 
r//s0PAPl_I12OmG6H; Lane 5, r//saPAPl_Q180mE; Lane 6, r//5aPAPl_Q180mE.N177mY6H.
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Figure 5.13 RT-PCR analysis of pRV5 mutants
(A): RT-PCR analysis (Sections 2.8.1 to 2.8.2) of RNA isolated (Section 2.4.4) from E. coli XLIO-Gold 
cultures harbouring pRV5 and some mutant derivatives (Table 5.1). rHsa-papl specific primers PAPHsM 
& PAPHsN (627 bp product) and ampR specific primers Amp-for & Amp-rev (856 bp product) were used 
(Table 2.2). Negative controls carried out by omitting RTase (data not shown). Lane 1, DNA Ladder 
(sizes as in Figure 2.5); Lane 2, pRV5; Lane 3, pPC223 -ve control; Lane 4, pRV5_C149mW; Lane 5, 
pRV5_N98mV; Lane 6, pRV5_pRV5_Dl 17+GGG. Ratios of rHsa-papl to ampR product, determined by 
densitometry (Section 2.16.5), are shown in bar chart (B).
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Figure 5.14 Comparison of r//saPAPl6H with r//saPAPl_AC
Analysis o f r//saPAPl6H compared to r//saPAPl_AC in cleared lysate, by 15% SDS-PAGE (Section 
2.16). Lane 1, Mr (sizes given in Figure 2.6); Lane 2, r//saPA Pl6H; Lane 3, rHsaPAP\6n & 
iHsaPAP\_AC, Lane 4, rHsa?A?\_AC; Lane 5, Mr
Figure 5.15 Purification of r//saPAPl6H mutants
Mutant derivatives of r//stfPAPl6H (Table 5.1) purified by IMAC (Section 2.13.1) and analysed by 15% 
SDS-PAGE (Section 2.16). Lane 1, Mr (sizes given in Figure 2.6); Lane 2, r//5aPAPl6H; Lane 3, 
r//.saPAPl_ D97mE6H, Lane 4, r//saPAPl_D97mE.N98C99mM6H; Lane 5, r//saPAPl_N98mQ6H; Lane 
6, rHsaPAP1 _N98mV6H; Lane 7, r//5flPAPl_F13mY6H; Lane 8, r//saPAPl_F16mY6H; Lane 9, 
r//5flPAPl_F16mL6H; Lane 10, r//saPAPl_Y147mF6H; Lane 11, r//5flPAPl_F13mL6H; Lane 11, 
r//saPAPl_F13mL6H; Lane 13, r//saPAPl_Q180mE6H; Lane 14, r//saPAPl_Q180mE.N177mY6H, Lane 
15,r//sflPAPl_AC.
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Table 5.2 Kinetic parameters of r/foflPAPl6n mutants
Enzyme Specific Activity 
(units/mg)
Km
(HM)
kcat
(s'1)
r//sflPAPl6H 9334.3 51.8 3.75
r//saPAPl C149mW6H - - -
rHsaPAP 1 H168mD6H - - -
rHsaPAP 1 F13mW6H - - -
rHsaPAPl F13mY6H 4032.0 96.1 1.62
rHsaPAPl F13mY.P175mS6H 503.4 93.6 0.20
rHsaPAP 1 F13mL6H 472.6 78.3 0.19
rHsaPAP 1 F13mL.F16mL6H - - -
rHsaPAP 1 F 16mL6H 1213.7 161.0 0.49
rHsaPAP] F16mY6H 8405.4 24.9 3.38
rHsaPAPl Y147mF6H 9823.3 41.6 3.94
rHsaPAP 1 D97mE6H 902.3 29.9 0.36
rHsaPAPl D97mE.N98C99mM6H 814.2 48.2 0.33
rHsaPAPl N98mQ6H 5048.9 44.4 2.03
rHsaPAP 1 N98mV6H 10237.2 58.6 4.11
rHsaPAP 1 SID115mAYF6H 5742.3 27.7 2.31
rHsaPAP] D117+GGG6H - - -
rHsaPAP 1 I120mG6H - - -
rHsaPAP] Q180mE6H 5516.6 39.7 2.22
rHsaPAP 1 Q180mE.N177mY6H 5583.0 57.1 2.25
rHsaPAP 1 AC6H 12301.7 56.1 4.72
[Km values are averages of those obtained from the three kinetic models 
described in Appendix C. kcat values calculated as outlined in Appendix C.]
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Figure 5.16 Effect of mutations on specific activity
Values for specific activity (units/mg) taken from Table 5.2
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Figure 5.17 Effect of mutations on Km
Values for Km (¿iM) taken from Table 5.2
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Figure 5.18 Effect of mutations on kcat
Values for k ^  (s'1) taken from Table 5.2
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Figure 5.19 Western blot analysis of rHsaPAPl mutants
Western blot (Section 2.18) analysis, using anti-His antibodies, of cleared lysate sample from E. coli 
XLIO-Gold cultures expressing (Section 2.12) r/ZsaPAPl mutants (Table 5.1). (A): Ponceau S transfer. 
(B): Western blot. Lane 1, Mr (sizes given in Figure 2.6); Lane 2, rHsaPAP16h; Lane 3, pPC223 (-ve 
control); Lane 4, r//5aPAPl_C149mW6H; Lane 5, r//saPAPl_N98mV; Lane 6, r//saPAPl_AC; Lane 7, 
r//saPA Pl; Lane 8, r//saPAPl_AC6H; Lane 9, CMr (sizes given in Figure 2.7).
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Figure 5.20 Zymogram analysis of rHsaPAPl mutants
Zymogram analysis (Section 2.17) of cleared lysate samples from E. coli XL 10-Gold cultures expressing 
(Section 2.12) iHsaPAPl mutants (Table 5.1). Lane 1, r/faaPAPl6H; Lane 2, pPC223 (-ve control); Lane 
3, r//saPAP1 _C 149mW6H; Lane 4, r//saPAPl_N98mV; Lane 5, r//saPAPl_F13mW6H; Lane 6, 
r//saPAPl_AC; Lane 7, rHsaPAPl, Lane 8, r//saPAPl_AC6H. The fluorescence bands correspond to the 
prominent protein bands visible after coomassie staining (data not shown).
5.3 Discussion
To date, no protein crystal structure has been published for human or any other 
eukaryotic PAP1. Although some preliminary work was done, as part of these studies 
on HsaPAPl, in an attempt to crystallise the protein (Section 4.3) to a quality fit for X- 
ray diffraction, this work is still ongoing. However, the availability o f four prokaryotic 
PAP1 crystal structures (Section 1.3.10), together with the considerable homology 
observed between HsaPAPl and various prokaryotic PAP1 sequences, e.g. BamPAP\
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(Figures 1.6 and 5.3), gave the impetus to attempt 3D homology modelling using the 
SWISS-MODEL server (Section 5.1).
SWISS-MODEL successfully predicted a 3D model for //saPAPl by taking three of the 
existing prokaryotic PAP1 structures as templates (Figure 5.1). The HsaPAPl model 
exhibits a very similar folding pattern to the template structures, with a-helices and p- 
sheets in comparable locations along the primary sequence (Figure 5.2). As shown in 
Figure 5.4, the orientation of the catalytic triad (Glu-Cys-His, Section 1.3.7) of the 
prokaryotic structures is identical to the corresponding, conserved residues (Glu85, 
Cysl49 and Hisl68) in the HsaPAP1 3D model. Mutation of the residues Cysl49 and 
Hisl68 individually (Section 5.1.1) in //saPAPUh resulted in complete loss of catalytic 
activity, strongly implicating them in the catalytic triad of HsaPAP] and supporting the 
use of the HsaPAP\ 3D model (Figure 5.1) as a reference structure to the mutational 
analysis in this work.
Figure 5.14 demonstrates the size difference between rHsaPAPlen and rHsaPAP\_AC, 
the mutant having nine C-terminal residues deleted and lacking a His-tag. The lack of a 
His-tag in r//saPAPl_AC, as well as r/fttfPAPl (Figure 3.13), was confirmed by 
Western blot analysis (Figure 5.19) using anti-His antibodies. A considerable (24 
residue) C-terminal domain of HsaPAP\ was not incorporated into the 3D model. The 
most likely reason this domain was excluded is probably due to the observed reduced 
homology, between HsaPAP\ and the prokaryotic sequences (Figure 5.3). In the 
prokaryotic PAP1 enzymes this C-terminal region contributes greatly toward 
interactions between monomeric subunits resulting in a tetrameric arrangement, as 
described in detail in Section 1.3.10.1. Human and other eukaryotic PAP1 enzymes are 
known to be monomeric (Section 1.3.9), hence one might not expect to find these 
specific C-terminal features necessary for quaternary structure formation.
The mutation of Gin 180 (Section 5.2.3), caused only a slight reduction in specific 
activity and turnover. Dramatically, it was shown that removal of nine residues from the 
C-terminal of //mtPAPUh did not affect binding capacity and even seemed to cause an 
increase in specific activity and turnover. Furthermore, the addition of six residues to 
the C-terminal (the His-tag, Section 3.4), a mutation in its own right, did not affect the 
catalytic properties of the enzyme (Section 4.2). It seems, therefore, that some residues 
of the C-terminal region do not have any functional necessity in HsaPAP\ and 
modification of this region could make the enzyme more catalytically efficient. As 
outlined in Section 1.3.10.1, this region features in the formation of a quaternary
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structure in prokaryotic PAP1 enzymes, which is not observed in eukaryotes (Section
1.3.9).
By co-introduction of diagnostic restriction sites, using silent mutations, each mutant 
construct could be verified (Figure 5.8) prior to commercial DNA sequencing. 
However, in light of the discussion in Section 3.8, it must be noted that silent mutations 
may change mRNA conformation, which could result in altered mRNA stability and/or 
translation efficiency. Therefore, based on the work carried out here, a possible 
alternative approach to identify mutations prior to DNA sequencing would be to further 
develop the gradient PCR screening strategy, as described in Section 3.6.2 (Figure 
3.28).
As reported in Section 5.2.4, the r/&tfPAPl6H mutant enzymes could be successfully 
expressed at levels comparable to r//stfPAP1 6h (Figure 5.12), with the exception of 
r//^PAPl_Dl 17+GGG6H (Table 5.1). No protein band of expected molecular weight 
24,277 was detected for that mutant. RT-PCR analysis (Figure 5.13) shows that the 
amount of mRNA transcript produced was equivalent to that for rHsaPAPXeu. It may be 
that the mutant mRNA structure folded in a way which impeded efficient translation. 
Alternatively, the addition of the three Gly residues may have dramatically altered the 
protein structure, resulting in an unstable folding and subsequent degradation of the 
protein.
The catalytically active mutants were purified (Figure 5.15) and their kinetic parameters 
determined (Table 5.2; Figures 5.16 to 5.18). As outlined in Section 5.2.1, mutagenesis 
of residues Phel3, Phel6 and Tyel47 was carried out to determine to what extent these 
residues contribute to the substrate binding pocket of //stfPAPl (Figure 5.7). A similar 
study of these binding pocket residues in BamPAP] was carried out by Ito et al. (2001), 
as reported in Section 1.3.11. This BamPAPX study identified the PhelO residue 
(corresponding to Phel3 in HsaPAPX) as an essential contributor to the binding pocket. 
In the present study, changing //stfPAPl Phel3 to the larger, aromatic Trp resulted in 
complete loss of activity. Substitution of Phel3 with the aromatic, yet polar Tyr caused 
a reduction of specific activity and rate of turnover (kcat), in correlation with an increase 
in Km. The unintentional co-mutation of Pro 175 to Ser (Table 5.1) caused a significant 
decrease in specific activity and k t^, while not further affecting the binding capacity 
(Km). The substitution of Phel6 to Tyr caused a more subtle reduction in specific 
activity and k^ (compared to Phel3), while increasing the binding capacity, 
characterised by a drop in Km. The changing of Tyr 147 to Phe, creating the triple Phe
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arrangement seen in many prokaryotic PAP1 enzymes (Figure 1.4), did not affect the 
kinetic properties to any notable extent. The individual substitution of both Phel3 and 
Phel6 with the smaller, hydrophobic Leu caused dramatic reduction in specific activity 
and kcat and a corresponding drop in binding capacity (rise in Km). When both these 
mutations were imposed simultaneously, activity was lost completely. These results are 
in correlation with the Bam?AP\ study. It is assumed these residues contribute similarly 
to the substrate recognition mechanism in HsaPAPl. Their similar positioning within 
the /fctfPAPl 3D model as the Bam?A?\ residues (Figure 5.21) suggests that the model 
gives an accurate prediction of the //raPAPl substrate binding pocket structure.
BamPAPX Hsa PAPl
Figure 5.21 Comparison of //saPAPl and BamPAVi binding pockets
The side-chain orientation of the BamPAPX substrate binding pocket residues PhelO, Phel3 and Phel42, 
(indicated in blue), compared to the corresponding HsaPAPl 3D model residues Phel3, Phel6 and 
Tyrl47. Catalytic triad residues (Figure 5.4) are represented in CPK colour scheme (C = white, 0  = red, 
N = blue and S = yellow). For amino acid information see Appendix D. Generated using DeepView 
(Section 2.11).
The mutation of Asp97 caused a significant decrease in specific activity and kcat, while 
not affecting binding capacity greatly. Changing Asn98 to Gin reduced the specific 
activity and turnover slightly, while the change to Val did not cause any effect. 
Mutation of Seri 15-Ilel 16-Aspl 17 to A-Y-F (Section 5.2.2), a motif found in 
prokaryotes (Figure 1.4), on an extended external loop (Figure 5.7) caused a slight 
reduction in catalytic efficiency.
The loss of activity caused by the mutation of I lei 20 to Gly implicates this residue to be 
in a structurally significant location. In the /ZswPAPl 3D model Ilel 20 is located at the 
N-terminal o f an external a-helix (Figure 5.7). In the prokaryotic primary sequences this 
residue is conservatively substituted with Leu (Figure 5.6) and similarly located at the
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N-terminal of a corresponding a-helix (data not shown). This lends further support for 
the Hsa?A?\ 3D model.
5.3.1 Structure-based drug design
The conventional process by which the pharmaceutical industry facilitates the discovery 
of new drugs involves the screening of large (ever increasing) libraries of chemical 
compounds in search for those with a particular biological or medicinal relevance 
(Malhotra and Taqueti, 2000). The anticipation is that a sufficiently large collection of 
molecules will harbour enough structural diversity to prove effective for any particular 
biological target of interest. Compounds that are found to produce the desired biological 
effect (lead compounds) are then tested and optimised for their medicinal properties. 
Despite that many drugs have been successfully developed using this approach, the 
time-, money- and labour-intensity can often prove prohibitive unless the reward is 
sufficiently lucrative. Many previous efforts to minimise the time and resources 
necessary for such high-throughput screening (HTS) only resulted in compromised 
accuracy and sensitivity of the screenings.
The identification of lead compounds is the most critical stage in the process o f modem 
drug discovery. Structure-based strategies have become an integral part of this stage. 
This owes in particular to the volume and pace at which the structures of proteins (many 
of them important drug targets) and their co-crystals are presently becoming available, 
together with the growing sophistication of computational bio-informatics tools. 
Structural analysis and design methodologies are increasingly being used for the 
determination of new lead compounds and molecular scaffold generation as well as the 
optimisation of receptor or enzyme affinity. Such approaches show many advantages 
over traditional HTS, including reduced reagent storage, handling of large compound 
libraries, lowering of false positives often associated with HTS and the ability to find 
low-molecular-weight leads even when HTS fails. The structure-based approach to drug 
design relies on a firm understanding of the molecular recognition between a protein 
and its binding ligand, as well as knowledge of the structure-activity relationships 
(Andricopulo and Montanari, 2005).
Here follows a case study of recently published findings by a multi-disciplinary research 
collaboration (Janssen et al., 2005; Das et al., 2005) demonstrating how extensive 
knowledge of crystallography, protein structure analysis and molecular modelling plays 
a vital role in modern drug discovery. In this research effort a new group of highly
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potent novel anti-HIV drugs has been developed. These drugs will contribute to 
evermore effective therapies against the acquired immunodeficiency syndrome (AIDS) 
caused by this virus. The global pandemic of HIV/AIDS is one of the most significant 
medical challenges facing humanity today. The death toll to date stands at 23 million, 
with more than 42 million people presently infected.
Virally encoded enzymes that coordinate the replication of the virus, e.g. reverse 
transcriptase (RT), protease and integrase, are the primary conventional protein targets 
of HIV therapy. The therapeutic aim is to use inhibitors against these enzymes in an 
effort to suppress replication of the virus. The virus has a fast turnover rate, undergoing 
one replication approximately every two days. This, together with a high rate of 
mutation due to the lack of an efficient error correction mechanism during replication, 
results in the rapid emergence of enzyme variants that are resistant to current anti-HIV 
drugs. Such mutant enzymes, while still capable of carrying out normal HIV functions, 
owe their inhibitor resistance to subtle structural changes. The treatment of AIDS 
patients with combinations or “cocktails” o f anti-HIV drugs can often lead to multi­
drug-resistant variants. These resistant varieties are constantly being selected for by the 
use of these drugs and therefore dominate the viral population pool. The daunting 
challenge in HIV therapy is the design of drugs which retain their usefulness in the face 
of this ’’moving target” nature of the virus. Successful therapy must anticipate changes 
in the structure of these protein targets.
HIV-1 RT is a heterodimer, having one subunit containing polymerase and RNase H 
domains and another that contributes structural support. One widely used class of anti- 
HIV drugs, lead compounds from a HTS study, are non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). They specifically inhibit HIV-1 replication, at nanomolar 
concentration, by binding to HIV-1 RT. The location of the binding pocket for these 
inhibitors is in close proximity to the polymerase catalytic site. RT undergoes 
conformational changes in correlation with various stages of its function. Due to this 
dynamic nature of HIV-1 RT structure the NNRTI binding pocket is transitional and 
only truly exists when the inhibitor is bound. Upon NNRTI binding further 
conformational changes are obstructed and the process of polymerisation is inhibited. 
The researchers carried out in-depth analysis of the crystal structures of wild-type and 
mutant HIV-1 RT, in complex with nucleic acid substrates as well as several established 
NNRTIs. This provided a detailed overview of how substrate and/or inhibitor binding 
correlated with different functional conformations of HIV-1 RT, as well as giving
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insight as to how specific mutations might prevent NNRTIs from binding: While 
NNRTI binding does not block substrate binding, rather it prevents the chemical process 
of polymerisation. The NNRTI binding pocket is of a hydrophobic nature, conferred by 
several aromatic and hydrophobic amino acid side-chains. Binding of NNRTIs into the 
pocket is mediated by various hydrophobic interactions and hydrogen bonds. NNRTIs 
exhibit considerable variation in chemical composition and size and in consequence 
they each exhibit a unique interaction profile with the binding pocket. HIV-1 RT 
mutations conferring resistance represented specific side-chain substitutions in and 
around the NNRTI binding pocket, supporting their key role in the relevant NNRTI 
binding. The structural mechanism of drug resistance is accomplished by altered size, 
shape, polarity and accessibility of different regions in the binding pocket.
Figure 5.22 Structure-based design strategy for novel anti-HIV drugs
A flow chart highlighting the multi-disciplinary design, optimisation and assessment strategy employed in 
the discovery of novel HIV-1 RT inhibitors (Taken from Das et a l 2005).
A design strategy was initiated, in ultimate pursuit of a compound that could bind into 
the NNRTI binding pocket of HIV-1 RT despite various mutational structure changes 
(Figure 5.22). Derivatives of various NNRTIs were synthesised and investigated for 
their inhibition profiles. The crystal structures of HIV-1 RT/inhibitor complexes were 
solved and the ligand binding modes determined. Molecular modelling was carried out, 
involving the docking of inhibitor compounds into the binding pockets of the various 
crystal structures, to evaluate and analyse probable binding properties of further 
derivative compounds. The measured potencies of the inhibitors against mutated HIV-1
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RT isolates were correlated with the structure/modelling data and the results were 
filtered back into the design and development process.
As the cycles of this design strategy gradually progressed, new inhibitors were 
identified which had altered binding conformation to the compounds from which they 
were originally derived. These altered binding profiles also resulted in retained 
effectiveness against key NNRTI-resistant mutants, due to reduction/loss o f steric 
conflict caused by mutant amino acid side-chains. As the process continued, the newer 
compounds demonstrated potency against a broader spectrum of drug resistant HIV-1 
strains. Eventually a new class of NNRTI, the diarylpyrimidine (DAPY) compounds, 
was identified.
It was noticed from the crystal structures of the DAPY compounds in complex with 
HIV-1 RT, that their electron densities were weak relative to the first generation of 
NNRTIs. This was attributed to positional disorder within the binding pocket. This 
raised speculation that these compounds were able to bind HIV-1 RT in more than one 
conformation. Such conformational heterogeneity would also explain the low crystal 
resolution that was obtained for these complexes. This theory was confirmed using 
HIV-1 RT variants having reduced binding possibilities and therefore less 
heterogeneous crystals. A much better crystal resolution was achieved. Molecular 
modelling analysis confirmed that the DAPY compounds are able to undergo 
conformational changes and repositioning within the binding pocket. Molecular 
dynamics calculations show that the DAPY compounds exhibit significant torsional 
flexibility without encountering prohibitive energy barriers.
In summary, this HIV research collaboration has combined several structure-based 
methodologies, creating a powerful strategy to successfully address the need for 
sophisticated novel anti-HIV drugs. The ability to bind in multiple conformations 
permits the DAPY compounds to retain activity against HIV-1 RT despite structural 
variation, essentially compensating for the effects of resistance mutations. A single one 
of these drugs is able to perform the same task as a “cocktail” of first generation 
NNRTIs. The use o f these drugs could provide an environment where the manifestation 
of structural variety does not impart to HIV-1 RT any evolutionary benefit, thereby 
halting the emergence of drug-resistant variants. As such, this case study is an inspiring 
demonstration of how structure data can be exploited to serve the process of drug 
design.
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In this thesis, a structure model o f //.raPAPl was established (Section 5.1). The validity 
of this 3D model is supported by the results of mutational studies presented in Section
5.1.1. The /fotfPAPl model was used to identify residues and domains, whose role in 
the structure-activity properties of the enzyme were then determined by further 
mutational and catalytic studies (Section 5.2). Preliminary crystallisation studies on 
HsaPAPl were conducted as outlined in Section 4.3. So far, the crystal diffraction 
patterns to emerge form this work have not been of sufficient quality to allow 
elucidation of the protein structure. However, this work is ongoing within the research 
group and it is hoped that the true //.rarPAPl structure will soon be solved.
The involvement of PAP1 in the degradation of biologically active pGlu neuropeptides, 
such as TRH, has been widely documented (Section 1.3.1). Furthermore, a notable 
physiological correlation with levels o f the pharmacologically active compounds 
cyclo(His-Pro) and free pGlu have implicated PAPl’s involvement in several medical 
conditions such as Huntington’s disease, pyroglutamic academia, motor neuron disease 
and Alzheimer’s disease (Section 2.1). To date, substrate specificity studies of PAP1 
and identification of inhibitors have focused mainly on using synthetic chemical 
derivatives o f the pGlu substrate moiety, evaluated by biochemical and kinetic analysis 
(Section 1.3.8). The in vivo suitability o f those compounds found to have inhibitory 
potential has yet to be ascertained.
Crystal structures of the various HsaPAPl mutants created in this project and those that 
have been proposed as future work (Chapter 6), as well as possible co-structures, will 
subsequently be sought. If such a set of structures can be accumulated, it will be 
possible to initiate an extensive analysis and comparison project, including other data 
such as the prokaryotic PAP1 structures and co-structures reviewed in Section 1.3. The 
outcome of such an undertaking would be an extremely comprehensive knowledge of 
HsaPAPI's structural and catalytic profile. This knowledge base would serve as a 
foundation on which /ZsaPAPl inhibitor design projects could be built, studies that 
could draw on a variety of molecular modelling and analysis tools combined with the 
type of genetic and biochemical methodologies employed in this thesis. Successful 
design of new potent //saPAPl inhibitors, suitable for in vivo application, would 
represent valuable drugs that can be employed in future pharmacological studies of 
human PAP1.
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6.0 Summary & Recommendations
In this research thesis, the gene for human PAP1 was cloned into a bacterial expression 
system, enabling high level expression and purification of the recombinant enzyme 
(Chapter 3). An extensive characterisation of the recombinant PAP1 was undertaken 
(Chapter 4). The biochemical and kinetic profiles of the recombinant enzyme are 
comparable, and contribute significantly, to data on mammalian PAP1 reported in the 
literature (Cummins and O’Connor, 1998).
With the aid of homology modelling, a series of mutants were constructed and 
subsequently analysed (Chapter 5). The data revealed in this work contributes 
significant insight to the structural properties of human PAP1, in particular structure- 
function relationships of the active site region. Together with further data that may be 
determined by a number of recommended investigations (see below), these findings will 
open the way to a possible structure-based approach to PAP1 inhibitor design (as 
discussed in Section 5.3.1).
Some additional studies on recombinant human PAP1 that could provide more clarity 
on the relationship between the structure and function are hereby outlined:
In a similar way as was used in this study, the predicted 3D model o f human PAP1 
(Section 5.1) could provide a structural reference for the design of further site-specific 
mutagenesis work. The next phase should include an in-depth analysis o f the catalytic 
site and hydrophobic binding pocket. In this work, the residues Cysl49 and Hisl68 of 
the assumed catalytic triad were substituted, leading to loss of activity (Section 5.1.1). 
As shown in the crystal structures of several prokaryotic PAP1 enzymes, the Glu 
residue of the catalytic triad serves to orientate the His imidazole ring (Section
1.3.10.2). Thus it would be interesting to investigate the effect that a conservative 
substitution of the Glu85 residue would have in the human PAP1. In addition to this, 
further residues which are located in hydrophobic pocket should be investigated. An 
increase or reduction of the hydrophobicity of this region, as well as variation of side- 
chain size, will likely have a measurable effect on the binding properties and substrate 
specificity of the enzyme. This could be correlated with a hydrolysis study, using 
various known PAP1 substrates, as well as investigating the inhibition caused by active 
site-directed inhibitors of PAP 1 (Section 1.3.8).
The nine C-terminal residues of recombinant human PAP1 have no apparent necessity 
in enzyme function. Indeed their removal seemed to make the enzyme more 
catalytically efficient (Section 5.3). It would be of interest to determine what effect 
further deletion at the C-terminal would have on the enzyme. Furthermore, given that
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the C-terminal region of the prokaryotic PAP1 enzymes plays a role in quaternary 
structure formation (Section 1.3.10.1), it would be interesting to construct a hybrid 
enzyme, having a prokaryotic C-terminal domain. Would such a hybrid protein assume 
a quaternary arrangement and, if so, what kinetic properties would this multimer have?
Figure 6.1 Development of a fluorescence plate assay for PAP1 activity
A suitable fluorescence plate assay was developed for the detection of E. coli expressing PAP1 activity. 
E. coli XLIO-Gold, harbouring expression plasmids for active wild-type (pRV5, Section 3.5) and inactive 
mutant (pRV5_C149mW, Section 5.1.1) His-tagged recombinant human PAP1 were used as positive and 
negative controls respectively. Cells from 1 ml of culture (A^ oo of 1.0) were re-suspended in 100 p.1 dH20 .
1 \i\ ‘spots’ were applied to selective LB agar containing 100 IPTG. After overnight incubation at 
37°C (A) the plate assay was carried out as described in Section 2.15.4. Fluorescence can be clearly seen 
(B) for the wild-type (wt) enzyme compared to the mutant (m).
Site-specific mutagenesis relies minimally on knowing the amino acid sequence but in 
practice becomes powerful as a tool when either structural and/or comparative 
homology data is available. Given this, one needs premonition of how an amino acid 
substitution might affect the structure and/or function of an enzyme. A limitation of this 
site-specific mutagenesis approach is that one can still never have absolute foresight of 
the outcome. To complement the work carried out in this study, an alternative, random 
mutagenesis approach, not based on the 3D modelling was considered. Initial studies 
were carried out on the PAP1 gene using an error-prone PCR approach as described by 
Nakaniwa et al. (2004) which includes using varying Mn2+ concentrations. In order to 
select potentially interesting mutants (using the random mutagenesis approach) one 
would need to devise a highly sensitive assay for screening large numbers of colonies. 
A fluorescent plate assay was developed, which can differentiate PAP1 active from 
inactive colonies. The methodology of this assay is described in Section 2.15.4. Figure
6.1 shows a demonstration o f this assay using positive and negative controls for PAP1
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activity. One can clearly see the fluorescence from the ‘spots’ of E. coli expressing the 
active form of human PAP1 compared to an inactive mutant. The assay was also very 
effective in differentiating between single colonies, unfortunately these images were of 
a poor quality and are not presented here.
Only preliminary progress was made, regarding the random mutagenesis, by the time 
this thesis was submitted (data not shown). In summary, specific primers PAPHsK and 
PAPHsS (Table 2.2) were used to PCR amplify the human PAP1 gene from the plasmid 
construct pRV5 (Figure 3.8) under conditions o f various MnS04 concentrations up to 
100 fiM. The amplified gene was re-inserted to the vector backbone, transformed into E. 
coli XL 10-Gold and then the transformation plates were screened using the fluorescent 
assay. The higher the MnS04 concentration used, the higher the percentage of non- 
fluorescent colonies obtained. These preliminary findings indicate that mutations, which 
produce an inactive PAP1, can be obtained using this approach. Furthermore it would 
be worthwhile to use the gene of an inactive PAP1 mutant (or one with reduced activity) 
as template in the random mutagenesis reaction, in an attempt to regain (or increase) 
activity.
Finally, this work now provides some useful tools for the continued research o f human 
PAP1 and its in vivo role. The clone presents a probe, which can be used in various 
tissue and array-hybridisation studies and to investigate possible tissue-specific forms 
and expression of the enzyme. Also, antibodies can be raised against the purified 
recombinant protein and subsequently used in immuno-histochemical investigations and 
in applications such as high-resolution tissue microscopy coupled with immuno- 
cytochemical amplification.
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Appendix A 
Standard Curves
1j600 - i
BSA (ygixO)
BSA standard curve for quantitative BCA assay
Standard curve of BSA (fig/ml) versus absorbance at 562 nm for the determination of protein 
concentration by the BCA assay described in Section 2.14.1.
B S A
BSA standard curve for quantitative Coomassie assay
Standard curve of BSA (jig/ml) versus absorbance at 595 nm for the determination of protein 
concentration by the quantitative Coomassie assay described in Section 2.14.2.
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BSA standard curve for qualitative Coomassie assay
Standard curve of BSA (jig/ml) versus absorbance at 595 nm for the determination of protein 
concentration by the qualitative Coomassie assay described in Section 2.14.3.
AMCOiM)
AMC standard curve
Standard curve of AMC (fiM) versus fluorescence intensity as described in Section 2.15.1, for the 
determination of AMC released by PAPI activity.
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Appendix B 
Sequence Data
>pRVl forward read, MWG (top strand)
GACTCACTATAGGGCGAATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGG
ATATCTGCAGAATTCGGCTAACAGAAGCAGGTCCGAGGCACAGCCCGATCCCGCCATGGAG
CAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACG
CCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCA
TGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGA
AGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACT
GGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGC
TCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGT
GTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCA
GATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCG
TCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGC
CATCATTGAGGAGATGTTGGACC
>pRVI reverse read, MWG (top strand)
TGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGCCAGTTGGATTGCAGTT
CAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGG
TTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCT
GGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACAC
AACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGA
GGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACC
ACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTT
TACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACT
GGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCATCATTGAGGAGATG
TTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAACACTGAGGGACGC
TCAGGTCTCCTAAGACCTCATCCTGAAGCCGAATTCCAGCACACTGGCGGCCGTTACTAGTG
GATCCGAGCTCGGTACCAAGCTT
>pRV3_forward read, MWG (top strand)
AATCATAAAAAATTTATTTGCTTTGTGAGCGGATAACAATTTCACACAGAATTCATTAAAGA
GGAGAAATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTT
GGGGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTG
GCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACT
CATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGC
ATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACA
ACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCC
ATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGAC
CATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAG
TCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGC
TGGGCAGGGCACTGAGAGCCATCATTGA
>pRV3_reverse read, MWG (top strand)
AGCCGAGGAAGGCGGTGGTAGTGACGGAATTTGGCCCTTTTGGGGAACACACCGTGAACGC
CAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCAT
GTGT ACG AGATTCCGGTTGAGT ACC AA ACAGTCCAG AGACTCATCCCCGCCCTGTGGGAG AA
GCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTG
GAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCT
CCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTG
TGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAG
ATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGT
CCACAGTGCCCCCACTGGGGAAGCCAGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAG
CCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCAC
AAACACGGATCTCATCACCATCACCATCACTAAGCTTAATTAGC
2
>pRV8_forward read, Qiagen (top strand)
GAGAAATCATAAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAGATTCAATTGT
GAGCGGATAACAATTTCACACAGAATTCATTAAAGAGGAGAAATTAACCATGGAGCAGCCG
AGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGCCAGTT
GGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTA
CGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCAC
AGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGA
AATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCA
GTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCA
AGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATAT
CTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCAC
GTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCATCA
TTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAACA
CGGATCTCATCACCATCACCATCACTAAGCTTAATTAGCTGAGCTTGGACTCCTGTTGATAG
ATCCAGTAATGACCTCAGAACTTCATCTGGATTTGTTCA
>pRV8_reverse read, Qiagen (top strand)
AGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAA
CGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTG
CATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGA
GAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACA
CTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCG
GCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCT
GTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGG
CAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTT
CGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGA
GCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCC
ACAAACACGGATCTCATCACCATCACCATCACTAAGCTTAATTAGACTGAGCTTG
>pRV5_forward read, Qiagen (top strand)
TCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGAATTCA
TTAAAGAGGAGAAATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGG
CCCTTTTGGGGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTA
GGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCA
GAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTG
TCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGC
TGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATT
GACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTC
GGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTA
CCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGG
ACCAGCTGGGCAGGGCACTTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGT
CAGAGGGCAAAATCAAC
>pRV5_reverse read, Qiagen (top strand)
ATTCATTAAAGAGGAGAAATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGA
TTTGGCCCTTTTGGGGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAA
GCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAG
TCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGG
GGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAG
GGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAG
CATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATG
TGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTT
TGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAAC
GCGGACCAGCTGGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGC
AGTCAGAGGGCAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAA
GCTTGGCTGTTTTG
3
>pRV5_A6xHis_reverse read, Qiagen (top strand)
AATCACTGCATATTTAGGTCGCTCAAGGCGCACTCCCTTCTGGATAATGTTTATGCGCCGAC
ATCATAACGGTTCTGGCAAATAATCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGTAT
AATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGAATTCATTAAAGAGGA
GAA ATTA ACC ATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGG
GAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCG
ACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATC
CCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGG
CGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTG
CCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCA
TCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATC
TCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCAC
GGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGG
GCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAA
AATCAACTATTGCCACAAACACTAAGGATCCGTCGACCTGCAGCCAAGCTTCTGTTT
>pRV5_R5sK6s_forward read, MWG (top strand)
CGCGTAAAGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGCCAG
TTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGT
ACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCA
CAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAG
AAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCC
AGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGC
AAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGAT
ATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCC
ACGTGCCCCCACTGGGGAAGCCGTACAA
>pRV5_R5sa_forward read, MWG (top strand)
TTAACCATGGAGCAGCCGCGCAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAAC
ACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAG
CGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCG
CCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGAC
CACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGC
TTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGA
CATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGC
AGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGT
CGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCA
GGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAAT
CAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGC
GGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAA
AACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGA
AGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCCATGCGAGAGTAGGGAACTG
CCAGGCATCAAATAAAAC
>pRV5_R5sa_reverse read, MWG (top strand)
TCGTGTCGCTCAAGGCGCACTCCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGT
TCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAA
TTGTGAGCGGATAACAATTTCACACAGGAAACAGAATTCATTAAAGAGGAGAAATTAACCA
TGGAGCAGCCGCGCAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGT
GAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGAC
CTGC ATGTGT ACG AG ATTCCGGTTG AGT ACC AAAC AGTCC AGAGACTC ATCCCCGCCCTGTG
GGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTC
ACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCC
CCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGAT
GCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGC
CGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGC
CTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTG
AGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATT
GCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTGGCG
4
>pRV5_R5sb_forward read, MWG (top strand)
TTAACCATGGAGCAGCCGCGTAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAAC
ACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAG
CGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCG
CCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGAC
CACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGC
TTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGA
CATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGC
AGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGT
CGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCA
GGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAAT
CAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGC
GGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAA
AACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGA
AGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGC
CAGGCATCAAATAAAACGAAAA
>pRV5_C149mW_forward read, Lark Technologies (top strand)
GNAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAAC
AATTTCACACAGGAAACAGAATTCATTAAAGAGGAGAAATTAACCATGGAGCAGCCGAGGA
AGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGCCAGTTGGATT
GCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGA
TTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCA
CAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTG
GACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGC
GTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAG
TCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATACCTCTGG
GACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCC
CCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCATCATTGAGG
AGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAAACTATTGCCACAAACACGGAT
TTCATCACCATCACCATCACTAAANCTNGGCTGTTTTNGGCGGATGAAANAAAATTTTTAGC
CCTGATTCAGAATTAAATCAGAANCCCAGAAACGGGTCTGANAAAANAAAANTTTGCCTGG
GNGGNANNAACCCCGGGGGGTCCCCCCNTGANCCCCTTGCCNAAANTNAAAAATGAAAACC
CCCCTNCCCCCCNATNGT ATTTGNGGGG
>pRV5_C149mW_reverse read, Lark Technologies (top strand)
NAANNAACCNGGGTTTTAATNTCCGGGGGNCAAATTTTTGGGTGANGAANCNNNGNAAATT
GGGGAAGGGTGGGCGGGGGNAAANCNGCNAAATTNGGTNGNCNNAGGGCCCTCCNGTTTG
GNAAAATTTTTGGCCCNACATAAAACGGTTTGGCAAAATTTTAAAANAACNGTNGNNANTT
ATTATCGGCTCGTAAAATTGNGNANTNTAGCGGATAACNATTTCACACAGGAACAGAATTC
ATAAAGAGGAGAAATTANCCATGANCAGCCCAGGAAGGCGGTGGTAGTGACGGGATTTGNC
CNTTTTGGGAACACACCGTGAACGCCAGTTGGANTGCAGTTCAGGAGCTAGAAAAGCTAGG
CCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGA
GACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCA
GGCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGG
ACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGAC
TCCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGT
GACCATCTCGCAGGATGCCGGCAGATACCTCTGGGACTTTACCTACTACACCTCTTTGTACC
AGAGTCACGGTCGATCAGCCTTNGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGA
CCAGCTGGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCA
GAGGGCAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTG
GCTGTTNNGC
5
>pRV5_H168mD_forward read, Lark Technologies (top strand)
GNAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAAC
AATTTCACACAGGAAACAGAATTCATTAAAGAGGAGAAATTAACCATGGAGCAGCCGAGGA
AGAGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGCCAGTTGGA
TTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGA
GATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTC
CACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATG
TGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCT
GCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCG
AGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCANGATGCCGGCAGATATCTCT
GCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCGGNCNTTCGTCGACGT
GCCCCCACTGGGGAAGCCGTACACGCGGACCAGCTGGGCAGGGCACTGANANCATCATGGA
GGAAATTTGGNNCTNCTGGAGCATTCAGAGGNCAAANTCAATTTTGGCCNAAAANCGGNTT
TTNTTNCCNTCNCNTTNTTNAGTTNGNNTGTTTNGGNGGANNAAAAAAANTTTTNNCCCTGT
TCNAAANTNAANNNAAANCNCNAAANCGGNNTTTNAAAAAAAANTTTTCTTGGGGGNNAA
NACCCGGGGGNNCCCCCTNGNCCCTNGGCCAAANTAAAAAAAAANNCCCCCNNCCCCCNNG
GGNGTGGGGGGGGGNNCCCCCNCCCANAAAAAN
>pRV5_H168mD_reverse read, Lark Technologies (top strand)
AAANGAAANNNGGNTTTNNANNNGGGCGGGGGNCCCNANNTTTTNGGGGTTNGGANNCCN
TNTGNAAAATTTGGNTANGNTTNNCCAAGGTTTTAAAACCNNGGAAAANTTNGTTGGKNCA
ANGGGGCANTCCCNTTTNGNAAANNTTTTTTGGCCCNNAATTNAAACGGNTTTNGCAAAAA
NTTTNAAATAAGCNNTTGNCAANTAATCATCGGCTCGTAAAAGNNGGNAATNNNANCGGAT
ANCAATTTCCCCCAGGAANCAGAATTCATTAAAGAGGAGAAATTANCCATGGAGCAGCCNA
GNAAGGCGGTGGTAGTGACGGGATTTGNCCNTTTNGGGAACACACCGTGAACGCCAGTTGG
ATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACG
AGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAG
TCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAA
TGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTG
CTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCAAGC
GAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTC
TGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCGGCCTTNGTCGACGTG
CCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCATCATTG
AGGAGATGTTGGACCTCCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAACACG
GATCTCATCACCATCACCATCACTAAGNCTTGGCTGTTNTGGCGGNATAAAA
>pRV5_F 13mW forward read, MWG (top strand)
CAGCCGAGGAAGGCGGTGGTAGTGACGGGATGGGGCCCTTTTGGGGAACACACCGTGAACG
CCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCA
TGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGA
AGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACT
GGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGC
TCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGT
GTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCA
GATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCG
TCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGC
CATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCAC
AAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGA
TTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCT
GGCGGCAGTAGCGCGGTGGTCCCACCTGAC
6
>pRV5_F13mY.P175mS_forward read, MWG (top strand)
GGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATATGGCCCTTTTGGCGAACACACCGTG
AACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACC
TGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGG
GAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCA
CACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCC
CGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATG
CTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCC
GGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCC
TTCGTCCACGTGCCCCCACTGGGGAAGTCGTACAACGCGGACCAGCTGGGCAGGGCACTGA
GAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTG
CCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAG
AAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATT
TGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCC
>pRV5_F13mY.P175mS forward read, MWG (top strand) repeat
AGCCGAGGAAGGCGGTGGTAGTGACGGGATATGGCCCTTTTGGCGAACACACCGTGAACGC
CAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCAT
GTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAA
GCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTG
GAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCT
CCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTG
TGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAG
AT ATCTCTGCGACTTT ACCT ACT AC ACCTCTTTGT ACCAGAGTCACGGTCGATCAGCCTTCGT
CCACGTGCCCCCACTGGGGAAGTCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCC
ATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACA
AACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGAT
TTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCT
>pRV5_F13mY_forward read, MWG (top strand)
GCGGTGGTAGTGACGGGATATGGCCCTTTTGGCGAACACACCGTGAACGCCAGTTGGATTGC
AGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATT
CCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCAC
AGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGG
ACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCG
TGGAGGACGGGCCTGAAAGTATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGTC
ACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGA
CTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCC
ACTGGGGAAGCCGT
>pRV5_F 1 3mL_forward read, MWG (top strand)
TGGATTGCAGTTCATGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTA
CGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCAC
AGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGA
AATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCA
GTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCA
AGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCT
7
>pRV5_F13mL.F16mL_forward read, Qiagen (top strand)
CAATTCTGAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCG
GATAACAATTTCACACAGGAAACAGAATTCATTAAAGAGGAGAAATTAACCATGGAGCAGC
CGAGGAAGGCGGTGGTAGTGACGGGATTGGGCCCTTTGGGGGAACACACCGTGAACGCCAG
TTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGT
ACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCA
CAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAG
AAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCC
AGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGC
AAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGAT
ATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCC
ACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCAT
CATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAA
CACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGTTTT
CAGCCTGATACAGATTAATCAGAACGCAGAAGCGGTCTGGATAAACAGATTTGCCTGGCGT
>pRV5_F16mL_forward read, MWG (top strand)
TGACGGGATTTGGCCCTCTGGGCGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAG
CTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTA
CCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTG
CATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGG
GCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGG
CCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGG
CCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACT
ACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAG
CCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACC
TCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCAC
CATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAAT
CAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCC
ACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGT
>pRV5_F16mL_reverse read, MWG (top strand)
GC AGGTCGT A A ATC ACTGC AT A ATTCGT GTCGCTC AAGGCGC ACTCCCGTTCTGG AT A ATGT
TTTTTGCGCCGACATCATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATC
ATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGAATTC
ATTAAAGAGGAGAAATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTG
GCCCTCTGGGCGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCT
AGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCC
AGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGT
GTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGG
CTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCAT
TGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGT
CGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGT
ACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCG
GACCAGCTGGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGT
CAGAGGGCAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCT
TGGCTGTTTGGCG
8
>pRV5_F16mY_forward read, MWG (top strand)
CGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTG
CATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGA
GAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACA
CTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCG
GCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCT
GTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGG
CAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTT
CGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGA
GCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCC
ACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAA
GATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGC
CT
>pRV5_F16mY_reverse read, MWG (top strand)
TTTTTGCGCCGACATCATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATC
ATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGAATTC
ATTAAAGAGGAGAAATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTG
GCCCTTATGGCGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCT
AGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCC
AGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGT
GTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGG
CTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCAT
TGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGT
CGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGT
ACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCG
GACCAGCTGGGCAGGGCACTGAGAGCCATCATTGA
>pRV5_Y147mF_forward read, MWG (top strand)
AGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGC
CAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCAT
GTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAA
GCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTG
GAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCT
CCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTG
TGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAG
ATTTCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGT
CCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCC
ATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACA
AACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGAT
TTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTG
GCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAG
CGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAA
A
>pRV5_Y147mF_reverse read, MWG (top strand)
TGCATAAATTCGTGTCGCTCAAGGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATC
ATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGTATAAT
GTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGAATTCATTAAAGAGGAGAA
ATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAA
CACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACA
GCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCC
GCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGA
CCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCG
CTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCG
ACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCG
CAGGATGCCGGCAGATTTCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGT
CGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCA
GGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAAT
CAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTGGCG
9
>pRV5_D97mE.N98C99mM_forward read, MWG (top strand)
GAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGA
ACGCCAGTTGGATTGCAGTTC AGGAGCT AGAA AAGCT AGGCCTTGGCGACAGCGTGGACCT
GCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGG
AGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCAC
ACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGAAATGCGCTTTTGCCCCGGA
TCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGT
GTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCA
GATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCG
TCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGC
CATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCAC
AAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGA
TTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAAACAGAATTTGCC
TGGCGGCAGTAGCGCGGTGGTCCCCACCTGACCCCATGCCGAAACTC
>pRV5_D97mE_forward read, MWG (top strand)
AGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGC
CAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCAT
GTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAA
GCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTG
GAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGAGAACTGCCGCTTTTGCCCCGGAT
CCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTG
TGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAG
ATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGT
CCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCC
ATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACA
AACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGAT
TTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTG
GCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAG
CGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAAACTGCCAGGCATCAAATAA
ACGAAAGGCTCAGTCGAAAGACTGGGCCTTTTCGTTTTATCTGTTGGTTGTCGGTGAACGCT
CTCCTGAGTAGGACAAATCCGCCCGGAGCGGATTTGAACG
>pRV5_D97mE_reverse read, MWG (top strand)
GCCGACATCATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATCATCGGC
TCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGAATTCATTAAA
GAGGAGAAATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTT
TTGGGGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCT
TGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGA
CTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGG
CATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGAG
AACTGCCGCTTTTGCCCCGGATCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTC
CATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGA
CCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGA
GTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAG
CTGGGCAGGGCACTGAGAGCCATCATTGAGAGAGATGTTGGACCTCCTGG
10
>pRV5_N98mQ_forward read, MWG (top strand)
AGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAA
CGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTG
CATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGA
GAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACA
CTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACCAGTGCCGCTTTTGCCCCG
GATCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCT
GTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGG
CAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTT
CGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGA
GCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCC
ACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAA
GATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGC
CTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCG
TAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAAT
AAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTGGTTGTCGGTGAACGC
TCTCCTGAGTAGGACAA
>pRV5_N98mQ_reverse read, MWG (top strand)
TGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTG
ACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGA
AACAGAATTCATTAAAGAGGAGAAATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTG
ACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCT
AGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTAC
CAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGC
ATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGG
CTACAAGGGGCTGGACCAGTGCCGCTTTTGCCCCGGATCCCAGTGCTGCGTGGAGGACGGGC
CTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGC
CTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTA
CACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGC
CGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCT
CCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAACACGGATCTCATCACCATCAC
CATCACTAAGCTTGGCTGTTTGGCG
>pRV5_N98mV forward read, MWG (top strand)
TAACCATGGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAAC
ACACCGGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACA
GCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCC
GCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGA
CCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACGTCTGCCG
CTTTTGCCCCGGATCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCG
ACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCG
CAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGG
TCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCA
GGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAAT
CAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGC
GGATG AG AG A AG ATTTTC AGCCTG AT AC AGATT A AATC AG A ACGC AG AAGCGGTCTGAT A A
AACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGA
AGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAG
11
>pRV5_N98mV_reverse read, MWG (top strand)
TGCATAATTCGTGTCGCTCAAGGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCA
TAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATG
TGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGAATTCATTAAAGAGGAGAAA
TTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAAC
ACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAG
CGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCG
CCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGAC
CACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACGTCTGCCGC
TTTTGCCCCGGATCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGA
CATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGC
AGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGT
CGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCA
GGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAAT
CAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTG
>pRV5_SIDl 15mAYF forward read, MWG (top strand)
ATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAA
CACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACA
GCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCC
GCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGA
CCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCG
CTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAGGCCTATTTCTCCATCATCG
ACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCG
CAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGG
TCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCA
GGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAAT
CAACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGC
GGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAA
AACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGA
AGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGC
CAGGCATCAAATAA
>pRV5_Dl 1 7+GGG_forward read, MWG (top strand)
GCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGCC
AGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATG
TGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAG
CACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGG
AGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTC
CCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACGGCGGCGGATCCATCATCGACATG
GATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGA
TGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATC
AGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCA
CTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTC
>pRV5_I120mG_forward read, MWG (top strand)
CAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACG
CCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCA
TGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGA
AGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACT
GGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGC
TCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCGATCGGCGACATGGATGCTGT
GTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCA
GATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCG
TCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGC
CATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCAC
AAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCGGATGAGAGAAGA
TTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCT
GGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGA
12
>pRV5_Q180mE.N177mY_forward read, MWG (top strand)
TTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAAC
ACACCGTGAACGCCAGTTGGATTGCAGTTC AGGAGCT AG AAAAGCT AGGCCTTGGCGACAG
CGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCG
CCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGAC
CACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGC
TTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGA
CATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGC
AGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGT
CGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACTACGCGGACGAGCTCGGCAG
GGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGCAAAATC
AACTATTGCCACAAACACGGATCTCATCACCATCACCATCACTAAGCTTGGCTGTTTTGGCG
GATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAA
ACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAA
GTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCC
AGGCATCAAA
>pRV5_Q180mE_forward read, MWG (top strand)
TTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAAC
ACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAG
CGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCG
CCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGAC
CACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGC
TTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGA
CATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGC
AGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGT
CGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACGAGCTCGGCA
GGGCACTGAGAGCCATCATTGAGGAGATGT
>pRV5_Q180mE_reverse read, MWG (top strand)
GTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACA
AGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGAC
GGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTT
GGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCT
ACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGG
AAGCCGTACAACGCGGACGAGCTCGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGG
ACCTCCTGGAGCAGTCAGAGGGCAAAATCAACTATTGCCACAAACACGGATCTCATCACCAT
CACCATCACTAAGCTTGGCTGTTTGGCG
>pRV5_A3’_forward read, MWG (top strand)
TAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACA
CACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGC
GTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGC
CCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACC
ACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCT
TTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGAC
ATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCA
GGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTC
GATCAGCCTTCGTCCACGTGC
>pRV5_A3'_reverse read, MWG (top strand)
GACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCT
GTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACA
GTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTT
GCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATG
GATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGA
TGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATC
AGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCA
CTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAGGGATCTCATCACCA
TCACCATCACTAAGCTTGGCTGTTTGGCG
13
>pRV5_A3’A6H_forward read, MWG (top strand)
TAAGAGGAGAATTAACCATGGAGCAGCCGAGGAAGGCGGTGGTAGTGACGGGATTTGGCCC
TTTTGGGGAACACACCGTGAACGCCAGTTGGATTGCAGTTCAGGAGCTAGAAAAGCTAGGC
CTTGGCGACAGCGTGGACCTGCATGTGTACGAGATTCCGGTTGAGTACCAAACAGTCCAGAG
ACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCACAGCTGGTGGTGCATGTGGGGGTGTCAG
GCATGGCGACCACAGTCACACTGGAGAAATGTGGACACAACAAGGGCTACAAGGGGCTGGA
CAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCGTGGAGGACGGGCCTGAAAGCATTGACT
CCATCATCGACATGGATGCTGTGTGCAAGCGAGTCACCACGTTGGGCCTGGATGTGTCGGTG
ACCATCTCGCAGGATGCCGGCAGATATCTCTGCGACTTTACCTACTACACCTCTTTGTACCAG
AGTCACGGTCGATCAGCCTTCGTCCACGTGCCCCCACTGGGGAAGCCGTACAACGCGGACCA
GCTGGGCAGGGCACTGAGAGCCATCATTGAGGAGATGTTGGACCTCCTGGAGCAGTCAGAG
TAAGGATCCGTCGACCTGCAGCCAAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGC
CTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCA
GTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGA
TGGTAGTGTGGGG
>pRV5_A3’A6H_reverse read, MWG (top strand)
ATCGGAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTCGTGTCGCTCAAGG
CGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAAATATTCTG
AAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACA
ATTTCACACAGGAAACAGAATTCATTAAAGAGGAGAAATTAACCATGGAGCAGCCGAGGAA
GGCGGTGGTAGTGACGGGATTTGGCCCTTTTGGGGAACACACCGTGAACGCCAGTTGGATTG
CAGTTCAGGAGCTAGAAAAGCTAGGCCTTGGCGACAGCGTGGACCTGCATGTGTACGAGAT
TCCGGTTGAGTACCAAACAGTCCAGAGACTCATCCCCGCCCTGTGGGAGAAGCACAGTCCAC
AGCTGGTGGTGCATGTGGGGGTGTCAGGCATGGCGACCACAGTCACACTGGAGAAATGTGG
ACACAACAAGGGCTACAAGGGGCTGGACAACTGCCGCTTTTGCCCCGGCTCCCAGTGCTGCG
TGGAGGACGGGCCTGAAAGCATTGACTCCATCATCGACATGGATGCTGTGTGCAAGCGAGT
CACCACGTTGGGCCTGGATGTGTCGGTGACCATCTCGCAGGATGCCGGCAGATATCTCTGCG
ACTTTACCTACTACACCTCTTTGTACCAGAGTCACGGTCGATCAGCCTTCGTCCACGTGCCCC
CACTGGGGAAGCCGTACAACGCGGACCAGCTGGGCAGGGCACTGAGAGCCATCATTGAGGA
GATGTTGGACCTCCTGGAGCAGTCAGAGTAAGGATCCGTCGACCTGCAGCCAAGCTTGGCTG
TTTGGCG
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Appendix C 
Activity & Kinetics
Quantification of PAP1 activity
One unit of activity is defined as the amount of enzyme, which releases 1 nanomole of 
AMC per minute at 37°C (unit = nmoles.min'1)
Derivation:
AMC released (X) is defined as fluorescent intensity (Fi) divided by the slope of the 
appropriate AMC standard curve (Appendix A).
Fi
— =X*iM 
m
= jimoles.L"1
The reaction volume is 500x10"6 L and duration is 15 min
X(500xl0‘6) , ,
AMC released = -------—-------- jimoles.L .L.min
Reaction uses 100x1 O'6 L enzyme
AW„  , X^OOxlO*6) , . .l T .,.. AMC released by enzyme =  — umoles.min .L
15(100 x 10 6)
X(500 xl0*6)(1000) , . i ,i
=    nmoles.min .ml
15(100 xlO )(1000)
x  • i-i= — units.ml
3
Fi
= —  units.ml'1 
3m
From AMC standard curve, m = 10.535
Fi
Enzyme activity =  units.ml-1
31.605
2
Determination of Km and Vm**
The Michaelis constant (Km) of an enzyme, for a particular substrate, is defined as the 
substrate concentration which gives rise to half the maximal enzyme velocity (Vmax). 
This constant can be determined by measuring reaction velocity at various 
concentrations of substrate, giving rise to the Michaelis-Menten hyperbola curve. In the 
case of PAP 1, activity is determined by measuring fluorescent intensity (Fi) resulting at 
various concentrations of the substrate pGlu-AMC, as described in Section 2.19.3. A 
plot of Fi versus [pGlu-AMC] yields the Michaelis-Menten curve. Once an enzyme- 
catalysed reaction follows normal Michaelis-Menten kinetics, data can be applied to a 
choice of kinetic models:
Lineweaver-Burk: Plot of 1 /Fi versus l/[pGlu-AMC]. The intercept of the line on the x- 
axis gives -1/Km and the intercept of the line on the y-axis gives 1/Vmax.
Eadie-Hofstee: Plot of Fi versus Fi/[pGlu-AMC]. The slope is -Km and the intercept on 
the y-axis represents Vmax.
Hanes-Woolf: Plot of [pGlu-AMC]/Fi versus [pGlu-AMC]. The intercept on the x-axis 
gives -Km, and the slope is 1/Vmax.
3
Determination of kcat
The turnover constant (k^) of an enzyme can be determined if the and total 
enzyme (Et) are known:
nmoles, min 1 .ml 1 . -i , -u------------------:------= min (s )
nmoles.ml
In the case of PAP1, Vmax (nmoles.mm'.ml'1 or units.ml'1) is determined experimentally 
as described above. Et (nmoles.ml'1) can be calculated from the molecular weight 
(g.mole'1) and amount of enzyme used (g.ml1). The molecular weight of His-tagged 
recombinant human PAP1 (rHsa?AP1 6h) is 24,105 g.mole1, as deduced from the amino 
acid sequence.
Determination of Kj
The inhibition constant (Kj), or dissociation constant for the enzyme-inhibitor complex, 
can be determined by measuring the apparent Km (Kmapp) observed in the presence of an 
inhibitor at a specific concentration ([I]), as described in Section 2.19.4 and applied to 
the following equation:
4
Appendix D 
Amino Acids
Tiny
C harged
Amino acid properties
Venn diagram presenting properties of the 20 amino acids
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic acid Asp D
Cysteine Cys C
Glutamic acid Glu E
Glutamine Gin Q
CH,
NH,
NH2 O
OH
Glycine
Histidine
Iso leucine
Leucine
Lysine
Methionine
Phenylalanine
Pro line
Serine
Threonine
Tryptophan
Tyrosine
Valine
SecondPosition
FirstPosition
U C A G
u
UUU Phe 
UUC Phe 
UUA Leu 
UUG Leu
UCU Ser 
UCC Ser 
UCA Ser 
UCG Ser
UAU Tyr 
UACTyr
UAA Stop 
UAG Stop
UGU Cys 
UGC Cys
UGA Stop 
UGG Trp
U
c
CUU Leu 
CUC Leu 
CUA Leu 
CUG Leu
CCU Pro 
CCC Pro 
CCA Pro 
CCG Pro
CAU His 
CAC His 
CAA Gin 
CAG Gin
CGU Arg 
CGC Arg 
CGA Arg 
CGG Arg
C
A
AUU Ile 
AUC Ile 
AUA Ile 
AUG Met
ACU Thr 
ACC Thr 
ACA Thr 
ACGThr
AAU Asn 
AAC Asn 
AAA Lys 
AAG Lys
AGU Ser 
AGC Ser 
AGA Arg 
AGG Arg
A
G
GUU Val 
GUC Val 
GUA Val 
GUG Val
GCU Ala 
GCC Ala 
GCA Ala 
GCG Ala
GAU Asp 
GAC Asp 
GAA Glu 
GAG Glu
GGU Gly 
GGC Gly 
GGAGIy 
GGG Gly
G
ThirdPosition
Genetic code
Amino acid codons applicable to both H. sapiens and E. coli.
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